BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327-3334. [PMID: 23816960 DOI: 10.1200/jco.2012.44.2806] [Cited by in Crossref: 1857] [Cited by in F6Publishing: 1018] [Article Influence: 206.3] [Reference Citation Analysis]
Number Citing Articles
1 Rugo HS, Di Palma JA, Tripathy D, Bryce R, Moran S, Olek E, Bosserman L. The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. Breast Cancer Res Treat 2019;175:5-15. [PMID: 30671765 DOI: 10.1007/s10549-018-05102-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 8.3] [Reference Citation Analysis]
2 Truini A, Starrett JH, Stewart T, Ashtekar K, Walther Z, Wurtz A, Lu D, Park JH, DeVeaux M, Song X, Gettinger S, Zelterman D, Lemmon MA, Goldberg SB, Politi K. The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma. Clin Cancer Res 2019;25:6382-91. [PMID: 31182434 DOI: 10.1158/1078-0432.CCR-19-0780] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
3 Attwa MW, Abdelhameed AS, Kadi AA. LC-MS/MS Estimation of Rociletinib Levels in Human Liver Microsomes: Application to Metabolic Stability Estimation. Drug Des Devel Ther 2021;15:3915-25. [PMID: 34552321 DOI: 10.2147/DDDT.S321330] [Reference Citation Analysis]
4 Gregorc V, Lazzari C, Karachaliou N, Rosell R, Santarpia M. Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer. Transl Lung Cancer Res 2018;7:S165-70. [PMID: 29782558 DOI: 10.21037/tlcr.2018.03.19] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
5 Sogawa R, Nakashima C, Nakamura T, Takeuchi K, Kimura S, Komiya K, Narisawa Y, Kimura S, Sueoka-Aragane N. Association of Genetic Polymorphisms With Afatinib-induced Diarrhoea. In Vivo 2020;34:1415-9. [PMID: 32354939 DOI: 10.21873/invivo.11922] [Reference Citation Analysis]
6 Isla D, De Castro J, Juan O, Grau S, Orofino J, Gordo R, Rubio-Terrés C, Rubio-Rodríguez D. Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer. Clinicoecon Outcomes Res 2017;9:31-8. [PMID: 28115857 DOI: 10.2147/CEOR.S121093] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
7 de Biase D, Genestreti G, Visani M, Acquaviva G, Di Battista M, Cavallo G, Paccapelo A, Cancellieri A, Trisolini R, Degli Esposti R, Bartolini S, Pession A, Tallini G, Brandes AA. The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma. PLoS One 2017;12:e0177822. [PMID: 28520821 DOI: 10.1371/journal.pone.0177822] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
8 Wang CC, Lai CH, Chang YP, Chang HC, Tseng CC, Huang KT, Lin MC. Comparing survival and treatment response of patients with acquired T790M mutation second-line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real-world study. Thorac Cancer 2021;12:3263-72. [PMID: 34704378 DOI: 10.1111/1759-7714.14198] [Reference Citation Analysis]
9 Guo L, Chen Z, Xu C, Zhang X, Yan H, Su J, Yang J, Xie Z, Guo W, Li F, Wu Y, Zhou Q. Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level. BMC Cancer 2019;19:369. [PMID: 31014278 DOI: 10.1186/s12885-019-5555-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
10 Akazawa Y, Saito Y, Yoshikawa T, Saito K, Nosaka K, Shimomura M, Mizuno S, Nakamoto Y, Nakatsura T. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer. Cancer Sci 2020;111:2736-46. [PMID: 32391625 DOI: 10.1111/cas.14451] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
11 Melosky B, Banerji S, Blais N, Chu Q, Juergens R, Leighl NB, Liu G, Cheema P. Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer. Curr Oncol 2020;27:e146-55. [PMID: 32489263 DOI: 10.3747/co.27.6007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Chu CY, Choi J, Eaby-Sandy B, Langer CJ, Lacouture ME. Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer. Oncologist 2018;23:891-9. [PMID: 29650685 DOI: 10.1634/theoncologist.2017-0582] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
13 Zhang X, Goldstein DY, Khader SN. Educational Case: Non-Small Cell Lung Cancer: Pathologic Diagnosis and Molecular Understanding. Acad Pathol 2019;6:2374289519881951. [PMID: 31696153 DOI: 10.1177/2374289519881951] [Reference Citation Analysis]
14 Lin L, Pan H, Li X, Zhao C, Sun J, Hu X, Zhang Y, Wang M, Ren X, Luo X, Shan G, Hui A, Wu Z, Liu H, Tian L, Shi Y. A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.01.025] [Reference Citation Analysis]
15 Gotfrit J, Shin JJW, Mallick R, Stewart DJ, Wheatley-Price P. Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada. Oncologist 2020;25:e130-7. [PMID: 31506392 DOI: 10.1634/theoncologist.2019-0314] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Nie X, Zhang P, Gao JY, Cheng G, Liu W, Li L. Sarcopenia as a predictor of initial administration dose of afatinib in patients with advanced non-small cell lung cancer. Thorac Cancer 2021;12:1824-30. [PMID: 33951292 DOI: 10.1111/1759-7714.13934] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Blumenthal GM, Zhang L, Zhang H, Kazandjian D, Khozin S, Tang S, Goldberg K, Sridhara R, Keegan P, Pazdur R. Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis. JAMA Oncol 2017;3:e171029. [PMID: 28617920 DOI: 10.1001/jamaoncol.2017.1029] [Cited by in Crossref: 34] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
18 Santabarbara G, Maione P, Rossi A, Palazzolo G, Gridelli C. The role of pembrolizumab in the treatment of advanced non-small cell lung cancer. Ann Transl Med 2016;4:215. [PMID: 27386489 DOI: 10.21037/atm.2016.05.64] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
19 Hirsh V, Singh J. Optimal sequencing strategies in the treatment of EGFR mutation-positive non-small cell lung cancer: Clinical benefits and cost-effectiveness. Am J Health Syst Pharm 2020;77:1466-76. [PMID: 32885829 DOI: 10.1093/ajhp/zxaa197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Yao Y, Zhu Z, Wu Y, Chai Y. Histologic transformation from adenocarcinoma to both small cell lung cancer and squamous cell carcinoma after treatment with gefitinib: A case report. Medicine (Baltimore) 2018;97:e0650. [PMID: 29718881 DOI: 10.1097/MD.0000000000010650] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
21 Buonerba C, Iaccarino S, Dolce P, Pagliuca M, Izzo M, Scafuri L, Costabile F, Riccio V, Ribera D, Mucci B, Carrano S, Picozzi F, Bosso D, Formisano L, Bianco R, De Placido S, Di Lorenzo G. Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E1259. [PMID: 31466227 DOI: 10.3390/cancers11091259] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
22 Moriguchi S, Uruga H, Fujii T, Yasunaga Y, Takahashi Y, Kishi K. Transformation of epidermal growth factor receptor T790M mutation-positive adenosquamous carcinoma of the lung to small cell carcinoma and large-cell neuroendocrine carcinoma following osimertinib therapy: an autopsy case report. Respirol Case Rep 2019;7:e00402. [PMID: 30828454 DOI: 10.1002/rcr2.402] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
23 Passaro A, Gori B, de Marinis F. Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials. J Thorac Dis 2013;5:383-4. [PMID: 23991291 DOI: 10.3978/j.issn.2072-1439.2013.07.32] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
24 Yoo KH, Lee SJ, Cho J, Lee KH, Park KU, Kim KH, Cho EK, Choi YH, Kim HR, Kim HG, Ahn HJ, Lee HY, Yun HJ, Kang JH, Jeong J, Choi MY, Jung SH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. Cancer Res Treat 2019;51:718-26. [PMID: 30177585 DOI: 10.4143/crt.2018.324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
25 Migliorino MR, Santo A, Romano G, Cortinovis D, Galetta D, Alabiso O, Cartenì G, Vari S, Fasola G, Pazzola A, Giuffrida D, Zaniboni A, Caprioli A, Longo F, Acciai V, de Marinis F. Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study. J Cancer Res Clin Oncol 2017;143:783-91. [PMID: 28215027 DOI: 10.1007/s00432-016-2326-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
26 Sekine I. Are there any differences in genomic characterization of non-small cell lung cancer between African Americans and Whites? J Thorac Dis 2016;8:E1517-9. [PMID: 28066648 DOI: 10.21037/jtd.2016.11.65] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Carmichael JA, Wing-San Mak D, O'Brien M. A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC. Cancers (Basel) 2018;10:E236. [PMID: 30021993 DOI: 10.3390/cancers10070236] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
28 Hayakawa D, Takahashi F, Mitsuishi Y, Tajima K, Hidayat M, Winardi W, Ihara H, Kanamori K, Matsumoto N, Asao T, Ko R, Shukuya T, Takamochi K, Hayashi T, Suehara Y, Takeda Nakamura I, Ueno T, Kohsaka S, Mano H, Takahashi K. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation. Thorac Cancer 2020;11:140-9. [PMID: 31758670 DOI: 10.1111/1759-7714.13255] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
29 Fumagalli C, Catania C, Ranghiero A, Bosi C, Viale G, de Marinis F, Barberis M, Guerini-Rocco E. Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients. J Clin Med 2019;8:E112. [PMID: 30669267 DOI: 10.3390/jcm8010112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
30 Carrizosa DR, Gold KA. New strategies in immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res 2015;4:553-9. [PMID: 26629424 DOI: 10.3978/j.issn.2218-6751.2015.06.05] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
31 Tao H, Guo L, Tang J, Zhu Y, Xu L, Meng Q, Wu W, Li M, Wu W, Tong L, Wu H, Shi L, Liu Z. [Adverse events of afatinib as first-line treatment for five cases of advanced lung adenocarcinoma and review of literature]. Zhongguo Fei Ai Za Zhi 2014;17:342-6. [PMID: 24758910 DOI: 10.3779/j.issn.1009-3419.2014.04.09] [Reference Citation Analysis]
32 Lu S, Shih JY, Jang TW, Liam CK, Yu Y. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence. Adv Ther 2021;38:2038-53. [PMID: 33730350 DOI: 10.1007/s12325-021-01696-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
33 De Grève J, Van Meerbeeck J, Vansteenkiste JF, Decoster L, Meert AP, Vuylsteke P, Focan C, Canon JL, Humblet Y, Berchem G, Colinet B, Galdermans D, Bosquée L, Vermeij J, Dewaele A, Geers C, Schallier D, Teugels E. Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT). PLoS One 2016;11:e0147599. [PMID: 27032107 DOI: 10.1371/journal.pone.0147599] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
34 Otsuka T, Tanaka A, Azukizawa H, Sasaki S, Ishijima M, Matsuki T, Osa A, Nakatani T, Kuroyama M, Hirata H, Kijima T. Successful treatment with gefitinib after Stevens-Johnson syndrome associated with afatinib therapy in a patient with adenocarcinoma of the lung. Int Cancer Conf J 2017;6:38-41. [PMID: 31149467 DOI: 10.1007/s13691-016-0269-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
35 Stratmann JA, Michels S, Hornetz S, Christoph DC, Sackmann S, Spengler W, Bischoff H, Schäfer M, Alt J, Müller A, Laack E, Kimmich M, Griesinger F, Sebastian M. Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer. J Cancer Res Clin Oncol 2018;144:2457-63. [PMID: 30244389 DOI: 10.1007/s00432-018-2754-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Patel JN, Ersek JL, Kim ES. Lung cancer biomarkers, targeted therapies and clinical assays. Transl Lung Cancer Res 2015;4:503-14. [PMID: 26629419 DOI: 10.3978/j.issn.2218-6751.2015.06.02] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
37 Liang SK, Keng LT, Chang CH, Wen YF, Lee MR, Yang CY, Wang JY, Ko JC, Shih JY, Yu CJ. Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort. Front Oncol 2020;10:590356. [PMID: 33489886 DOI: 10.3389/fonc.2020.590356] [Reference Citation Analysis]
38 Ahn MJ, Han JY, Kim DW, Cho BC, Kang JH, Kim SW, Yang JC, Mitsudomi T, Lee JS. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. Cancer Res Treat 2020;52:284-91. [PMID: 31345012 DOI: 10.4143/crt.2019.200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Chiang CL, Huang HC, Shen CI, Luo YH, Chen YM, Chiu CH. Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI. Target Oncol 2020;15:503-12. [PMID: 32696212 DOI: 10.1007/s11523-020-00737-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Yap TA, Popat S. Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. Pharmgenomics Pers Med 2014;7:285-95. [PMID: 25278773 DOI: 10.2147/PGPM.S55339] [Cited by in Crossref: 5] [Cited by in F6Publishing: 20] [Article Influence: 0.6] [Reference Citation Analysis]
41 Du X, Bai H, Wang Z, Daun J, Liu Z, Xu J, Chang G, Zhu Y, Wang J. Establishment of prognostic nomograms for predicting the progression free survival of EGFR-sensitizing mutation, advanced lung cancer patients treated with EGFR-TKIs. Thorac Cancer 2022. [PMID: 35347870 DOI: 10.1111/1759-7714.14380] [Reference Citation Analysis]
42 Gao W, Wang M, Wang L, Lu H, Wu S, Dai B, Ou Z, Zhang L, Heymach JV, Gold KA, Minna J, Roth JA, Hofstetter WL, Swisher SG, Fang B. Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst 2014;106:dju204. [PMID: 25214559 DOI: 10.1093/jnci/dju204] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 7.4] [Reference Citation Analysis]
43 Drilon A, Wang L, Arcila ME, Balasubramanian S, Greenbowe JR, Ross JS, Stephens P, Lipson D, Miller VA, Kris MG, Ladanyi M, Rizvi NA. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clin Cancer Res 2015;21:3631-9. [PMID: 25567908 DOI: 10.1158/1078-0432.CCR-14-2683] [Cited by in Crossref: 143] [Cited by in F6Publishing: 90] [Article Influence: 20.4] [Reference Citation Analysis]
44 Passiglia F, Rizzo S, Di Maio M, Galvano A, Badalamenti G, Listì A, Gulotta L, Castiglia M, Fulfaro F, Bazan V, Russo A. The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis. Sci Rep 2018;8:13379. [PMID: 30190486 DOI: 10.1038/s41598-018-30780-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 8.3] [Reference Citation Analysis]
45 Corre R, Gervais R, Guisier F, Tassy L, Vinas F, Lamy R, Fraboulet G, Greillier L, Doubre H, Descourt R, Chouaid C, Auliac JB. Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study). Oncotarget 2018;9:8253-62. [PMID: 29492192 DOI: 10.18632/oncotarget.23836] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
46 Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531-548. [PMID: 28252003 DOI: 10.1038/nrclinonc.2017.14] [Cited by in Crossref: 770] [Cited by in F6Publishing: 743] [Article Influence: 154.0] [Reference Citation Analysis]
47 Choi H, Chang J, Shin HJ, Park CK, Oh IJ, Kim KS, Kim YC. Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma. Thorac Cancer 2015;6:224-6. [PMID: 26273363 DOI: 10.1111/1759-7714.12171] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
48 Paz-Ares L, Tan EH, O'Byrne K, Zhang L, Hirsh V, Boyer M, Yang JC, Mok T, Lee KH, Lu S, Shi Y, Lee DH, Laskin J, Kim DW, Laurie SA, Kölbeck K, Fan J, Dodd N, Märten A, Park K. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol 2017;28:270-7. [PMID: 28426106 DOI: 10.1093/annonc/mdw611] [Cited by in Crossref: 230] [Cited by in F6Publishing: 237] [Article Influence: 46.0] [Reference Citation Analysis]
49 Fouad M, Helvenstein M, Blankert B. Ultra High Performance Liquid Chromatography Method for the Determination of Two Recently FDA Approved TKIs in Human Plasma Using Diode Array Detection. J Anal Methods Chem 2015;2015:215128. [PMID: 26101692 DOI: 10.1155/2015/215128] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
50 Aggarwal C, Borghaei H. Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design. Oncologist 2017;22:700-8. [PMID: 28408617 DOI: 10.1634/theoncologist.2016-0345] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
51 Schuler M, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Massey D, Märten A, Paz-Ares L, Park K. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. J Cancer Res Clin Oncol 2019;145:1569-79. [PMID: 30783814 DOI: 10.1007/s00432-019-02862-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
52 Goto Y, Arakawa S, Shirasawa M, Higashiyama R, Baba K, Masuda K, Shinno Y, Matsumoto Y, Okuma Y, Yoshida T, Horinouchi H, Yamamoto N, Ohe Y. Performance of Japanese patients in registrational studies. Jpn J Clin Oncol 2022;52:53-64. [PMID: 34978326 DOI: 10.1093/jjco/hyab171] [Reference Citation Analysis]
53 Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, Li BT, Drilon A, Kris MG, Rudin CM, Schultz N, Arcila ME, Ladanyi M, Riely GJ, Yu H, Hellmann MD. Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. Clin Cancer Res 2019;25:1063-9. [PMID: 30045933 DOI: 10.1158/1078-0432.CCR-18-1102] [Cited by in Crossref: 108] [Cited by in F6Publishing: 78] [Article Influence: 27.0] [Reference Citation Analysis]
54 Chang IS, Jiang SS, Yang JC, Su WC, Chien LH, Hsiao CF, Lee JH, Chen CY, Chen CH, Chang GC, Wang Z, Lo FY, Chen KY, Wang WC, Chen YM, Huang MS, Tsai YH, Su YC, Hsieh WS, Shih WC, Shieh SH, Yang TY, Lan Q, Rothman N, Chen CJ, Chanock SJ, Yang PC, Hsiung CA. Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors. Am J Respir Crit Care Med 2017;195:663-73. [PMID: 27669169 DOI: 10.1164/rccm.201602-0300OC] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
55 Savas P, Hughes B, Solomon B. Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. J Thorac Dis 2013;5 Suppl 5:S579-92. [PMID: 24163750 DOI: 10.3978/j.issn.2072-1439.2013.08.52] [Cited by in F6Publishing: 22] [Reference Citation Analysis]
56 O'Kane GM, Leighl NB. Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors. CNS Drugs 2018;32:527-42. [PMID: 29799091 DOI: 10.1007/s40263-018-0526-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
57 Prabhash K. Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line - Indian consensus statement update. South Asian J Cancer 2019;8:1-17. [PMID: 30766843 DOI: 10.4103/sajc.sajc_227_18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
58 Pasello G, Vicario G, Zustovich F, Oniga F, Gori S, Rosetti F, Bonetti A, Favaretto A, Toso S, Redelotti R, Santo A, Bernardi D, Giovanis P, Oliani C, Calvetti L, Gatti C, Palazzolo G, Baretta Z, Bortolami A, Bonanno L, Basso M, Menis J, Corte DD, Frega S, Guarneri V, Conte P; Veneto Oncology Network. From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study). Oncologist 2019;24:e318-26. [PMID: 30846513 DOI: 10.1634/theoncologist.2018-0712] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
59 Van Luan P, Tien ND, Hai NM, Tien ND, Duyen TT. Real-world analysis of the effect of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer with EGFR mutations. Ther Adv Med Oncol 2021;13:1758835921992977. [PMID: 33680095 DOI: 10.1177/1758835921992977] [Reference Citation Analysis]
60 Rajan A, Kim C, Heery CR, Guha U, Gulley JL. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother 2016;12:2219-31. [PMID: 27135835 DOI: 10.1080/21645515.2016.1175694] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
61 Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014;25:282-303. [PMID: 24651011 DOI: 10.1016/j.ccr.2014.02.025] [Cited by in Crossref: 537] [Cited by in F6Publishing: 490] [Article Influence: 67.1] [Reference Citation Analysis]
62 Garinet S, Laurent-Puig P, Blons H, Oudart JB. Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies? J Clin Med. 2018;7. [PMID: 29890761 DOI: 10.3390/jcm7060144] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
63 Reardon DA, Wen PY, Mellinghoff IK. Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro Oncol 2014;16 Suppl 8:viii7-13. [PMID: 25342602 DOI: 10.1093/neuonc/nou232] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 9.3] [Reference Citation Analysis]
64 Spaans JN, Goss GD. Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future. Front Oncol 2014;4:233. [PMID: 25221748 DOI: 10.3389/fonc.2014.00233] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
65 Kulkarni AA, Fujioka N, Reinhardt L, Patel MR, Kratzke RA. Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC. Lung Cancer Manag 2022;11:LMT54. [PMID: 35463918 DOI: 10.2217/lmt-2021-0001] [Reference Citation Analysis]
66 Costa HA, Neal JW, Bustamante CD, Zehnder JL. Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer. Mol Diagn Ther 2017;21:431-6. [PMID: 28357677 DOI: 10.1007/s40291-017-0275-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
67 Tan WL, Ng QS, Lim C, Tan EH, Toh CK, Ang MK, Kanesvaran R, Jain A, Tan DSW, Lim DW. Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. BMC Cancer 2018;18:1198. [PMID: 30509246 DOI: 10.1186/s12885-018-5110-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
68 Andrews Wright NM, Goss GD. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Transl Lung Cancer Res 2019;8:S247-64. [PMID: 31857949 DOI: 10.21037/tlcr.2019.06.01] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
69 Yang G, Liu C, Hu J, Sun Y, Hu P, Liu L, Xu H, Li D, Li W, Yang Y, Sun N, He J, Wang Y. The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors. Front Oncol 2022;12:843299. [DOI: 10.3389/fonc.2022.843299] [Reference Citation Analysis]
70 Vishwanathan K, Dickinson PA, So K, Thomas K, Chen YM, De Castro Carpeño J, Dingemans AC, Kim HR, Kim JH, Krebs MG, Chih-Hsin Yang J, Bui K, Weilert D, Harvey RD. The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. Br J Clin Pharmacol 2018;84:1156-69. [PMID: 29381826 DOI: 10.1111/bcp.13534] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
71 Mancheril BG, Aubrey Waddell J, Solimando DA Jr. Drug monographs: afatinib and obinutuzumab. Hosp Pharm 2014;49:237-41. [PMID: 24715741 DOI: 10.1310/hpj4903-237] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
72 Patil VM, Noronha V, Joshi A, Choughule AB, Bhattacharjee A, Kumar R, Goud S, More S, Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open 2017;2:e000168. [PMID: 28761735 DOI: 10.1136/esmoopen-2017-000168] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
73 Pignata M, Chouaid C, Le Lay K, Luciani L, McConnachie C, Gordon J, Roze S. Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France. Clinicoecon Outcomes Res 2017;9:655-68. [PMID: 29123418 DOI: 10.2147/CEOR.S136657] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
74 Chien CR, Chen HJ. Lazarus response to treatment of patients with lung cancer and oncogenic mutations in the intensive care unit. J Thorac Dis 2016;8:E1455-61. [PMID: 28066630 DOI: 10.21037/jtd.2016.11.110] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Zhang H. Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer. Drug Des Devel Ther 2016;10:3867-72. [PMID: 27920501 DOI: 10.2147/DDDT.S119162] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
76 Mazza V, Cappuzzo F. Treating EGFR mutation resistance in non-small cell lung cancer - role of osimertinib. Appl Clin Genet 2017;10:49-56. [PMID: 28794650 DOI: 10.2147/TACG.S103471] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
77 Yoshimura A, Yamada T, Okura N, Takeda T, Furutani W, Kubota Y, Shiotsu S, Hiranuma O, Nishioka N, Chihara Y, Tamiya N, Kaneko Y, Uchino J, Takayama K. The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations. BMC Cancer 2018;18:1241. [PMID: 30537950 DOI: 10.1186/s12885-018-5153-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Wang J, Bai H, Hong C, Wang J, Mei TH. Analyzing epidermal growth factor receptor mutation status changes in advanced non-small-cell lung cancer at different sampling time-points of blood within one day. Thorac Cancer 2017;8:312-9. [PMID: 28437026 DOI: 10.1111/1759-7714.12443] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
79 Spicer J, Irshad S, Ang JE, Enting D, Kristeleit R, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, de Bono J. A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 2017;79:17-27. [PMID: 27872953 DOI: 10.1007/s00280-016-3189-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
80 Domvri K, Zarogoulidis P, Darwiche K, Browning RF, Li Q, Turner JF, Kioumis I, Spyratos D, Porpodis K, Papaiwannou A, Tsiouda T, Freitag L, Zarogoulidis K. Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy. J Cancer 2013;4:736-54. [PMID: 24312144 DOI: 10.7150/jca.7734] [Cited by in Crossref: 32] [Cited by in F6Publishing: 52] [Article Influence: 3.6] [Reference Citation Analysis]
81 Peretti U, Ferrara R, Pilotto S, Kinspergher S, Caccese M, Santo A, Brunelli M, Caliò A, Carbognin L, Sperduti I, Garassino M, Chilosi M, Scarpa A, Tortora G, Bria E. ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations. Respir Res 2016;17:105. [PMID: 27561692 DOI: 10.1186/s12931-016-0422-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
82 Ninatti G, Kirienko M, Neri E, Sollini M, Chiti A. Imaging-Based Prediction of Molecular Therapy Targets in NSCLC by Radiogenomics and AI Approaches: A Systematic Review. Diagnostics (Basel) 2020;10:E359. [PMID: 32486314 DOI: 10.3390/diagnostics10060359] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
83 Folch E, Costa DB, Wright J, VanderLaan PA. Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis. Transl Lung Cancer Res 2015;4:392-403. [PMID: 26380180 DOI: 10.3978/j.issn.2218-6751.2015.08.02] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
84 Wang H, Guo R, Zhang L. [TKI Resistance for T790M Mutation]. Zhongguo Fei Ai Za Zhi 2015;18:245-50. [PMID: 25936890 DOI: 10.3779/j.issn.1009-3419.2015.04.10] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 Dong L, Lei D, Zhang H. Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients. Oncotarget 2017;8:64600-6. [PMID: 28969097 DOI: 10.18632/oncotarget.19925] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
86 O'Kane GM, Leighl NB. Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives. Transl Lung Cancer Res 2016;5:628-36. [PMID: 28149757 DOI: 10.21037/tlcr.2016.09.05] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
87 Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, Dy GK, Ou SI, Stephens PJ, McPherson JD, Lara PN Jr, Burich RA, Ross JS, Miller VA, Ali SM, Mack PC, Schrock AB. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. J Thorac Oncol 2018;13:1560-8. [PMID: 29981927 DOI: 10.1016/j.jtho.2018.06.019] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 10.5] [Reference Citation Analysis]
88 Mooradian MJ, Piotrowska Z, Drapkin BJ, Dias-Santagata D, Marcoux N, Arnaoutakis K, Nagy RJ, Lanman R, Iafrate AJ, Farago AF, Mino-Kenudson M, Hata AN, Sequist LV. Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer-Transformed EGFR Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol 2017;1. [PMID: 31032471 DOI: 10.1200/PO.17.00123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
89 Proto C, Imbimbo M, Gallucci R, Brissa A, Signorelli D, Vitali M, Macerelli M, Corrao G, Ganzinelli M, Greco FG, Garassino MC, Lo Russo G. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. Transl Lung Cancer Res 2016;5:563-78. [PMID: 28149752 DOI: 10.21037/tlcr.2016.10.16] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
90 Liu Z, Ou W, Li N, Wang SY. Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy. Thorac Cancer 2018;9:1285-90. [PMID: 30126078 DOI: 10.1111/1759-7714.12836] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
91 Prasad V, Kumar H, Mailankody S. Ethics of Clinical Trials in Low-Resource Settings: Lessons From Recent Trials in Cancer Medicine. J Glob Oncol 2016;2:1-3. [PMID: 28717675 DOI: 10.1200/JGO.2015.000885] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
92 Saad S, Huang K, Halmos B. Overcoming resistance to EGF receptor tyrosine kinase inhibitors in EGFR -mutated NSCLC. Lung Cancer Management 2014;3:459-76. [DOI: 10.2217/lmt.14.35] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
93 Chmielecki J, Ross JS, Wang K, Frampton GM, Palmer GA, Ali SM, Palma N, Morosini D, Miller VA, Yelensky R. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. Oncologist. 2015;20:7-12. [PMID: 25480824 DOI: 10.1634./theoncologist.2014-0234] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Wang J, Wang B, Chu H, Yao Y. Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. Onco Targets Ther 2016;9:3711-26. [PMID: 27382309 DOI: 10.2147/OTT.S106399] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
95 Hayashi H, Nadal E, Gray JE, Ardizzoni A, Caria N, Puri T, Grohe C. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations. Clin Lung Cancer 2021:S1525-7304(21)00273-4. [PMID: 34865963 DOI: 10.1016/j.cllc.2021.10.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
96 Seiwert TY, Fayette J, Cupissol D, Del Campo JM, Clement PM, Hitt R, Degardin M, Zhang W, Blackman A, Ehrnrooth E, Cohen EEW. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol 2014;25:1813-20. [PMID: 24928832 DOI: 10.1093/annonc/mdu216] [Cited by in Crossref: 120] [Cited by in F6Publishing: 104] [Article Influence: 15.0] [Reference Citation Analysis]
97 Zou B, Lee VHF, Chen L, Ma L, Wang DD, Yan H. Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations. Sci Rep 2017;7:6595. [PMID: 28747773 DOI: 10.1038/s41598-017-06632-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
98 Califano R, Tariq N, Compton S, Fitzgerald DA, Harwood CA, Lal R, Lester J, McPhelim J, Mulatero C, Subramanian S, Thomas A, Thatcher N, Nicolson M. Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK. Drugs 2015;75:1335-48. [PMID: 26187773 DOI: 10.1007/s40265-015-0434-6] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 10.0] [Reference Citation Analysis]
99 Ando Y, Hayashi T, Ujita M, Murai S, Ohta H, Ito K, Yamaguchi T, Funatsu M, Ikeda Y, Imaizumi K, Kawada K, Yasuda K, Yamada S. Effect of renal function on pemetrexed-induced haematotoxicity. Cancer Chemother Pharmacol 2016;78:183-9. [PMID: 27286996 DOI: 10.1007/s00280-016-3078-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
100 Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16:e165-e172. [PMID: 25846096 DOI: 10.1016/s1470-2045(14)71180-5] [Cited by in Crossref: 331] [Cited by in F6Publishing: 248] [Article Influence: 47.3] [Reference Citation Analysis]
101 Salawu A, Hansen AR, Spreafico A, Al-ezzi E, Webster S, Bedard PL, Doi J, Wang L, Siu LL, Abdul Razak AR. A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study. Targ Oncol. [DOI: 10.1007/s11523-022-00884-z] [Reference Citation Analysis]
102 Vengoji R, Macha MA, Nimmakayala RK, Rachagani S, Siddiqui JA, Mallya K, Gorantla S, Jain M, Ponnusamy MP, Batra SK, Shonka N. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. J Exp Clin Cancer Res 2019;38:266. [PMID: 31215502 DOI: 10.1186/s13046-019-1264-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
103 Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046-1061. [PMID: 24893891 DOI: 10.1158/2159-8290.cd-14-0337] [Cited by in Crossref: 1059] [Cited by in F6Publishing: 547] [Article Influence: 132.4] [Reference Citation Analysis]
104 Blumenthal GM, Karuri SW, Zhang H, Zhang L, Khozin S, Kazandjian D, Tang S, Sridhara R, Keegan P, Pazdur R. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. J Clin Oncol 2015;33:1008-14. [PMID: 25667291 DOI: 10.1200/JCO.2014.59.0489] [Cited by in Crossref: 116] [Cited by in F6Publishing: 62] [Article Influence: 16.6] [Reference Citation Analysis]
105 Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. Int J Clin Oncol 2019;24:731-70. [PMID: 31049758 DOI: 10.1007/s10147-019-01431-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
106 Villadolid J, Ersek JL, Fong MK, Sirianno L, Story ES. Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance. Transl Lung Cancer Res 2015;4:576-83. [PMID: 26629426 DOI: 10.3978/j.issn.2218-6751.2015.10.01] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
107 Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther 2019;4:5. [PMID: 30854234 DOI: 10.1038/s41392-019-0038-9] [Cited by in Crossref: 81] [Cited by in F6Publishing: 81] [Article Influence: 27.0] [Reference Citation Analysis]
108 Sogawa R, Saita T, Yamamoto Y, Kimura S, Narisawa Y, Kimura S, Shin M. Development of a competitive enzyme-linked immunosorbent assay for therapeutic drug monitoring of afatinib. J Pharm Anal 2019;9:49-54. [PMID: 30740257 DOI: 10.1016/j.jpha.2018.09.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
109 Chevallier M, Borgeaud M, Addeo A, Friedlaender A. Oncogenic driver mutations in non-small cell lung cancer: Past, present and future . World J Clin Oncol 2021; 12(4): 217-237 [PMID: 33959476 DOI: 10.5306/wjco.v12.i4.217] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
110 Kong Y, Xu H, Huang Y, Wei Z, Ye X. Local thermal ablative therapies for extracranial oligometastatic disease of non-small-cell lung cancer. Asia Pac J Clin Oncol 2022. [PMID: 35599449 DOI: 10.1111/ajco.13766] [Reference Citation Analysis]
111 Landi L, Cappuzzo F. Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer. Ann Transl Med 2015;3:32. [PMID: 25815293 DOI: 10.3978/j.issn.2305-5839.2015.02.12] [Reference Citation Analysis]
112 Anjali VR, Pandey R, Srivastava A, Rajeshwari M, Pandey D, Sharma MC. Sequential EGFR mutation and ALK rearrangement in adenocarcinoma lung, with rare metastasis to bilateral breast, ovary and endometrium. Respir Med Case Rep 2019;28:100954. [PMID: 31720204 DOI: 10.1016/j.rmcr.2019.100954] [Reference Citation Analysis]
113 Holleman MS, Al MJ, Zaim R, Groen HJM, Uyl-de Groot CA. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. Eur J Health Econ 2020;21:153-64. [PMID: 31541309 DOI: 10.1007/s10198-019-01117-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
114 Sellmann L, Fenchel K, Dempke WC. Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer-the Holy Grail in cancer treatment? Transl Lung Cancer Res 2015;4:223-7. [PMID: 26207209 DOI: 10.3978/j.issn.2218-6751.2015.03.01] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
115 Wang S, Min X, Yang Y, Pei G, Liu Q, Liu J, Huang Y. [Comprehensive Treatment of An Advanced Lung Cancer Patient with 
EGFR Driver Gene Positive]. Zhongguo Fei Ai Za Zhi 2021;24:447-52. [PMID: 34157804 DOI: 10.3779/j.issn.1009-3419.2021.101.20] [Reference Citation Analysis]
116 Formisano L, Jansen VM, Marciano R, Bianco R. From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer. Anticancer Agents Med Chem 2018;18:1235-40. [PMID: 28901258 DOI: 10.2174/1871520617666170912123416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
117 Xu H, Chen H, Kong J, Zhang Y, Liu S, Yang G, Yang L, Wang Y. Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status. Ann Transl Med 2021;9:937. [PMID: 34350252 DOI: 10.21037/atm-21-1249] [Reference Citation Analysis]
118 Khaddour K, Jonna S, Deneka A, Patel JD, Abazeed ME, Golemis E, Borghaei H, Boumber Y. Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. Cancers (Basel) 2021;13:3164. [PMID: 34202748 DOI: 10.3390/cancers13133164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
119 Robichaux JP, Le X, Vijayan RSK, Hicks JK, Heeke S, Elamin YY, Lin HY, Udagawa H, Skoulidis F, Tran H, Varghese S, He J, Zhang F, Nilsson MB, Hu L, Poteete A, Rinsurongkawong W, Zhang X, Ren C, Liu X, Hong L, Zhang J, Diao L, Madison R, Schrock AB, Saam J, Raymond V, Fang B, Wang J, Ha MJ, Cross JB, Gray JE, Heymach JV. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature 2021;597:732-7. [PMID: 34526717 DOI: 10.1038/s41586-021-03898-1] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
120 ten Berge DM, Aarts MJ, Groen HJ, Aerts JG, Kloover JS. A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands. European Journal of Cancer 2022;165:195-204. [DOI: 10.1016/j.ejca.2022.01.038] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
121 Hayashi H, Yonesaka K, Nakamura A, Fujimoto D, Azuma K, Sakata S, Tachihara M, Ikeda S, Yokoyama T, Hataji O, Yano Y, Hirano K, Daga H, Okada H, Chiba Y, Sakai K, Nishio K, Yamamoto N, Nakagawa K. Alternating Therapy with Osimertinib and Afatinib for Treatment-Naive Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer: A Single-Group, Open-Label Phase 2 Trial (WJOG10818L). Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.04.004] [Reference Citation Analysis]
122 Wang Y, Wan Q, Xia X, Hu J, Liao Y, Wang P, Peng Y, Liu H, Li X. Value of radiomics model based on multi-parametric magnetic resonance imaging in predicting epidermal growth factor receptor mutation status in patients with lung adenocarcinoma. J Thorac Dis 2021;13:3497-508. [PMID: 34277045 DOI: 10.21037/jtd-20-3358] [Reference Citation Analysis]
123 Santarpia M, Liguori A, Karachaliou N, Gonzalez-Cao M, Daffinà MG, D'Aveni A, Marabello G, Altavilla G, Rosell R. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer (Auckl) 2017;8:109-25. [PMID: 28860885 DOI: 10.2147/LCTT.S119644] [Cited by in Crossref: 16] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
124 Economopoulou P, Mountzios G. The emerging treatment landscape of advanced non-small cell lung cancer. Ann Transl Med 2018;6:138. [PMID: 29862227 DOI: 10.21037/atm.2017.11.07] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
125 Zhu Z, Chai Y. Complete remission of liver metastasis in a lung cancer patient with epidermal growth factor mutation achieved with Icotinib. Thorac Cancer 2016;7:681-3. [PMID: 27807951 DOI: 10.1111/1759-7714.12380] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
126 Yang JC, Reckamp KL, Kim YC, Novello S, Smit EF, Lee JS, Su WC, Akerley WL, Blakely CM, Groen HJM, Bazhenova L, Carcereny Costa E, Chiari R, Hsia TC, Golsorkhi T, Despain D, Shih D, Popat S, Wakelee H. Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. JTO Clin Res Rep 2021;2:100114. [PMID: 34589984 DOI: 10.1016/j.jtocrr.2020.100114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
127 Tsiara A, Liontos M, Kaparelou M, Zakopoulou R, Bamias A, Dimopoulos MA. Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Ann Transl Med 2018;6:144. [PMID: 29862233 DOI: 10.21037/atm.2018.02.07] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
128 Cohen NA, Kim TS, DeMatteo RP. Principles of Kinase Inhibitor Therapy for Solid Tumors. Ann Surg 2017;265:311-9. [PMID: 27058947 DOI: 10.1097/SLA.0000000000001740] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
129 Chukwueke UN, Brastianos PK. Precision Medical Approaches to the Diagnoses and Management of Brain Metastases. Curr Treat Options Oncol 2019;20:49. [PMID: 31062107 DOI: 10.1007/s11864-019-0649-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
130 Takeda M, Nakagawa K. First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer? Int J Mol Sci 2019;20:E146. [PMID: 30609789 DOI: 10.3390/ijms20010146] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 19.3] [Reference Citation Analysis]
131 Lim C, Sekhon HS, Cutz JC, Hwang DM, Kamel-Reid S, Carter RF, Santos GDC, Waddell T, Binnie M, Patel M, Paul N, Chung T, Brade A, El-Maraghi R, Sit C, Tsao MS, Leighl NB. Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario. Curr Oncol 2017;24:103-10. [PMID: 28490924 DOI: 10.3747/co.24.3495] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
132 Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. [DOI: 10.1038/s41571-022-00639-9] [Reference Citation Analysis]
133 Gelatti ACZ, Drilon A, Santini FC. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer. 2019;137:113-122. [PMID: 31568888 DOI: 10.1016/j.lungcan.2019.09.017] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 13.3] [Reference Citation Analysis]
134 Mazzocchi A, Devarasetty M, Herberg S, Petty WJ, Marini F, Miller L, Kucera G, Dukes DK, Ruiz J, Skardal A, Soker S. Pleural Effusion Aspirate for use in 3D Lung Cancer Modeling and Chemotherapy Screening. ACS Biomater Sci Eng 2019;5:1937-43. [PMID: 31723594 DOI: 10.1021/acsbiomaterials.8b01356] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
135 Sakata Y, Kawamura K, Shingu N, Hiroshige S, Yasuda Y, Eguchi Y, Anan K, Hisanaga J, Nitawaki T, Nakano A, Ichikado K. The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events. Asia Pac J Clin Oncol 2020;16:e113-7. [PMID: 30506897 DOI: 10.1111/ajco.13103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
136 Qiu Y, Yin X, Li X, Wang Y, Fu Q, Huang R, Lu S. Untangling Dual-Targeting Therapeutic Mechanism of Epidermal Growth Factor Receptor (EGFR) Based on Reversed Allosteric Communication. Pharmaceutics 2021;13:747. [PMID: 34070173 DOI: 10.3390/pharmaceutics13050747] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
137 Schuler M, Fischer JR, Grohé C, Gütz S, Thomas M, Kimmich M, Schneider CP, Laack E, Märten A; Afatinib Compassionate Use Consortium. Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib. Oncologist 2014;19:1100-9. [PMID: 25232040 DOI: 10.1634/theoncologist.2014-0103] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
138 Jiang W, Zeng A, Ning R, Zhao W, Su C, Wang H, Zhou S, Yu Q. Predictive value of tumor genetic alteration profiling for chemotherapy and EGFR-TKI treatment in advanced NSCLC. Oncol Lett 2020;19:3859-70. [PMID: 32382334 DOI: 10.3892/ol.2020.11502] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
139 Katayama Y, Yamada T, Tokuda S, Okura N, Nishioka N, Morimoto K, Tanimura K, Morimoto Y, Iwasaku M, Horinaka M, Sakai T, Kita K, Yano S, Takayama K. Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR ‐T790M mutation in non‐small cell lung cancer cells. Cancer Medicine. [DOI: 10.1002/cam4.4504] [Reference Citation Analysis]
140 Saxon JA, Sholl LM, Jänne PA. EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib. J Thorac Oncol 2017;12:884-9. [PMID: 28088511 DOI: 10.1016/j.jtho.2017.01.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
141 Challa S, Guo JP, Ding X, Xu CX, Li Y, Kim D, Smith MA, Cress DW, Coppola D, Haura EB, Cheng JQ. IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non-Small Cell Lung Cancer with Activating Mutations of EGFR. Cancer Res 2016;76:4418-29. [PMID: 27287717 DOI: 10.1158/0008-5472.CAN-16-0069] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
142 Rybarczyk-Kasiuchnicz A, Ramlau R, Stencel K. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma. Int J Mol Sci 2021;22:E593. [PMID: 33435596 DOI: 10.3390/ijms22020593] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
143 Ito K, Murotani K, Kubo A, Kunii E, Taniguchi H, Shindoh J, Asada K, Imaizumi K, Takahashi K, Karayama M, Okuno M, Inui N, Hataji O, Morikawa S, Hayai S, Suda T, Abe T, Tsuda T, Yamagichi T, Kimura T, Oya Y, Yoshida T, Hida T. Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world data. Cancer Sci 2020;111:3705-13. [PMID: 32639668 DOI: 10.1111/cas.14560] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
144 Raman R, Ramamohan V, Rathore A, Jain D, Mohan A, Vashistha V. Prevalence of highly actionable mutations among Indian patients with advanced non-small cell lung cancer: A systematic review and meta-analysis. Asia Pac J Clin Oncol 2022. [PMID: 35634796 DOI: 10.1111/ajco.13802] [Reference Citation Analysis]
145 Riely GJ, Neal JW, Camidge DR, Spira AI, Piotrowska Z, Costa DB, Tsao AS, Patel JD, Gadgeel SM, Bazhenova L, Zhu VW, West HL, Mekhail T, Gentzler RD, Nguyen D, Vincent S, Zhang S, Lin J, Bunn V, Jin S, Li S, Jänne PA. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. Cancer Discov 2021;11:1688-99. [PMID: 33632775 DOI: 10.1158/2159-8290.CD-20-1598] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
146 Zwitter M, Stanic K, Rajer M, Kern I, Vrankar M, Edelbaher N, Kovac V. Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations. Radiol Oncol 2014;48:361-8. [PMID: 25435849 DOI: 10.2478/raon-2014-0038] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
147 Pottier C, Fresnais M, Gilon M, Jérusalem G, Longuespée R, Sounni NE. Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. Cancers (Basel) 2020;12:E731. [PMID: 32244867 DOI: 10.3390/cancers12030731] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 27.5] [Reference Citation Analysis]
148 Huang KY, Wang TH, Chen CC, Leu YL, Li HJ, Jhong CL, Chen CY. Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin. Biomolecules 2021;11:1271. [PMID: 34572484 DOI: 10.3390/biom11091271] [Reference Citation Analysis]
149 Yu HA, Sima CS, Hellmann MD, Naidoo J, Busby N, Rodriguez K, Riely GJ, Kris MG. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas. Cancer 2015;121:2078-82. [PMID: 25781862 DOI: 10.1002/cncr.29313] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
150 Kawana S, Saito R, Miki Y, Kimura Y, Abe J, Sato I, Endo M, Sugawara S, Sasano H. Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma. Cancer Med 2021;10:718-27. [PMID: 33305905 DOI: 10.1002/cam4.3639] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
151 Ouyang Y, Zhao B, Chen X, Wang C, Zhang H, Jia S, Zhu W, Zheng P. Design, Synthesis and Antitumor Activity of Quinazoline Derivatives Bearing 2,3-Dihydro-indole or 1,2,3,4-Tetrahydroquinoline. LDDD 2019;16:533-46. [DOI: 10.2174/1570180815666180801121220] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
152 Popat S, Jung HA, Lee SY, Hochmair MJ, Lee SH, Escriu C, Lee MK, Migliorino MR, Lee YC, Girard N, Daoud H, Märten A, Miura S. Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG). Lung Cancer 2021;162:9-15. [PMID: 34649106 DOI: 10.1016/j.lungcan.2021.09.009] [Reference Citation Analysis]
153 Kawasumi K, Kujirai A, Matsui R, Kawano Y, Yamaguchi M, Aoyama T. Survey of serious adverse events and safety evaluation of oral anticancer drug treatment in Japan: A retrospective study. Mol Clin Oncol 2021;14:12. [PMID: 33282287 DOI: 10.3892/mco.2020.2174] [Reference Citation Analysis]
154 Daoud A, Chu QS. Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer. Front Oncol 2017;7:222. [PMID: 29034207 DOI: 10.3389/fonc.2017.00222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
155 Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, Arcila ME, Arrieta O, Planchard D, de Marinis F, Dingemans AM, Dziadziuszko R, Faivre-Finn C, Feldman J, Felip E, Curigliano G, Herbst R, Jänne PA, John T, Mitsudomi T, Mok T, Normanno N, Paz-Ares L, Ramalingam S, Sequist L, Vansteenkiste J, Wistuba II, Wolf J, Wu YL, Yang SR, Yang JCH, Yatabe Y, Pentheroudakis G, Peters S. ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer. Ann Oncol 2022:S0923-7534(22)00112-0. [PMID: 35176458 DOI: 10.1016/j.annonc.2022.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
156 Del Re M, Tiseo M, Bordi P, D'Incecco A, Camerini A, Petrini I, Lucchesi M, Inno A, Spada D, Vasile E, Citi V, Malpeli G, Testa E, Gori S, Falcone A, Amoroso D, Chella A, Cappuzzo F, Ardizzoni A, Scarpa A, Danesi R. Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. Oncotarget 2017;8:13611-9. [PMID: 26799287 DOI: 10.18632/oncotarget.6957] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 10.8] [Reference Citation Analysis]
157 Bria E, Pilotto S, Amato E, Fassan M, Novello S, Peretti U, Vavalà T, Kinspergher S, Righi L, Santo A, Brunelli M, Corbo V, Giglioli E, Sperduti I, Milella M, Chilosi M, Scarpa A, Tortora G. Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. Oncotarget 2015;6:12783-95. [PMID: 25904052 DOI: 10.18632/oncotarget.3727] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 6.7] [Reference Citation Analysis]
158 Greillier L, Tomasini P, Barlesi F. The clinical utility of tumor mutational burden in non-small cell lung cancer. Transl Lung Cancer Res 2018;7:639-46. [PMID: 30505708 DOI: 10.21037/tlcr.2018.10.08] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 12.3] [Reference Citation Analysis]
159 Zhao B, Wang Y, Wang Y, Chen W, Zhou L, Liu PH, Kong Z, Dai C, Wang Y, Ma W. Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses. Aging (Albany NY) 2020;12:14244-70. [PMID: 32669477 DOI: 10.18632/aging.103455] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
160 Reungwetwattana T, Rohatgi N, Mok TS, Prabhash K. Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer. Expert Review of Precision Medicine and Drug Development 2021;6:161-71. [DOI: 10.1080/23808993.2021.1909420] [Reference Citation Analysis]
161 Wang A, Zhang X, Yi J, Zhu M, Zhang Y. Successful treatment of advanced lung adenocarcinoma complicated with Lambert-Eaton myasthenic syndrome: A case report and literature review. Thorac Cancer 2020;11:1334-8. [PMID: 32154996 DOI: 10.1111/1759-7714.13385] [Reference Citation Analysis]
162 Kuo SW, Chen PH, Lu TP, Chen KC, Liao HC, Tsou KC, Tsai TM, Lin MW, Hsu HH, Chen JS. Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Retrospective Case-Control Study. Ann Surg Oncol 2022. [PMID: 35254583 DOI: 10.1245/s10434-022-11483-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
163 Ando T, Arang N, Wang Z, Costea DE, Feng X, Goto Y, Izumi H, Gilardi M, Ando K, Gutkind JS. EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1. Commun Biol 2021;4:1237. [PMID: 34725466 DOI: 10.1038/s42003-021-02744-4] [Reference Citation Analysis]
164 Xia L, Wang H, Xiao H, Lan B, Liu J, Yang Z. EEF1A2 and ERN2 could potentially discriminate metastatic status of mediastinal lymph node in lung adenocarcinomas harboring EGFR 19Del/L858R mutations. Thorac Cancer 2020;11:2755-66. [PMID: 32881299 DOI: 10.1111/1759-7714.13554] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
165 Shonka N, Venur VA, Ahluwalia MS. Targeted Treatment of Brain Metastases. Curr Neurol Neurosci Rep 2017;17. [DOI: 10.1007/s11910-017-0741-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
166 Gozzo L, Navarria A, Drago V, Longo L, Mansueto S, Pignataro G, Cicchetti A, Salomone S, Drago F. Linking the Price of Cancer Drug Treatments to Their Clinical Value. Clin Drug Investig 2016;36:579-89. [PMID: 27153824 DOI: 10.1007/s40261-016-0403-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
167 Nasser NJ, Gorenberg M, Agbarya A. First line Immunotherapy for Non-Small Cell Lung Cancer. Pharmaceuticals (Basel) 2020;13:E373. [PMID: 33171686 DOI: 10.3390/ph13110373] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
168 Arrieta O, Carmona A, de Jesus Vega MT, Lopez-Mejia M, Cardona AF. Skin communicates what we deeply feel: antibiotic prophylactic treatment to reduce epidermal growth factor receptor inhibitors induced rash in lung cancer (the Pan Canadian rash trial). Ann Transl Med 2016;4:313. [PMID: 27668233 DOI: 10.21037/atm.2016.08.19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
169 Hou H, Qin K, Liang Y, Zhang C, Liu D, Jiang H, Liu K, Zhu J, Lv H, Li T, Zhang X. Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC. Cancer Manag Res 2019;11:5665-75. [PMID: 31417310 DOI: 10.2147/CMAR.S201513] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
170 Wu H, Zhou J, Mei S, Wu D, Mu Z, Chen B, Xie Y, Ye Y, Liu J. Circulating exosomal microRNA-96 promotes cell proliferation, migration and drug resistance by targeting LMO7. J Cell Mol Med 2017;21:1228-36. [PMID: 28026121 DOI: 10.1111/jcmm.13056] [Cited by in Crossref: 57] [Cited by in F6Publishing: 68] [Article Influence: 9.5] [Reference Citation Analysis]
171 Liao BC, Griesing S, Yang JC. Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients. Ther Adv Med Oncol 2019;11:1758835919890286. [PMID: 31803256 DOI: 10.1177/1758835919890286] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
172 Davies RS, Smith C, Edwards G, Butler R, Parry D, Lester JF. Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma. Lung Cancer Int 2017;2017:9614938. [PMID: 28367333 DOI: 10.1155/2017/9614938] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
173 Tanaka F, Yoneda K. Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC). Surg Today 2016;46:25-37. [PMID: 25925615 DOI: 10.1007/s00595-015-1174-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
174 Saito Y, Matsui A, Michiyuki S, Morooka H, Ibi T, Yamauchi Y, Takahashi N, Shimizu Y, Ikeya T, Hoshi E, Sakao Y, Kawamura M. Loop-Mediated Isothermal Amplification as Point-of-Care Testing for EGFR-Mutated Lung Adenocarcinoma. Micromachines 2022;13:897. [DOI: 10.3390/mi13060897] [Reference Citation Analysis]
175 Lin JJ, Shaw AT. Resisting Resistance: Targeted Therapies in Lung Cancer. Trends Cancer 2016;2:350-64. [PMID: 27819059 DOI: 10.1016/j.trecan.2016.05.010] [Cited by in Crossref: 78] [Cited by in F6Publishing: 72] [Article Influence: 19.5] [Reference Citation Analysis]
176 Le T, Gerber DE. Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used? Cancers (Basel). 2019;11. [PMID: 30875928 DOI: 10.3390/cancers11030366] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
177 Serra-solé Ò, Pujol-riqué M, Camacho-cuartero L. Long progression-free survival with afatinib in a patient with heavily pretreated lung adenocarcinoma without common activating EGFR mutations. Lung Cancer Management 2015;4:263-9. [DOI: 10.2217/lmt.15.20] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
178 Felip E, Concha Á, de Castro J, Gómez-Román J, Garrido P, Ramírez J, Isla D, Sanz J, Paz-Ares L, López-Ríos F. Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2015;17:103-12. [PMID: 25351175 DOI: 10.1007/s12094-014-1248-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
179 Tamura T, Kawakado K, Makimoto G, Nakanishi M, Kuyama S. Limited effect of afatinib in a non-small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report. Thorac Cancer 2021;12:1770-4. [PMID: 33942527 DOI: 10.1111/1759-7714.13941] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
180 Panvichian R, Tantiwetrueangdet A, Sornmayura P, Leelaudomlipi S. Missense Mutations in Exons 18-24 of EGFR in Hepatocellular Carcinoma Tissues. Biomed Res Int 2015;2015:171845. [PMID: 26436086 DOI: 10.1155/2015/171845] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
181 Shi Y, Sun Y, Yu J, Ding C, Wang Z, Wang C, Wang D, Wang C, Wang Z, Wang M, Zhi X, Lu Y, Feng J, Liu Y, Liu X, Liu W, Wu G, Li X, Li K, Li E, Li W, Chen G, Chen Z, Yu P, Wu N, Wu M, Xiao W, Zhang L, Zhang Y, Zhang S, Yang S, Song X, Lin D, Luo R, Shan L, Zhou C, Zhou Z, Zhao Q, Hu C, Hu Y, Guo Q, Chang J, Huang C, Zeng X, Han B, Han X, Jia B, Han Y, Huang Y. [China Experts Consensus on the Diagnosis and Treatment of Advanced Stage Primary Lung Cancer (2016 Version)]. Zhongguo Fei Ai Za Zhi 2016;19:1-15. [PMID: 26805732 DOI: 10.3779/j.issn.1009-3419.2016.01.01] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
182 Tokudome N, Koh Y, Akamatsu H, Fujimoto D, Okamoto I, Nakagawa K, Hida T, Imamura F, Morita S, Yamamoto N. Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy. BMC Cancer 2020;20:103. [PMID: 32028909 DOI: 10.1186/s12885-020-6593-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
183 Deslypere G, Gullentops D, Wauters E, Vansteenkiste J. Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages? Ther Adv Med Oncol 2018;10:1758835918772810. [PMID: 29774061 DOI: 10.1177/1758835918772810] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
184 Gilardi L, de Marinis F, Grana CM. PET/CT characterization of non-small-cell lung cancer heterogeneity. Nucl Med Commun 2015;36:411-3. [PMID: 25816217 DOI: 10.1097/MNM.0000000000000270] [Reference Citation Analysis]
185 Womack JP, Varella-Garcia M, Camidge DR. Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure. J Thorac Oncol 2015;10:e115-8. [PMID: 26709484 DOI: 10.1097/JTO.0000000000000642] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
186 Yang B, Ji HS, Zhou CS, Dong H, Ma L, Ge YQ, Zhu CH, Tian JH, Zhang LJ, Zhu H, Lu GM. 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based radiomic features for prediction of epidermal growth factor receptor mutation status and prognosis in patients with lung adenocarcinoma. Transl Lung Cancer Res 2020;9:563-74. [PMID: 32676320 DOI: 10.21037/tlcr-19-592] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
187 Nguyen PA, Chang CC, Galvin CJ, Wang YC, An SY, Huang CW, Wang YH, Hsu MH, Li YJ, Yang HC. Statins use and its impact in EGFR-TKIs resistance to prolong the survival of lung cancer patients: A Cancer registry cohort study in Taiwan. Cancer Sci 2020;111:2965-73. [PMID: 32441434 DOI: 10.1111/cas.14493] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
188 Zhu J, Yang Q, Xu W. Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective. Pharmaceutics 2021;13:1500. [PMID: 34575576 DOI: 10.3390/pharmaceutics13091500] [Reference Citation Analysis]
189 Takayuki N, Keiko T, Junji U, Yoshiko K, Nobuyo T, Tadaaki Y, Koichi T. Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management. Biomed Res Int 2018;2018:8202971. [PMID: 29854794 DOI: 10.1155/2018/8202971] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
190 Tran HT, Lam VK, Elamin YY, Hong L, Colen R, Elshafeey NA, Hassan ISA, Altan M, Blumenschein GR, Rinsurongkawong W, Rivera MJ, Vasquez ME, Carter BW, Byers LE, Tsao AS, Gibbons DL, Fossella F, Glisson BS, Zhang J, Heymach JV. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. JCO Precis Oncol 2021;5:PO. [PMID: 34377884 DOI: 10.1200/PO.20.00532] [Reference Citation Analysis]
191 Takahama T, Sakai K, Takeda M, Azuma K, Hida T, Hirabayashi M, Oguri T, Tanaka H, Ebi N, Sawa T, Bessho A, Tachihara M, Akamatsu H, Bandoh S, Himeji D, Ohira T, Shimokawa M, Nakanishi Y, Nakagawa K, Nishio K. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study). Oncotarget 2016;7:58492-9. [PMID: 27542267 DOI: 10.18632/oncotarget.11303] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 11.0] [Reference Citation Analysis]
192 Ricciuti B, Brambilla M, Metro G, Baglivo S, Matocci R, Pirro M, Chiari R. Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. Med Oncol 2017;34:105. [PMID: 28444624 DOI: 10.1007/s12032-017-0967-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
193 Clay TD, Russell PA, Do H, Sundararajan V, Conron M, Wright GM, Solomon B, Dobrovic A, McLachlan SA, Moore MM. EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma. Med Oncol 2017;34:175. [PMID: 28879441 DOI: 10.1007/s12032-017-1031-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
194 Li X, Xing S, Dong Q. Epidermal growth factor receptor-mutant lung cancer in Down syndrome: a case presentation and review of the literature. Oncotarget 2017;8:55760-5. [PMID: 28903458 DOI: 10.18632/oncotarget.17406] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
195 Hu Y, Ren S, Yang L, Tong Z, Wang R, Han W, Zeng C, Li J, Xiao P, Wang L, Yu F, Liu W. Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series. Front Pharmacol 2022;13:912153. [DOI: 10.3389/fphar.2022.912153] [Reference Citation Analysis]
196 Camidge DR, Moran T, Demedts I, Grosch H, Mileham K, Molina J, Juan-vidal O, Bepler G, Goldman JW, Park K, Wallin J, Wijayawardana SR, Wang XA, Wacheck V, Smit E. A Randomized, Open-Label Phase 2 Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib. Clinical Lung Cancer 2022. [DOI: 10.1016/j.cllc.2022.03.003] [Reference Citation Analysis]
197 Roth JA, Goulart BH, Ravelo A, Kolkey H, Ramsey SD. Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities. Oncologist 2017;22:304-10. [PMID: 28242792 DOI: 10.1634/theoncologist.2016-0253] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
198 Wang S, Shi J, Ye Z, Dong D, Yu D, Zhou M, Liu Y, Gevaert O, Wang K, Zhu Y, Zhou H, Liu Z, Tian J. Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning. Eur Respir J 2019;53:1800986. [PMID: 30635290 DOI: 10.1183/13993003.00986-2018] [Cited by in Crossref: 101] [Cited by in F6Publishing: 76] [Article Influence: 33.7] [Reference Citation Analysis]
199 Wagner MJ, Cranmer LD, Loggers ET, Pollack SM. Propranolol for the treatment of vascular sarcomas. J Exp Pharmacol 2018;10:51-8. [PMID: 30233257 DOI: 10.2147/JEP.S146211] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
200 Hasegawa Y, Ando M, Maemondo M, Yamamoto S, Isa S, Saka H, Kubo A, Kawaguchi T, Takada M, Rosell R, Kurata T, Ou SH. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials. Oncologist 2015;20:307-15. [PMID: 25657199 DOI: 10.1634/theoncologist.2014-0285] [Cited by in Crossref: 24] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
201 Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, Yang JC, Barrett JC, Jänne PA. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2016;34:3375-82. [PMID: 27354477 DOI: 10.1200/JCO.2016.66.7162] [Cited by in Crossref: 489] [Cited by in F6Publishing: 302] [Article Influence: 81.5] [Reference Citation Analysis]
202 Drilon A, Hu ZI, Lai GGY, Tan DSW. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol 2018;15:151-67. [PMID: 29134959 DOI: 10.1038/nrclinonc.2017.175] [Cited by in Crossref: 98] [Cited by in F6Publishing: 97] [Article Influence: 19.6] [Reference Citation Analysis]
203 Rajan A, Schrump DS. Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond. Semin Thorac Cardiovasc Surg 2015;27:36-48. [PMID: 26074108 DOI: 10.1053/j.semtcvs.2015.04.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
204 Tanaka M, Ishii H, Moribuchi H, Naito Y, Matsuo N, Nakamura M, Tokito T, Azuma K, Yamada K, Hoshino T. Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation. Invest New Drugs 2018;36:715-7. [PMID: 29546681 DOI: 10.1007/s10637-018-0586-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
205 Salvador-Coloma C, Lorente D, Palanca S, Simarro J, Mancheño N, Sandoval J, Lahoz A, Juan Ó. Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations. J Thorac Dis 2018;10:1386-93. [PMID: 29707288 DOI: 10.21037/jtd.2018.02.30] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
206 Rybarczyk-Kasiuchnicz A, Ramlau R. Current views on molecularly targeted therapy for lung cancer - a review of literature from the last five years. Kardiochir Torakochirurgia Pol 2018;15:119-24. [PMID: 30069193 DOI: 10.5114/kitp.2018.76478] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
207 Yufen X, Binbin S, Wenyu C, Jialiang L, Xinmei Y. The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer. Springerplus 2016;5:1244. [PMID: 27536527 DOI: 10.1186/s40064-016-2873-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
208 Breitenbuecher F, Hoffarth S, Worm K, Cortes-Incio D, Gauler TC, Köhler J, Herold T, Schmid KW, Freitag L, Kasper S, Schuler M. Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients. PLoS One 2014;9:e85350. [PMID: 24465542 DOI: 10.1371/journal.pone.0085350] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
209 Vu TH, Nguyen HTT, Dao LK, Duong CK, Nguyen CV, Doan TT, Nguyen HTT, Hoang HH, Dinh DK, Le GV, Vu TT, Truong MC, Nguyen LT. Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam. Asian Pac J Cancer Prev 2021;22:1581-90. [PMID: 34048189 DOI: 10.31557/APJCP.2021.22.5.1581] [Reference Citation Analysis]
210 Garon EB, Abarca PA, Strunck JL, Nameth D, Neumann C, Wolf B, Kim KY, Marx C, Elashoff RM. Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come. Crit Rev Oncog 2015;20:339-47. [PMID: 27279233 DOI: 10.1615/CritRevOncog.v20.i5-6.70] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
211 Yu W, Lu W, Chen G, Cheng F, Su H, Chen Y, Liu M, Pang X. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo. Br J Pharmacol 2017;174:3608-22. [PMID: 28749535 DOI: 10.1111/bph.13961] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
212 Poonia S, Berge EM, Aisner DL, Damek D, Doebele RC. EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: clinical correlations and response to therapy. Clin Lung Cancer 2014;15:387-9. [PMID: 24894944 DOI: 10.1016/j.cllc.2014.04.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
213 Liao BC, Lin CC, Yang JC. Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. Curr Oncol Rep 2017;19:4. [PMID: 28138934 DOI: 10.1007/s11912-017-0560-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
214 Nishimura T, Nakamura H, Yachie A, Hase T, Fujii K, Koizumi H, Naruki S, Takagi M, Matsuoka Y, Furuya N, Kato H, Saji H. Disease-related cellular protein networks differentially affected under different EGFR mutations in lung adenocarcinoma. Sci Rep 2020;10:10881. [PMID: 32616892 DOI: 10.1038/s41598-020-67894-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
215 Zhang Y, He D, Fang W, Kang S, Chen G, Hong S, Sheng J, Zhan J, Chen N, Hu Z, Xue C, Yang Y, Ma Y, Qin T, Zhou T, Huang Y, Zhang L. The Difference of Clinical Characteristics Between Patients With Exon 19 Deletion and Those With L858R Mutation in Nonsmall Cell Lung Cancer. Medicine (Baltimore) 2015;94:e1949. [PMID: 26554801 DOI: 10.1097/MD.0000000000001949] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
216 Pan H, Jiang T, Cheng N, Wang Q, Ren S, Li X, Zhao C, Zhang L, Cai W, Zhou C. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer. Oncotarget 2016;7:49948-60. [PMID: 27409677 DOI: 10.18632/oncotarget.10521] [Cited by in Crossref: 62] [Cited by in F6Publishing: 67] [Article Influence: 15.5] [Reference Citation Analysis]
217 Melosky B. Rapidly changing treatment algorithms for metastatic nonsquamous non-small-cell lung cancer. Curr Oncol 2018;25:S68-76. [PMID: 29910649 DOI: 10.3747/co.25.3839] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
218 Melosky B, Blais N, Cheema P, Couture C, Juergens R, Kamel-Reid S, Tsao MS, Wheatley-Price P, Xu Z, Ionescu DN. Standardizing biomarker testing for Canadian patients with advanced lung cancer. Curr Oncol 2018;25:73-82. [PMID: 29507487 DOI: 10.3747/co.25.3867] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
219 Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S Jr, Brahmer JR, Ellis PM, Gajra A, Rackear N, Schiller JH, Smith TJ, Strawn JR, Trent D, Johnson DH; American Society of Clinical Oncology Clinical Practice. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015;33:3488-515. [PMID: 26324367 DOI: 10.1200/JCO.2015.62.1342] [Cited by in Crossref: 300] [Cited by in F6Publishing: 157] [Article Influence: 42.9] [Reference Citation Analysis]
220 Graham DM, Leighl NB. Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine. Front Oncol 2014;4:258. [PMID: 25295228 DOI: 10.3389/fonc.2014.00258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
221 Igawa S, Fukui T, Kasajima M, Ono T, Ozawa T, Kakegawa M, Kusuhara S, Sato T, Nakahara Y, Hisashi M, Sasaki J, Naoki K. First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study. Invest New Drugs 2021. [PMID: 34807331 DOI: 10.1007/s10637-021-01195-2] [Reference Citation Analysis]
222 Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci 2016;107:1179-86. [PMID: 27323238 DOI: 10.1111/cas.12996] [Cited by in Crossref: 152] [Cited by in F6Publishing: 151] [Article Influence: 25.3] [Reference Citation Analysis]
223 Palmirotta R, Lovero D, Cafforio P, Felici C, Mannavola F, Pellè E, Quaresmini D, Tucci M, Silvestris F. Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Ther Adv Med Oncol 2018;10:1758835918794630. [PMID: 30181785 DOI: 10.1177/1758835918794630] [Cited by in Crossref: 149] [Cited by in F6Publishing: 136] [Article Influence: 37.3] [Reference Citation Analysis]
224 Miyamoto S, Azuma K, Ishii H, Bessho A, Hosokawa S, Fukamatsu N, Kunitoh H, Ishii M, Tanaka H, Aono H, Nakahara Y, Kusaka K, Hosomi Y, Kikuchi N, Mori Y, Itani H, Hamada A, Yamada K, Okamoto H. Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial. JAMA Oncol 2020;6:e201250. [PMID: 32407455 DOI: 10.1001/jamaoncol.2020.1250] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
225 Tran LS, Pham HT, Tran VU, Tran TT, Dang AH, Le DT, Nguyen SL, Nguyen NV, Nguyen TV, Vo BT, Dao HT, Nguyen NH, Tran TH, Nguyen CV, Pham PC, Dang-Mai AT, Dinh-Nguyen TK, Phan VH, Do TT, Truong Dinh K, Do HN, Phan MD, Giang H, Nguyen HN. Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients. PLoS One 2019;14:e0226193. [PMID: 31841547 DOI: 10.1371/journal.pone.0226193] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
226 Abdallah SM, Wong A. Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options? Curr Oncol 2018;25:S103-14. [PMID: 29910653 DOI: 10.3747/co.25.3733] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
227 Ichiki M, Wataya H, Yamada K, Tsuruta N, Takeoka H, Okayama Y, Sasaki J, Hoshino T. Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer. Onco Targets Ther 2017;10:5107-13. [PMID: 29123409 DOI: 10.2147/OTT.S145613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
228 Hanna NH, Dahlberg SE, Kolesar JM, Aggarwal C, Hirsch FR, Ramalingam SS, Schiller JH. Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). Cancer 2015;121:2253-61. [PMID: 25740387 DOI: 10.1002/cncr.29308] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
229 Cho JH, Lim SH, An HJ, Kim KH, Park KU, Kang EJ, Choi YH, Ahn MS, Lee MH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).J Clin Oncol. 2020;38:488-495. [PMID: 31825714 DOI: 10.1200/JCO.19.00931] [Cited by in Crossref: 73] [Cited by in F6Publishing: 44] [Article Influence: 24.3] [Reference Citation Analysis]
230 Hirsh V. Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors. Ther Adv Med Oncol 2018;10:1758834017753338. [PMID: 29383041 DOI: 10.1177/1758834017753338] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 8.3] [Reference Citation Analysis]
231 Tsimberidou AM. Targeted therapy in cancer. Cancer Chemother Pharmacol 2015;76:1113-32. [PMID: 26391154 DOI: 10.1007/s00280-015-2861-1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 9.0] [Reference Citation Analysis]
232 Xu N, Fang W, Mu L, Tang Y, Gao L, Ren S, Cao D, Zhou L, Zhang A, Liu D, Zhou C, Wong KK, Yu L, Zhang L, Chen L. Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer. Oncotarget 2016;7:3884-96. [PMID: 26646697 DOI: 10.18632/oncotarget.6461] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
233 Attili I, Passaro A, Spaggiari L, Spitaleri G, de Marinis F. Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way. Ann Transl Med 2020;8:1111. [PMID: 33145330 DOI: 10.21037/atm.2020.04.35] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
234 Zago G, Muller M, van den Heuvel M, Baas P. New targeted treatments for non-small-cell lung cancer - role of nivolumab. Biologics 2016;10:103-17. [PMID: 27536062 DOI: 10.2147/BTT.S87878] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
235 Rangachari D, Costa DB. Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease. Transl Cancer Res 2017;6:S151-7. [PMID: 30613479 DOI: 10.21037/tcr.2017.02.28] [Reference Citation Analysis]
236 Wen S, Dai L, Wang L, Wang W, Wu D, Wang K, He Z, Wang A, Chen H, Zhang P, Dong X, Dong YA, Wang K, Yao M, Wang M. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. Oncologist 2019;24:e1070-81. [PMID: 30902917 DOI: 10.1634/theoncologist.2018-0572] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 7.7] [Reference Citation Analysis]
237 Pasini L, Ulivi P. Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers. J Clin Med 2019;8:E998. [PMID: 31323990 DOI: 10.3390/jcm8070998] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
238 Leighl NB, Rizvi NA, de Lima LG Jr, Arpornwirat W, Rudin CM, Chiappori AA, Ahn MJ, Chow LQ, Bazhenova L, Dechaphunkul A, Sunpaweravong P, Eaton K, Chen J, Medley S, Poondru S, Singh M, Steinberg J, Juergens RA, Gadgeel SM. Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. Clin Lung Cancer 2017;18:34-42.e2. [PMID: 27686971 DOI: 10.1016/j.cllc.2016.07.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
239 Wang G, Xu J, Qi Y, Xiu J, Li R, Han M. Distribution Of Brain Metastasis From Lung Cancer. Cancer Manag Res 2019;11:9331-8. [PMID: 31802951 DOI: 10.2147/CMAR.S222920] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
240 Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. Clin Lung Cancer 2020;21:e191-204. [PMID: 31859066 DOI: 10.1016/j.cllc.2019.11.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
241 Gu W, Zhu Y, Ye D. Beyond chemotherapy for advanced disease-the role of EGFR and PD-1 inhibitors. Transl Androl Urol 2017;6:848-54. [PMID: 29184782 DOI: 10.21037/tau.2017.03.92] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
242 Cao Y, Qiu X, Xiao G, Hu H, Lin T. Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study. PLoS One 2019;14:e0221575. [PMID: 31442277 DOI: 10.1371/journal.pone.0221575] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
243 Longo V, Catino A, Montrone M, Pizzutilo P, Pesola F, Marech I, Capone I, Prelaj A, Galetta D. Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib. Thorac Cancer 2021;12:2031-4. [PMID: 34008923 DOI: 10.1111/1759-7714.13953] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
244 Cheng WC, Hsia TC, Tu CY, Chen HJ. The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy. Onco Targets Ther 2020;13:13425-35. [PMID: 33447048 DOI: 10.2147/OTT.S279540] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
245 Kasahara N, Imai H, Naruse I, Tsukagoshi Y, Kotake M, Sunaga N, Kaira K, Maeno T, Asao T, Hisada T. Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment. Thorac Cancer 2020;11:2188-95. [PMID: 32495520 DOI: 10.1111/1759-7714.13526] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
246 Chen YC, Tsai MJ, Lee MH, Kuo CY, Shen MC, Tsai YM, Chen HC, Hung JY, Huang MS, Chong IW, Yang CJ. Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations. BMC Cancer 2021;21:495. [PMID: 33941115 DOI: 10.1186/s12885-021-08235-3] [Reference Citation Analysis]
247 Wang S, Xing P, Yang K, Hao X, Ma D, Mu Y, Li J. Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations. Thorac Cancer 2019;10:1461-8. [PMID: 31095895 DOI: 10.1111/1759-7714.13095] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
248 Seshacharyulu P, Baine MJ, Souchek JJ, Menning M, Kaur S, Yan Y, Ouellette MM, Jain M, Lin C, Batra SK. Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochim Biophys Acta Rev Cancer 2017;1868:69-92. [PMID: 28249796 DOI: 10.1016/j.bbcan.2017.02.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
249 Owen S, Souhami L. The management of brain metastases in non-small cell lung cancer. Front Oncol 2014;4:248. [PMID: 25309873 DOI: 10.3389/fonc.2014.00248] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
250 To C, Jang J, Chen T, Park E, Mushajiang M, De Clercq DJH, Xu M, Wang S, Cameron MD, Heppner DE, Shin BH, Gero TW, Yang A, Dahlberg SE, Wong KK, Eck MJ, Gray NS, Jänne PA. Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. Cancer Discov 2019;9:926-43. [PMID: 31092401 DOI: 10.1158/2159-8290.CD-18-0903] [Cited by in Crossref: 73] [Cited by in F6Publishing: 30] [Article Influence: 24.3] [Reference Citation Analysis]
251 Kuan FC, Kuo LT, Chen MC, Yang CT, Shi CS, Teng D, Lee KD. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. Br J Cancer 2015;113:1519-28. [PMID: 26461059 DOI: 10.1038/bjc.2015.356] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 7.3] [Reference Citation Analysis]
252 Liao BC, Lin CC, Shih JY, Yang JC. Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. Ther Adv Med Oncol 2015;7:274-90. [PMID: 26327925 DOI: 10.1177/1758834015590593] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
253 Alshami J, Guiot MC, Owen S, Kavan P, Gibson N, Solca F, Cseh A, Reardon DA, Muanza T. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report. Oncotarget 2015;6:34030-7. [PMID: 26423602 DOI: 10.18632/oncotarget.5297] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
254 Hopkins AM, Nguyen AM, Karapetis CS, Rowland A, Sorich MJ. Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials. Cancers (Basel) 2018;10:E384. [PMID: 30326638 DOI: 10.3390/cancers10100384] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
255 Fuggetta MP, Migliorino MR, Ricciardi S, Osman G, Iacono D, Leone A, Lombardi A, Ravagnan G, Greco S, Remotti D, Romano MCP. Prophylactic Dermatologic Treatment of Afatinib-Induced Skin Toxicities in Patients with Metastatic Lung Cancer: A Pilot Study. Scientifica (Cairo) 2019;2019:9136249. [PMID: 30838155 DOI: 10.1155/2019/9136249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
256 Shinohara S, Ichiki Y, Fukuichi Y, Honda Y, Kanayama M, Taira A, Nabe Y, Kuwata T, Takenaka M, Oka S, Chikaishi Y, Hirai A, Imanishi N, Kuroda K, Yoneda K, Noguchi H, Tanaka F. Squamous cell carcinoma transformation from adenocarcinoma as an acquired resistance after the EGFR TKI therapy in (EGFR-mutated) non-small cell lung cancer. J Thorac Dis 2018;10:E526-31. [PMID: 30174925 DOI: 10.21037/jtd.2018.06.83] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
257 Tran PN, Klempner SJ. Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer. Lung Cancer (Auckl) 2016;7:91-7. [PMID: 28210165 DOI: 10.2147/LCTT.S94337] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
258 Gondi SR, Bera AK, Westover KD. Green Synthesis of Substituted Anilines and Quinazolines from Isatoic Anhydride-8-amide. Sci Rep 2019;9:14258. [PMID: 31582788 DOI: 10.1038/s41598-019-50776-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
259 Fu Y, Zhang Y, Lei Z, Liu T, Cai T, Wang A, Du W, Zeng Y, Zhu J, Liu Z, Huang JA. Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer. J Hematol Oncol 2020;13:169. [PMID: 33287873 DOI: 10.1186/s13045-020-01009-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
260 Khattab M, Wang F, Clayton AHA. A pH-induced conformational switch in a tyrosine kinase inhibitor identified by electronic spectroscopy and quantum chemical calculations. Sci Rep 2017;7:16271. [PMID: 29176733 DOI: 10.1038/s41598-017-16583-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
261 Yu HA, Riely GJ, Lovly CM. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. Clin Cancer Res 2014;20:5898-907. [PMID: 25303979 DOI: 10.1158/1078-0432.CCR-13-2437] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
262 Carcereny E, Morán T, Capdevila L, Cros S, Vilà L, de Los Llanos Gil M, Remón J, Rosell R. The epidermal growth factor receptor (EGRF) in lung cancer. Transl Respir Med 2015;3:1. [PMID: 25810955 DOI: 10.1186/s40247-015-0013-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
263 Delgado Sillero I, Lopetegui Lia N, Sánchez Cousido LF, Rojas Piedra M, Távara Silva B, Garrido Onecha ML, Medina Valdivieso S, Alonso Horcajo N, Díez Tascón C, López González A, Castañón López C, Pedraza Lorenzo M, García Palomo A, Martín V, Diz Tain P. EGFR-mutated advanced lung cancer. Data from a single institution, the Hospital of Leon, in Spain. J Oncol Pharm Pract 2022;:10781552221085253. [PMID: 35306915 DOI: 10.1177/10781552221085253] [Reference Citation Analysis]
264 Nacchio M, Sgariglia R, Gristina V, Pisapia P, Pepe F, De Luca C, Migliatico I, Clery E, Greco L, Vigliar E, Bellevicine C, Russo A, Troncone G, Malapelle U. KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting. J Thorac Dis 2020;12:3836-43. [PMID: 32802465 DOI: 10.21037/jtd.2020.01.19] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
265 Thomas R, Weihua Z. Rethink of EGFR in Cancer With Its Kinase Independent Function on Board. Front Oncol 2019;9:800. [PMID: 31508364 DOI: 10.3389/fonc.2019.00800] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
266 Thomas A, Liu SV, Subramaniam DS, Giaccone G. Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol 2015;12:511-26. [PMID: 25963091 DOI: 10.1038/nrclinonc.2015.90] [Cited by in Crossref: 155] [Cited by in F6Publishing: 157] [Article Influence: 22.1] [Reference Citation Analysis]
267 Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman JW. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34:2980-2987. [PMID: 27354485 DOI: 10.1200/jco.2016.66.9929] [Cited by in Crossref: 272] [Cited by in F6Publishing: 164] [Article Influence: 45.3] [Reference Citation Analysis]
268 Nakao A, Hiranuma O, Uchino J, Sakaguchi C, Araya T, Hiraoka N, Ishizuka T, Takeda T, Kawasaki M, Goto Y, Imai H, Hattori N, Nakatomi K, Uramoto H, Uryu K, Fukuda M, Uchida Y, Yokoyama T, Akai M, Mio T, Nagashima S, Chihara Y, Tamiya N, Kaneko Y, Mouri T, Yamada T, Yoshimura K, Fujita M, Takayama K. Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. J Clin Med 2020;9:E1762. [PMID: 32517152 DOI: 10.3390/jcm9061762] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
269 Wang C, Li Y, Ke L, Cao L, Fan P, Wu Z, Wu Q. The Impact of Afatinib on Survival in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. J Cancer 2019;10:885-92. [PMID: 30854094 DOI: 10.7150/jca.27528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
270 Digumarthy SR, Mendoza DP, Padole A, Chen T, Peterson PG, Piotrowska Z, Sequist LV. Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer. Cancers (Basel). 2019;11. [PMID: 31540242 DOI: 10.3390/cancers11091360] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
271 Qin S, Yu H, Wu X, Luo Z, Wang H, Sun S, Huang M, Jin J, Tao Z, Qiao J, Feng Y, Wang J, Chang J. Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study. Chin J Cancer Res 2019;31:339-48. [PMID: 31156304 DOI: 10.21147/j.issn.1000-9604.2019.02.08] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
272 Haentschel M, Boeckeler M, Bonzheim I, Schimmele F, Spengler W, Stanzel F, Petermann C, Darwiche K, Hagmeyer L, Buettner R, Tiemann M, Schildhaus HU, Muche R, Boesmueller H, Everinghoff F, Mueller R, Atique B, Lewis RA, Zender L, Fend F, Hetzel J. Influence of Biopsy Technique on Molecular Genetic Tumor Characterization in Non-Small Cell Lung Cancer-The Prospective, Randomized, Single-Blinded, Multicenter PROFILER Study Protocol. Diagnostics (Basel) 2020;10:E459. [PMID: 32640669 DOI: 10.3390/diagnostics10070459] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
273 Kim D, Lee YS, Kim DH, Bae SC. Lung Cancer Staging and Associated Genetic and Epigenetic Events. Mol Cells 2020;43:1-9. [PMID: 31999917 DOI: 10.14348/molcells.2020.2246] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
274 Abdallah SM, Hirsh V. Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer. Curr Oncol 2018;25:S9-S17. [PMID: 29910643 DOI: 10.3747/co.25.3732] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
275 Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, Camidge DR, Ou SI, Costa DB, Gadgeel SM, Steuer CE, Forde PM, Zhu VW, Fukuda Y, Clark JW, Jänne PA, Mok T, Sholl LM, Heist RS. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer 2019;133:96-102. [PMID: 31200835 DOI: 10.1016/j.lungcan.2019.05.011] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 11.7] [Reference Citation Analysis]
276 Park K, Wan-Teck Lim D, Okamoto I, Yang JC. First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting. Ther Adv Med Oncol 2019;11:1758835919836374. [PMID: 31019567 DOI: 10.1177/1758835919836374] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
277 Costa DB, Kobayashi SS. Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M. Transl Lung Cancer Res 2015;4:809-15. [PMID: 26798593 DOI: 10.3978/j.issn.2218-6751.2015.05.05] [Cited by in F6Publishing: 25] [Reference Citation Analysis]
278 Shaurova T, Zhang L, Goodrich DW, Hershberger PA. Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer. Front Genet 2020;11:281. [PMID: 32292420 DOI: 10.3389/fgene.2020.00281] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
279 Paz-ares L, Gondos A, Saldana D, Thomas M, Mascaux C, Bubendorf L, Barlesi F. Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.01.021] [Reference Citation Analysis]
280 Lee CS, Sharma S, Miao E, Mensah C, Sullivan K, Seetharamu N. A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity. Lung Cancer (Auckl) 2020;11:73-103. [PMID: 33117017 DOI: 10.2147/LCTT.S258444] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
281 Nishio M, Murakami H, Ohe Y, Hida T, Sakai H, Kasahara K, Imamura F, Baba T, Kubota K, Hosomi Y, Shimokawa T, Hayashi H, Miyadera K, Tamura T. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations. Invest New Drugs 2019;37:1207-17. [PMID: 30790152 DOI: 10.1007/s10637-019-00732-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
282 Schabath MB, Dalvi TB, Dai HA, Crim AL, Midha A, Shire N, Gimbrone NT, Walker J, Greenawalt DM, Lawrence D, Rigas JR, Brody R, Potter D, Kumar NS, Huntsman SA, Gray JE. A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer. Cancer Manag Res 2019;11:9469-81. [PMID: 31819612 DOI: 10.2147/CMAR.S218635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
283 Chen H, Zhang Q, Zhang Y, Jia B, Zhang B, Wang C. Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway. Onco Targets Ther 2018;11:8201-9. [PMID: 30568455 DOI: 10.2147/OTT.S173008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
284 Neel DS, Bivona TG. Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma. NPJ Precis Oncol 2017;1:3. [PMID: 29152593 DOI: 10.1038/s41698-017-0007-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 7.6] [Reference Citation Analysis]
285 Drilon A, Cappuzzo F, Ou SI, Camidge DR. Targeting MET in Lung Cancer: Will Expectations Finally Be MET? J Thorac Oncol. 2017;12:15-26. [PMID: 27794501 DOI: 10.1016/j.jtho.2016.10.014] [Cited by in Crossref: 145] [Cited by in F6Publishing: 152] [Article Influence: 24.2] [Reference Citation Analysis]
286 Park JE, Hong MJ, Lee SY, Lee JH, Choi JE, Kang HG, Do SK, Jeong JY, Shin KM, Lee WK, Choi SH, Lee YH, Seo HW, Yoo SS, Lee J, Cha SI, Kim CH, Park JY. Nuclear Pore Glycoprotein 62 Genetic Variant rs9523 is Associated with Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients. Pharmgenomics Pers Med 2021;14:1291-302. [PMID: 34629889 DOI: 10.2147/PGPM.S329055] [Reference Citation Analysis]
287 Roviello G. The distinctive nature of adenocarcinoma of the lung. Onco Targets Ther 2015;8:2399-406. [PMID: 26366094 DOI: 10.2147/OTT.S89225] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
288 Becker K, Xu Y. Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation. World J Clin Oncol 2014; 5(4): 560-567 [PMID: 25302160 DOI: 10.5306/wjco.v5.i4.560] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
289 Matsuo N, Azuma K, Sakai K, Hattori S, Kawahara A, Ishii H, Tokito T, Kinoshita T, Yamada K, Nishio K, Hoshino T. Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients. Sci Rep 2016;6:36458. [PMID: 27811988 DOI: 10.1038/srep36458] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 7.7] [Reference Citation Analysis]
290 Kurata T, Nakaya A, Yokoi T, Niki M, Kibata K, Takeyasu Y, Torii Y, Katashiba Y, Ogata M, Miyara T, Nomura S. Phase I/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation. Genes Cancer 2017;8:559-65. [PMID: 28740574 DOI: 10.18632/genesandcancer.145] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
291 Yang SC, Lin CC, Lai WW, Chang SM, Hwang JS, Su WC, Wang JD. Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer. Ther Adv Med Oncol 2018;10:1758834018755072. [PMID: 29434678 DOI: 10.1177/1758834018755072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
292 Tsironis G, Ziogas DC, Kyriazoglou A, Lykka M, Koutsoukos K, Bamias A, Dimopoulos MA. Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore? Ann Transl Med. 2018;6:143. [PMID: 29862232 DOI: 10.21037/atm.2018.02.18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
293 Yang K, Tian C, Zhang C, Xiang M. The Controversial Role of IL-33 in Lung Cancer. Front Immunol 2022;13:897356. [DOI: 10.3389/fimmu.2022.897356] [Reference Citation Analysis]
294 Blumenthal GM, Kluetz PG, Schneider J, Goldberg KB, McKee AE, Pazdur R. Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies. Oncologist 2017;22:762-7. [PMID: 28576856 DOI: 10.1634/theoncologist.2017-0152] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 7.6] [Reference Citation Analysis]
295 Melosky B, Leighl NB, Rothenstein J, Sangha R, Stewart D, Papp K. Management of egfr tki-induced dermatologic adverse events. Curr Oncol 2015;22:123-32. [PMID: 25908911 DOI: 10.3747/co.22.2430] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
296 Taverna S, Giallombardo M, Gil-Bazo I, Carreca AP, Castiglia M, Chacártegui J, Araujo A, Alessandro R, Pauwels P, Peeters M, Rolfo C. Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice. Oncotarget 2016;7:28748-60. [PMID: 26919248 DOI: 10.18632/oncotarget.7638] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 12.2] [Reference Citation Analysis]
297 Wu YL, Xu CR, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Märten A, Fan J, Peil B, Zhou C. Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial. Onco Targets Ther 2018;11:8575-87. [PMID: 30584317 DOI: 10.2147/OTT.S160358] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
298 Pirker R. Systemic therapy of elderly patients with advanced non-small cell lung cancer-individualized treatment is key. Ann Transl Med 2019;7:S48. [PMID: 31032327 DOI: 10.21037/atm.2019.03.10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
299 Jacobsen K, Bertran-Alamillo J, Molina MA, Teixidó C, Karachaliou N, Pedersen MH, Castellví J, Garzón M, Codony-Servat C, Codony-Servat J, Giménez-Capitán A, Drozdowskyj A, Viteri S, Larsen MR, Lassen U, Felip E, Bivona TG, Ditzel HJ, Rosell R. Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nat Commun 2017;8:410. [PMID: 28871105 DOI: 10.1038/s41467-017-00450-6] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 13.6] [Reference Citation Analysis]
300 Wang Y, Li RQ, Ai YQ, Zhang J, Zhao PZ, Li YF, He WJ, Xia YX, Li WH. Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients. Clin Transl Oncol 2015;17:727-36. [PMID: 26041721 DOI: 10.1007/s12094-015-1300-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
301 Tanaka H, Taima K, Itoga M, Ishioka Y, Baba K, Shiratori T, Sakamoto H, Tsuchiya J, Nakagawa H, Hasegawa Y, Yasugahira H, Okudera K, Takanashi S, Tasaka S. Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer. Med Oncol 2019;36:57. [PMID: 31089973 DOI: 10.1007/s12032-019-1278-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
302 Haratake N, Takenoyama M, Edagawa M, Shimamatsu S, Toyozawa R, Nosaki K, Hirai F, Yamaguchi M, Taguchi K, Seto T, Ichinose Y. A case of different EGFR mutations in surgically resected synchronous triple lung cancer. J Thorac Dis 2018;10:E255-9. [PMID: 29850164 DOI: 10.21037/jtd.2018.03.105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
303 Luo J, Makhnin A, Tobi Y, Ahn L, Hayes SA, Iqbal A, Ng K, Arcila ME, Riely GJ, Kris MG, Yu HA. Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor. JCO Precis Oncol 2021;5:PO. [PMID: 34250388 DOI: 10.1200/PO.20.00315] [Reference Citation Analysis]
304 Ikemura S, Yasuda H, Matsumoto S, Kamada M, Hamamoto J, Masuzawa K, Kobayashi K, Manabe T, Arai D, Nakachi I, Kawada I, Ishioka K, Nakamura M, Namkoong H, Naoki K, Ono F, Araki M, Kanada R, Ma B, Hayashi Y, Mimaki S, Yoh K, Kobayashi SS, Kohno T, Okuno Y, Goto K, Tsuchihara K, Soejima K. Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. Proc Natl Acad Sci U S A 2019;116:10025-30. [PMID: 31043566 DOI: 10.1073/pnas.1819430116] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
305 Chen YY, Yen YT, Lai WW, Huang WL, Chang CC, Tseng YL. Outcomes of salvage lung resections in advanced EGFR-mutant lung adenocarcinomas under EGFR TKIs. Thorac Cancer 2021;12:2655-65. [PMID: 34498378 DOI: 10.1111/1759-7714.13646] [Reference Citation Analysis]
306 Ercan D, Choi HG, Yun CH, Capelletti M, Xie T, Eck MJ, Gray NS, Jänne PA. EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. Clin Cancer Res 2015;21:3913-23. [PMID: 25948633 DOI: 10.1158/1078-0432.CCR-14-2789] [Cited by in Crossref: 202] [Cited by in F6Publishing: 119] [Article Influence: 28.9] [Reference Citation Analysis]
307 Karachaliou N, Gimenez-Capitan A, Drozdowskyj A, Viteri S, Moran T, Carcereny E, Massuti B, Vergnenegre A, de Marinis F, Molina MA, Teixido C, Rosell R. ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation. Transl Lung Cancer Res 2014;3:122-30. [PMID: 25806291 DOI: 10.3978/j.issn.2218-6751.2014.03.02] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
308 Sonehara K, Kobayashi T, Tateishi K, Morozumi N, Yoshiike F, Hachiya T, Ono Y, Takasuna K, Agatsuma T, Masubuchi T, Matsuo A, Tanaka H, Morikawa A, Hanaoka M, Koizumi T. Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group. Thorac Cancer 2019;10:1078-85. [PMID: 31006178 DOI: 10.1111/1759-7714.13047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
309 Pazarentzos E, Bivona TG. Adaptive stress signaling in targeted cancer therapy resistance. Oncogene 2015;34:5599-606. [PMID: 25703329 DOI: 10.1038/onc.2015.26] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
310 Xia P, Cao J, Lv X, Wang L, Lv W, Hu J. Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation. Thorac Cancer 2018;9:656-61. [PMID: 29575765 DOI: 10.1111/1759-7714.12624] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
311 Rangachari D, VanderLaan PA, Le X, Folch E, Kent MS, Gangadharan SP, Majid A, Haspel RL, Joseph LJ, Huberman MS, Costa DB. Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice. Cancer Treat Commun 2015;4:174-81. [PMID: 26601054 DOI: 10.1016/j.ctrc.2015.10.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
312 Tanaka H, Taima K, Tanaka Y, Itoga M, Ishioka Y, Nakagawa H, Baba K, Hasegawa Y, Takanashi S, Tasaka S. A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations. Med Oncol 2018;35:34. [PMID: 29423683 DOI: 10.1007/s12032-018-1098-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
313 Kauffmann-Guerrero D, Syunyaeva Z, Kahnert K, Tufman A. Excellent platinum dependent response to chemotherapy after relapse under TKI treatment in NSCLC with sensitizing EGFR mutations and no detectable resistance mutations: three case studies. AME Case Rep 2019;3:36. [PMID: 31728434 DOI: 10.21037/acr.2019.09.02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
314 Jazieh AR, Al Kattan K, Bamousa A, Al Olayan A, Abdelwarith A, Ansari J, Al Twairqi A, Al Fayea T, Al Saleh K, Al Husaini H, Abdelhafiez N, Mahrous M, Faris M, Al Omair A, Hebshi A, Al Shehri S, Al Dayel F, Bamefleh H, Khalbuss W, Al Ghanem S, Loutfi S, Khankan A, Al Rujaib M, Al Ghamdi M, Ibrahim N, Swied A, Al Kayait M, Datario M; AR Jazieh on Behalf of Saudi Lung Cancer Guidelines Association, Saudi Lung Cancer Guidelines Members. Saudi lung cancer management guidelines 2017. Ann Thorac Med 2017;12:221-46. [PMID: 29118855 DOI: 10.4103/atm.ATM_92_17] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
315 Shepherd-Littlejohn AL, Hanft WJ, Kennedy VA, Alvarez EA. Afatinib use in recurrent epithelial ovarian carcinoma. Gynecol Oncol Rep 2019;29:70-2. [PMID: 31360743 DOI: 10.1016/j.gore.2019.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
316 Gaut D, Sim MS, Yue Y, Wolf BR, Abarca PA, Carroll JM, Goldman JW, Garon EB. Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). Clin Lung Cancer 2018;19:e19-28. [PMID: 28712979 DOI: 10.1016/j.cllc.2017.06.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
317 Khoo C, Rogers TM, Fellowes A, Bell A, Fox S. Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. Transl Lung Cancer Res 2015;4:126-41. [PMID: 25870795 DOI: 10.3978/j.issn.2218-6751.2015.01.10] [Cited by in F6Publishing: 27] [Reference Citation Analysis]
318 Tsutani Y, Miyata Y, Masuda T, Fujitaka K, Doi M, Awaya Y, Kuyama S, Kitaguchi S, Ueda K, Hattori N, Okada M. Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study. BMC Cancer 2018;18:1231. [PMID: 30526545 DOI: 10.1186/s12885-018-5146-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
319 Belchis DA, Tseng LH, Gniadek T, Haley L, Lokhandwala P, Illei P, Gocke CD, Forde P, Brahmer J, Askin FB, Eshleman JR, Lin MT. Heterogeneity of resistance mutations detectable by nextgeneration sequencing in TKI-treated lung adenocarcinoma. Oncotarget 2016;7:45237-48. [PMID: 27304188 DOI: 10.18632/oncotarget.9931] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
320 Anguera G, Majem M. BRAF inhibitors in metastatic non-small cell lung cancer. J Thorac Dis 2018;10:589-92. [PMID: 29607117 DOI: 10.21037/jtd.2018.01.129] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
321 Kim Y, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib. Cancer Res Treat 2019;51:502-9. [PMID: 29898592 DOI: 10.4143/crt.2018.117] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
322 Nanjo S, Yamada T, Nishihara H, Takeuchi S, Sano T, Nakagawa T, Ishikawa D, Zhao L, Ebi H, Yasumoto K, Matsumoto K, Yano S. Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. PLoS One 2013;8:e84700. [PMID: 24386407 DOI: 10.1371/journal.pone.0084700] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
323 Nosaki K, Yamanaka T, Hamada A, Shiraishi Y, Harada T, Himeji D, Kitazaki T, Ebi N, Shimose T, Seto T, Takenoyama M, Sugio K. Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101). Oncologist 2020;25:e1869-78. [PMID: 32654250 DOI: 10.1634/theoncologist.2020-0640] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
324 Cheng B, Deng H, Zhao Y, Xiong J, Liang P, Li C, Liang H, Shi J, Li J, Xiong S, Lai T, Chen Z, Wu J, Qian T, Huan W, Ng MTA, He J, Liang W. Predicting EGFR mutation status in lung adenocarcinoma presenting as ground-glass opacity: utilizing radiomics model in clinical translation. Eur Radiol. [DOI: 10.1007/s00330-022-08673-y] [Reference Citation Analysis]
325 Song Z, Yu X, Zhang Y. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients. Cancer Biol Ther 2017;18:883-7. [PMID: 27635639 DOI: 10.1080/15384047.2016.1235660] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
326 Zhang XY, Cao R, Guo YJ, Zhen YH, Zheng JH, Huang LT, Zhang SL, Jing W, Sun L, Zhao JZ, Han CB, Ma JT. Impact of pulmonary interstitial lesions on efficacy and prognosis of EGFR-TKI-treated advanced non-small cell lung cancers. J Thorac Dis 2020;12:839-48. [PMID: 32274151 DOI: 10.21037/jtd.2019.12.128] [Reference Citation Analysis]
327 Chen X, Yang S, Ma S. [Drug induced hepatotoxicity in targeted therapy for lung cancer]. Zhongguo Fei Ai Za Zhi 2014;17:685-8. [PMID: 25248711 DOI: 10.3779/j.issn.1009-3419.2014.09.08] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
328 Batson S, Mitchell SA, Windisch R, Damonte E, Munk VC, Reguart N. Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis. Onco Targets Ther 2017;10:2473-82. [PMID: 28503070 DOI: 10.2147/OTT.S134382] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
329 Wecker H, Waller CF. Afatinib. Recent Results Cancer Res 2018;211:199-215. [PMID: 30069769 DOI: 10.1007/978-3-319-91442-8_14] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
330 Arrieta O, De la Torre-Vallejo M, López-Macías D, Orta D, Turcott J, Macedo-Pérez EO, Sánchez-Lara K, Ramírez-Tirado LA, Baracos VE. Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer. Oncologist 2015;20:967-74. [PMID: 26173839 DOI: 10.1634/theoncologist.2015-0058] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 6.7] [Reference Citation Analysis]
331 Ezeife DA, Melosky B, Tudor R, Lin S, Lau A, Panzarella T, Leighl NB. Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience. Curr Oncol 2018;25:e385-90. [PMID: 30464688 DOI: 10.3747/co.25.3914] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
332 Hsu PC, Jablons DM, Yang CT, You L. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). Int J Mol Sci 2019;20:E3821. [PMID: 31387256 DOI: 10.3390/ijms20153821] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 12.0] [Reference Citation Analysis]
333 Yao ZH, Liao WY, Ho CC, Chen KY, Shih JY, Chen JS, Lin ZZ, Lin CC, Chih-Hsin Yang J, Yu CJ. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib. Oncologist 2017;22:1075-83. [PMID: 28507206 DOI: 10.1634/theoncologist.2016-0331] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
334 Bylicki O, Guisier F, Monnet I, Doubre H, Gervais R, Janicot H, Perol M, Fournel P, Lamy R, Auliac JB, Chouaid C. Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma. Medicine (Baltimore) 2020;99:e18726. [PMID: 32011450 DOI: 10.1097/MD.0000000000018726] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
335 Kuan FC, Li SH, Wang CL, Lin MH, Tsai YH, Yang CT. Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions. Oncotarget 2017;8:1343-53. [PMID: 27935868 DOI: 10.18632/oncotarget.13815] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
336 Chen Z, Wei J, Ma X, Yu J. Efficacy of EGFR-TKIs with or without angiogenesis inhibitors in advanced non-small-cell lung cancer: A systematic review and meta-analysis. J Cancer 2020;11:686-95. [PMID: 31942192 DOI: 10.7150/jca.34957] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
337 Peng S, Wang R, Zhang X, Ma Y, Zhong L, Li K, Nishiyama A, Arai S, Yano S, Wang W. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Mol Cancer 2019;18:165. [PMID: 31747941 DOI: 10.1186/s12943-019-1073-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 42] [Article Influence: 11.3] [Reference Citation Analysis]
338 Arriola E, García Gómez R, Diz P, Majem M, Martínez Aguillo M, Valdivia J, Paredes A, Sánchez-Torres JM, Peralta Muñoz S, Barneto I, Gutierrez V, Andrade Santiago JM, Aparisi F, Isla D, Ponce S, Vicente Baz D, Artal A, Amador M, Provencio M. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. BMC Cancer 2018;18:106. [PMID: 29382302 DOI: 10.1186/s12885-018-4004-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
339 Ding T, Zhou F, Chen X, Zhang S, Liu Y, Sun H, Ren S, Li X, Zhao C, Wang H, Zhou C. Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations. J Thorac Dis 2017;9:2923-34. [PMID: 29221264 DOI: 10.21037/jtd.2017.07.107] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
340 Schwab CL, Bellone S, English DP, Roque DM, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. Br J Cancer 2014;111:1750-6. [PMID: 25268372 DOI: 10.1038/bjc.2014.519] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
341 Yoon BW, Kim JH, Lee SH, Choi CM, Rho JK, Yoon S, Lee DH, Kim SW, Jang TW, Lee JC. Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis. Transl Oncol 2019;12:852-8. [PMID: 31030101 DOI: 10.1016/j.tranon.2019.04.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
342 Juan O, Popat S. Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. Ther Adv Med Oncol 2017;9:201-16. [PMID: 28344665 DOI: 10.1177/1758834016687262] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
343 Conley BA, Staudt L, Takebe N, Wheeler DA, Wang L, Cardenas MF, Korchina V, Zenklusen JC, McShane LM, Tricoli JV, Williams PM, Lubensky I, O'Sullivan-Coyne G, Kohn E, Little RF, White J, Malik S, Harris LN, Mann B, Weil C, Tarnuzzer R, Karlovich C, Rodgers B, Shankar L, Jacobs PM, Nolan T, Berryman SM, Gastier-Foster J, Bowen J, Leraas K, Shen H, Laird PW, Esteller M, Miller V, Johnson A, Edmondson EF, Giordano TJ, Kim B, Ivy SP. The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. J Natl Cancer Inst 2021;113:27-37. [PMID: 32339229 DOI: 10.1093/jnci/djaa061] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
344 Zhang Y, Sheng J, Yang Y, Fang W, Kang S, He Y, Hong S, Zhan J, Zhao Y, Xue C, Ma Y, Zhou T, Ma S, Gao F, Qin T, Hu Z, Tian Y, Hou X, Huang Y, Zhou N, Zhao H, Zhang L. Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network meta-analysis. Oncotarget 2016;7:20093-108. [PMID: 26933807 DOI: 10.18632/oncotarget.7713] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
345 Oyama B, Morikawa K, Sakaguchi T, Tsunoda A, Kida H, Inoue T, Mineshita M. Drug-induced Hypersensitivity Syndrome by EGFR-TKI in a Patient with Lung Cancer. Intern Med 2021;60:441-4. [PMID: 33518612 DOI: 10.2169/internalmedicine.4237-19] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
346 Takeuchi S, Hase T, Shimizu S, Ando M, Hata A, Murakami H, Kawakami T, Nagase K, Yoshimura K, Fujiwara T, Tanimoto A, Nishiyama A, Arai S, Fukuda K, Katakami N, Takahashi T, Hasegawa Y, Ko TK, Ong ST, Yano S. Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer. Cancer Sci 2020;111:561-70. [PMID: 31782583 DOI: 10.1111/cas.14260] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
347 Yamaoka T, Ohba M, Ohmori T. Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. Int J Mol Sci 2017;18:E2420. [PMID: 29140271 DOI: 10.3390/ijms18112420] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 10.6] [Reference Citation Analysis]
348 Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Nat Commun 2019;10:259. [PMID: 30651547 DOI: 10.1038/s41467-018-08074-0] [Cited by in Crossref: 78] [Cited by in F6Publishing: 78] [Article Influence: 26.0] [Reference Citation Analysis]
349 Fang B, Mehran RJ, Heymach JV, Swisher SG. Predictive biomarkers in precision medicine and drug development against lung cancer. Chin J Cancer 2015;34:295-309. [PMID: 26134262 DOI: 10.1186/s40880-015-0028-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
350 Chen LY, You Q, Lv DZ, Li SH, Zhang SY. GPCR-mediated EGFR transactivation ameliorates skin toxicities induced by afatinib. Acta Pharmacol Sin 2022;43:1534-43. [PMID: 34552215 DOI: 10.1038/s41401-021-00774-6] [Reference Citation Analysis]
351 Nishio M, Kato T, Niho S, Yamamoto N, Takahashi T, Nogami N, Kaneda H, Fujita Y, Wilner K, Yoshida M, Isozaki M, Wada S, Tsuji F, Nakagawa K. Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer. Cancer Sci 2020;111:1724-38. [PMID: 32159882 DOI: 10.1111/cas.14384] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
352 Lee CS, Milone M, Seetharamu N. Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data. Onco Targets Ther 2021;14:4579-97. [PMID: 34471361 DOI: 10.2147/OTT.S227032] [Reference Citation Analysis]
353 Azuma K, Kawahara A, Sonoda K, Nakashima K, Tashiro K, Watari K, Izumi H, Kage M, Kuwano M, Ono M, Hoshino T. FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor. Oncotarget 2014;5:5908-19. [PMID: 25115383 DOI: 10.18632/oncotarget.1866] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 10.4] [Reference Citation Analysis]
354 Liu WJ, Huang YX, Wang W, Zhang Y, Liu BJ, Qiu JG, Jiang BH, Liu LZ. NOX4 Signaling Mediates Cancer Development and Therapeutic Resistance through HER3 in Ovarian Cancer Cells. Cells 2021;10:1647. [PMID: 34209278 DOI: 10.3390/cells10071647] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
355 Huang J, Pan B, Xia G, Zhu J, Li C, Feng J. LncRNA SNHG15 regulates EGFR-TKI acquired resistance in lung adenocarcinoma through sponging miR-451 to upregulate MDR-1. Cell Death Dis 2020;11:525. [PMID: 32655137 DOI: 10.1038/s41419-020-2683-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
356 Maione P, Sacco PC, Sgambato A, Casaluce F, Rossi A, Gridelli C. Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application. Ther Adv Med Oncol 2015;7:263-73. [PMID: 26327924 DOI: 10.1177/1758834015595048] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
357 Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017;376:629-640. [PMID: 27959700 DOI: 10.1056/nejmoa1612674] [Cited by in Crossref: 1373] [Cited by in F6Publishing: 820] [Article Influence: 228.8] [Reference Citation Analysis]
358 Geng Y, Mei Y, Xi Y, Yu J, Meng K, Zhang T, Ma W. Bilirubin Can Be Used as a Prognostic Factor for Lung Adenocarcinoma Patients with EGFR Mutations. Onco Targets Ther 2020;13:11089-95. [PMID: 33149620 DOI: 10.2147/OTT.S266477] [Reference Citation Analysis]
359 Zhao D, Chen X, Qin N, Su D, Zhou L, Zhang Q, Li X, Zhang X, Jin M, Wang J. The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer. Sci Rep 2017;7:40374. [PMID: 28079142 DOI: 10.1038/srep40374] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
360 Cortiula F, Pasello G, Follador A, Nardo G, Polo V, Scquizzato E, Del Conte A, Miorin M, Giovanis P, D'Urso A, Girlando S, Settanni G, Picece V, Veccia A, Corvaja C, Indraccolo S, De Maglio G. A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients. Diagnostics (Basel) 2020;10:E765. [PMID: 32998450 DOI: 10.3390/diagnostics10100765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
361 Heigener DF, Reck M. [Lung cancer : What has been confirmed in therapy?]. Internist (Berl) 2017;58:1258-63. [PMID: 29043377 DOI: 10.1007/s00108-017-0339-4] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
362 Chen JA, Riess JW. Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors. J Thorac Dis 2020;12:2859-76. [PMID: 32642199 DOI: 10.21037/jtd.2019.08.32] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
363 Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin Cancer Res 2014;20:2264-75. [PMID: 24599935 DOI: 10.1158/1078-0432.CCR-13-1591] [Cited by in Crossref: 45] [Cited by in F6Publishing: 21] [Article Influence: 5.6] [Reference Citation Analysis]
364 Schmidt KT, Chau CH, Price DK, Figg WD. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment. J Clin Pharmacol 2016;56:1484-99. [PMID: 27197880 DOI: 10.1002/jcph.765] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 8.8] [Reference Citation Analysis]
365 Schaufler D, Ast DF, Tumbrink HL, Abedpour N, Maas L, Schwäbe AE, Spille I, Lennartz S, Fassunke J, Aldea M, Besse B, Planchard D, Nogova L, Michels S, Kobe C, Persigehl T, Westphal T, Koleczko S, Fischer R, Weber J, Altmüller J, Thomas RK, Merkelbach-bruse S, Gautschi O, Mezquita L, Büttner R, Wolf J, Peifer M, Brägelmann J, Scheffler M, Sos ML. Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer. npj Precis Onc 2021;5. [DOI: 10.1038/s41698-021-00241-9] [Reference Citation Analysis]
366 Spiegel ML, Goldman JW, Wolf BR, Nameth DJ, Grogan TR, Lisberg AE, Wong DJL, Ledezma BA, Mendenhall MA, Genshaft SJ, Gutierrez AJ, Abtin F, Wallace WD, Adame CR, McKenzie JR, Abarca PA, Li AJ, Strunck JL, Famenini S, Carroll JM, Tucker DA, Sauer LM, Moghadam NM, Elashoff DA, Abaya CD, Brennan MB, Garon EB. Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges. Cancer 2017;123:4800-7. [PMID: 29125624 DOI: 10.1002/cncr.31056] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
367 Ishii H, Azuma K, Yamada K, Matsuo N, Nakamura M, Tokito T, Kinoshita T, Hoshino T. Accuracy of transbronchial biopsy as a rebiopsy method for patients with relapse of advanced non-small-cell lung cancer after systemic chemotherapy. BMJ Open Respir Res 2017;4:e000163. [PMID: 28123750 DOI: 10.1136/bmjresp-2016-000163] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
368 Salgia R, Mambetsariev I, Tan T, Schwer A, Pearlstein DP, Chehabi H, Baroz A, Fricke J, Pharaon R, Romo H, Waddington T, Babikian R, Buck L, Kulkarni P, Cianfrocca M, Djulbegovic B, Pal SK. Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting-Role of Academic and Hybrid Modeling. J Clin Med 2020;9:E1884. [PMID: 32560187 DOI: 10.3390/jcm9061884] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
369 Lampaki S, Lazaridis G, Zarogoulidis K, Kioumis I, Papaiwannou A, Tsirgogianni K, Karavergou A, Tsiouda T, Karavasilis V, Yarmus L, Darwiche K, Freitag L, Sakkas A, Kantzeli A, Baka S, Hohenforst-Schmidt W, Zarogoulidis P. Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer. J Cancer 2015;6:568-74. [PMID: 26000049 DOI: 10.7150/jca.11893] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
370 Nguyen KSH, Neal JW, Wakelee H. Review of the current targeted therapies for non-small-cell lung cancer. World J Clin Oncol 2014; 5(4): 576-587 [PMID: 25302162 DOI: 10.5306/wjco.v5.i4.576] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
371 Schallenberg S, Merkelbach-Bruse S, Buettner R. Lung cancer as a paradigm for precision oncology in solid tumours. Virchows Arch 2017;471:221-33. [PMID: 28730537 DOI: 10.1007/s00428-017-2183-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
372 Nardo G, Carlet J, Marra L, Bonanno L, Boscolo A, Dal Maso A, Boscolo Bragadin A, Indraccolo S, Zulato E. Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors. Front Oncol 2020;10:607840. [PMID: 33520716 DOI: 10.3389/fonc.2020.607840] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
373 Diver EJ, Foster R, Rueda BR, Growdon WB. The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer. Oncologist 2015;20:1058-68. [PMID: 26099744 DOI: 10.1634/theoncologist.2015-0149] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
374 Zhang Y, Sheng J, Kang S, Fang W, Yan Y, Hu Z, Hong S, Wu X, Qin T, Liang W, Zhang L. Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis. PLoS One 2014;9:e107161. [PMID: 25222496 DOI: 10.1371/journal.pone.0107161] [Cited by in Crossref: 84] [Cited by in F6Publishing: 96] [Article Influence: 10.5] [Reference Citation Analysis]
375 Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med 2013;5:216ra177. [PMID: 24353160 DOI: 10.1126/scitranslmed.3007205] [Cited by in Crossref: 258] [Cited by in F6Publishing: 242] [Article Influence: 32.3] [Reference Citation Analysis]
376 Bulbul A, Husain H. First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option? Front Oncol 2018;8:94. [PMID: 29755953 DOI: 10.3389/fonc.2018.00094] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
377 Alanazi A, Yunusa I, Elenizi K, Alzarea AI. Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis. Lung Cancer Manag 2020;10:LMT43. [PMID: 33318755 DOI: 10.2217/lmt-2020-0011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
378 Sala González MÁ. Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report. Cancer Biol Ther 2015;16:1434-7. [PMID: 26186355 DOI: 10.1080/15384047.2015.1070993] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
379 Pizzutilo EG, Lauricella C, Cerea G, Giannetta LG, Tomasello G, Stabile S, Motta V, Alexiadis S, Scaglione F, Vanzulli A, Torre M, Bonoldi E, Veronese SM, Siena S, Sartore-bianchi A. Concurrent Small-Cell Transformation and Emergence of Trans -C797S and T790M Mutations Under Sequential Treatment With EGFR Inhibitors in Lung Adenocarcinoma. JCO Precision Oncology 2019. [DOI: 10.1200/po.19.00229] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
380 Pagliarini R, Shao W, Sellers WR. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep. 2015;16:280-296. [PMID: 25680965 DOI: 10.15252/embr.201439949] [Cited by in Crossref: 132] [Cited by in F6Publishing: 118] [Article Influence: 18.9] [Reference Citation Analysis]
381 Shang Y, Li X, Liu W, Shi X, Yuan S, Huo R, Fang G, Han X, Zhang J, Wang K, Dou Z, Zhang Y, Zang A, Zhang L. Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib. Sci Rep 2020;10:20243. [PMID: 33219256 DOI: 10.1038/s41598-020-76791-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
382 Syed YY. therascreen® EGFR RGQ PCR Kit: A Companion Diagnostic for Afatinib and Gefitinib in Non-Small Cell Lung Cancer. Mol Diagn Ther 2016;20:191-8. [PMID: 26891729 DOI: 10.1007/s40291-016-0189-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
383 Liu L, Wang C, Li S, Bai H, Wang J. Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review. Transl Lung Cancer Res 2021;10:3823-39. [PMID: 34733631 DOI: 10.21037/tlcr-21-572] [Reference Citation Analysis]
384 Liang SK, Lee MR, Liao WY, Ho CC, Ko JC, Shih JY. Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study. Oncotarget 2018;9:23749-60. [PMID: 29805772 DOI: 10.18632/oncotarget.25255] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
385 Cho BC, Felip E, Hayashi H, Thomas M, Lu S, Besse B, Sun T, Martinez M, Sethi SN, Shreeve SM, Spira AI. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small cell lung cancer. Future Oncol 2021. [PMID: 34911336 DOI: 10.2217/fon-2021-0923] [Reference Citation Analysis]
386 Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 2020;77:1745-70. [PMID: 31690961 DOI: 10.1007/s00018-019-03351-7] [Cited by in Crossref: 157] [Cited by in F6Publishing: 151] [Article Influence: 52.3] [Reference Citation Analysis]
387 Wang X, Goldstein D, Crowe PJ, Yang JL. Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence. Onco Targets Ther 2016;9:5461-73. [PMID: 27660463 DOI: 10.2147/OTT.S94745] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
388 Pellerino A, Bruno F, Rudà R, Soffietti R. Systemic Therapy for Lung Cancer Brain Metastases. Curr Treat Options Oncol 2021;22:110. [PMID: 34693454 DOI: 10.1007/s11864-021-00911-7] [Reference Citation Analysis]
389 He SY, Lin QF, Chen J, Yu GP, Zhang JL, Shen D. Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report. World J Clin Cases 2021; 9(6): 1329-1335 [PMID: 33644199 DOI: 10.12998/wjcc.v9.i6.1329] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
390 Dong H, Yin H, Zhao C, Cao J, Xu W, Zhang Y. Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors. Molecules 2019;24:E2407. [PMID: 31261881 DOI: 10.3390/molecules24132407] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
391 Miyashita Y, Ko R, Shimada N, Mitsuishi Y, Miura K, Matsumoto N, Asao T, Shukuya T, Shibayama R, Koyama R, Takahashi K. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation. Thorac Cancer 2021;12:329-38. [PMID: 33219754 DOI: 10.1111/1759-7714.13742] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
392 Janning M, Süptitz J, Albers-Leischner C, Delpy P, Tufman A, Velthaus-Rusik JL, Reck M, Jung A, Kauffmann-Guerrero D, Bonzheim I, Brändlein S, Hummel HD, Wiesweg M, Schildhaus HU, Stratmann JA, Sebastian M, Alt J, Buth J, Esposito I, Berger J, Tögel L, Saalfeld FC, Wermke M, Merkelbach-Bruse S, Hillmer AM, Klauschen F, Bokemeyer C, Buettner R, Wolf J, Loges S. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). Ann Oncol 2022:S0923-7534(22)00361-1. [PMID: 35263633 DOI: 10.1016/j.annonc.2022.02.225] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
393 Fujiwara A, Yoshida M, Fujimoto H, Nakahara H, Ito K, Nishihama K, Yasuma T, Hataji O, Taguchi O, D'Alessandro-Gabazza CN, Gabazza EC, Kobayashi T. A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer. Oncol Res 2018;26:1031-6. [PMID: 29321093 DOI: 10.3727/096504018X15151523767752] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
394 Chen PY, Wang CC, Hsu CN, Chen CY. Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation. Front Pharmacol 2021;12:720687. [PMID: 34434112 DOI: 10.3389/fphar.2021.720687] [Reference Citation Analysis]
395 Wang LY, Cui JJ, Guo AX, Yin JY. Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients. Onco Targets Ther 2018;11:529-38. [PMID: 29416353 DOI: 10.2147/OTT.S136579] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
396 Liu X, Xu J. [Treatment of advanced NSCLC with unknown EGFR gene status
--TKI or chemotherapy?]. Zhongguo Fei Ai Za Zhi 2014;17:709-14. [PMID: 25342036 DOI: 10.3779/j.issn.1009-3419.2014.10.01] [Reference Citation Analysis]
397 Liu J, Zhang H, Zhu X, Chen H, Li X, Ding Y. Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors. Front Pharmacol 2021;12:636324. [PMID: 33679419 DOI: 10.3389/fphar.2021.636324] [Reference Citation Analysis]
398 Sebastian M, Papachristofilou A, Weiss C, Früh M, Cathomas R, Hilbe W, Wehler T, Rippin G, Koch SD, Scheel B, Fotin-Mleczek M, Heidenreich R, Kallen KJ, Gnad-Vogt U, Zippelius A. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer 2014;14:748. [PMID: 25288198 DOI: 10.1186/1471-2407-14-748] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 8.1] [Reference Citation Analysis]
399 Li X, Yang H, Xu H, Wang S, Gao H. [Response of Erlotinib in Lung Adenocarcinoma Harboring EGFR Sensitive Mutation in Cerebrospinal Fluid: Case Report]. Zhongguo Fei Ai Za Zhi 2016;19:52-6. [PMID: 26805738 DOI: 10.3779/j.issn.1009-3419.2016.01.07] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
400 Wu G, Zhou C, Bai C, Qian G. Chinese expert consensus on molecularly targeted therapy for advanced non-small cell lung cancer (2013 edition). J Thorac Dis 2014;6:1489-98. [PMID: 25364528 DOI: 10.3978/j.issn.2072-1439.2014.09.20] [Reference Citation Analysis]
401 O'Brien MER, Sarker D, Bhosle J, Thillai K, Yap TA, Uttenreuther-Fischer M, Pemberton K, Jin X, Wiebe S, de Bono J, Spicer J. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2018;82:757-66. [PMID: 30088048 DOI: 10.1007/s00280-018-3661-1] [Reference Citation Analysis]
402 Cheema PK, Thawer A, Leake J, Cheng SY, Khanna S, Charles Victor J. Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib. Support Care Cancer 2019;27:1029-39. [PMID: 30116943 DOI: 10.1007/s00520-018-4392-x] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
403 Raboso Moreno B, Marguenda Contreras P, Matesanz López C. Presentación radiológica infrecuente del adenocarcinoma de pulmón: a propósito de un caso clínico. Open Respiratory Archives 2021;3:100129. [DOI: 10.1016/j.opresp.2021.100129] [Reference Citation Analysis]
404 West H. Prioritizing molecular markers to test for in the initial workup of advanced non-small cell lung cancer: wants versus needs. Ann Transl Med 2017;5:371. [PMID: 29057231 DOI: 10.21037/atm.2017.08.29] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
405 Hirsh V. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib. BioDrugs 2015;29:167-83. [PMID: 26123538 DOI: 10.1007/s40259-015-0130-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
406 Hirsh V. New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib. Onco Targets Ther 2017;10:2513-26. [PMID: 28546756 DOI: 10.2147/OTT.S104177] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
407 Pignatti F, Wilking U, Postmus D, Wilking N, Delgado J, Bergh J. The value of anticancer drugs - a regulatory view. Nat Rev Clin Oncol 2021. [PMID: 34873312 DOI: 10.1038/s41571-021-00584-z] [Reference Citation Analysis]
408 Chiang AC, Fernandes AW, Pavilack M, Wu JW, Laliberté F, Duh MS, Chehab N, Subramanian J. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors. BMC Cancer 2020;20:356. [PMID: 32345265 DOI: 10.1186/s12885-020-06826-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
409 Cummings CT, Linger RM, Cohen RA, Sather S, Kirkpatrick GD, Davies KD, DeRyckere D, Earp HS, Graham DK. Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer. Oncotarget 2014;5:10434-45. [PMID: 25372020 DOI: 10.18632/oncotarget.2142] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
410 Liu Z, Han C, Fu YX. Targeting innate sensing in the tumor microenvironment to improve immunotherapy. Cell Mol Immunol 2020;17:13-26. [PMID: 31844141 DOI: 10.1038/s41423-019-0341-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
411 Kozuki T. Skin problems and EGFR-tyrosine kinase inhibitor. Jpn J Clin Oncol 2016;46:291-8. [PMID: 26826719 DOI: 10.1093/jjco/hyv207] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
412 Sehgal K, Rangachari D, VanderLaan PA, Kobayashi SS, Costa DB. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. Oncologist 2021;26:281-7. [PMID: 32969527 DOI: 10.1002/onco.13537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
413 Thongprasert S, Geater SL, Clement D, Abdelaziz A, Reyes-Igama J, Jovanovic D, Alexandru A, Schenker M, Sriuranpong V, Serwatowski P, Suresh S, Cseh A, Gaafar R. Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study. Lung Cancer Manag 2019;8:LMT15. [PMID: 31807143 DOI: 10.2217/lmt-2019-0004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
414 Bennati C, Paglialunga L, Ricciuti B, Metro G, Marcomigni L, Gili A, Crinò L. Targeting EGFR and ALK in NSCLC: current evidence and future perspective. Lung Cancer Manag 2016;5:79-90. [PMID: 30643552 DOI: 10.2217/lmt-2016-0005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
415 Normanno N, Fenizia F, Castiglione F, Barberis M, Taddei GL, Truini M, De Rosa G, Pinto C, Marchetti A. External quality assessment for EGFR mutations in Italy: improvements in performances over the time. ESMO Open 2017;2:e000160. [PMID: 29181190 DOI: 10.1136/esmoopen-2017-000160] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
416 Mohan A, Garg A, Gupta A, Sahu S, Choudhari C, Vashistha V, Ansari A, Pandey R, Bhalla AS, Madan K, Hadda V, Iyer H, Jain D, Kumar R, Mittal S, Tiwari P, Pandey RM, Guleria R. Clinical profile of lung cancer in North India: A 10-year analysis of 1862 patients from a tertiary care center. Lung India 2020;37:190-7. [PMID: 32367839 DOI: 10.4103/lungindia.lungindia_333_19] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
417 Hirashima T, Satouchi M, Hida T, Nishio M, Kato T, Sakai H, Imamura F, Kiura K, Okamoto I, Kasahara K, Uchida H, Vowler SL, Mitsudomi T. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis. Cancer Sci 2019;110:2884-93. [PMID: 31265163 DOI: 10.1111/cas.14120] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
418 Zhang T, Wan B, Zhao Y, Li C, Liu H, Lv T, Zhan P, Song Y. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Transl Lung Cancer Res 2019;8:302-16. [PMID: 31367543 DOI: 10.21037/tlcr.2019.04.12] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
419 Villaruz LC, Burns TF, Ramfidis VS, Socinski MA. Personalizing therapy in advanced non-small cell lung cancer. Semin Respir Crit Care Med 2013;34:822-36. [PMID: 24258572 DOI: 10.1055/s-0033-1358552] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
420 Tomasini P, Serdjebi C, Khobta N, Metellus P, Ouafik L, Nanni I, Greillier L, Loundou A, Fina F, Mascaux C, Barlesi F. EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer. Int J Mol Sci 2016;17:E2132. [PMID: 27999344 DOI: 10.3390/ijms17122132] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
421 Gregg JP, Li T, Yoneda KY. Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey. Transl Lung Cancer Res 2019;8:286-301. [PMID: 31367542 DOI: 10.21037/tlcr.2019.04.14] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
422 Cheng C, Zhuang H. [Treatment for Brain Metastases from EGFR Mutations NSCLC Patients: How Should We Choose in Clinical Practice?]. Zhongguo Fei Ai Za Zhi 2020;23:631-7. [PMID: 32746605 DOI: 10.3779/j.issn.1009-3419.2020.101.29] [Reference Citation Analysis]
423 Igawa S, Kasajima M, Ono T, Ozawa T, Kakegawa M, Kusuhara S, Sato T, Nakahara Y, Fukui T, Yokoba M, Kubota M, Mitsufuji H, Sasaki J, Naoki K. A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer. Cancer Manag Res 2021;13:8695-705. [PMID: 34849025 DOI: 10.2147/CMAR.S339891] [Reference Citation Analysis]
424 Freidlin B, Korn EL. Biomarker enrichment strategies: matching trial design to biomarker credentials. Nat Rev Clin Oncol 2014;11:81-90. [PMID: 24281059 DOI: 10.1038/nrclinonc.2013.218] [Cited by in Crossref: 104] [Cited by in F6Publishing: 80] [Article Influence: 11.6] [Reference Citation Analysis]
425 Liang W, Wu X, Fang W, Zhao Y, Yang Y, Hu Z, Xue C, Zhang J, Zhang J, Ma Y, Zhou T, Yan Y, Hou X, Qin T, Dinglin X, Tian Y, Huang P, Huang Y, Zhao H, Zhang L. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. PLoS One 2014;9:e85245. [PMID: 24533047 DOI: 10.1371/journal.pone.0085245] [Cited by in Crossref: 81] [Cited by in F6Publishing: 83] [Article Influence: 10.1] [Reference Citation Analysis]
426 Suda K, Bunn PA Jr, Rivard CJ, Mitsudomi T, Hirsch FR. Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench. J Thorac Oncol 2017;12:27-35. [PMID: 27642065 DOI: 10.1016/j.jtho.2016.09.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
427 Liu S, Yu J, Zhang H, Liu J. TP53 Co-Mutations in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy. Front Oncol 2022;12:860563. [PMID: 35444951 DOI: 10.3389/fonc.2022.860563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
428 Cadranel J. Osimertinib in first-line treatment-is a comparison not proof? Ann Transl Med 2018;6:57. [PMID: 29611546 DOI: 10.21037/atm.2017.12.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
429 Xue C, Tian Y, Zhang J, Zhao Y, Zhan J, Fang W, Zhang L. In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma. Drug Des Devel Ther 2016;10:1299-306. [PMID: 27099475 DOI: 10.2147/DDDT.S94432] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
430 Yamada T, Hirai S, Katayama Y, Yoshimura A, Shiotsu S, Watanabe S, Kikuchi T, Hirose K, Kubota Y, Chihara Y, Harada T, Tanimura K, Takeda T, Tamiya N, Kaneko Y, Uchino J, Takayama K. Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer. Cancer Med 2019;8:1521-9. [PMID: 30790471 DOI: 10.1002/cam4.2037] [Cited by in Crossref: 23] [Cited by in F6Publishing: 32] [Article Influence: 7.7] [Reference Citation Analysis]
431 Shi Z, Fan Y. [Optimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptor]. Zhongguo Fei Ai Za Zhi 2015;18:110-6. [PMID: 25676406 DOI: 10.3779/j.issn.1009-3419.2015.02.11] [Reference Citation Analysis]
432 Cheung CHY, Juan HF. Quantitative proteomics in lung cancer. J Biomed Sci 2017;24:37. [PMID: 28615068 DOI: 10.1186/s12929-017-0343-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
433 Simone CB 2nd, Burri SH, Heinzerling JH. Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies. Transl Lung Cancer Res 2015;4:545-52. [PMID: 26629423 DOI: 10.3978/j.issn.2218-6751.2015.10.05] [Cited by in F6Publishing: 32] [Reference Citation Analysis]
434 Li M, Li C, Ke L, Zhan M, Cheng M. Significance of the epidermal growth factor receptor mutation status and differences among molecular subgroups in surgically resected lung microinvasive adenocarcinoma. Oncol Lett 2018;16:7057-67. [PMID: 30546439 DOI: 10.3892/ol.2018.9539] [Reference Citation Analysis]
435 Ma X, Zhu H, Guo H, Han A, Wang H, Jing W, Zhang Y, Kong L, Yu J. Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma. Oncotarget 2016;7:81906-17. [PMID: 27626317 DOI: 10.18632/oncotarget.11918] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
436 Tang MC, Wu MY, Hwang MH, Chang YT, Huang HJ, Lin AM, Yang JC. Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells. PLoS One 2015;10:e0119135. [PMID: 25807554 DOI: 10.1371/journal.pone.0119135] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
437 La Montagna M, Ginn L, Garofalo M. Mechanisms of drug resistance mediated by long non-coding RNAs in non-small-cell lung cancer. Cancer Gene Ther 2021;28:175-87. [PMID: 32843741 DOI: 10.1038/s41417-020-00214-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
438 Mohindra NA, Patel JD. Towards manageable toxicities from targeted lung cancer treatment. Lung Cancer Management 2015;4:279-87. [DOI: 10.2217/lmt.15.30] [Reference Citation Analysis]
439 Spagnuolo A, Muto M, Monaco F, Colantuoni G, Gridelli C. The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era. Transl Lung Cancer Res 2019;8:1134-51. [PMID: 32010591 DOI: 10.21037/tlcr.2019.12.24] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
440 Arrieta O, Cruz-Rico G, Soto-Perez-de-Celis E, Ramírez-Tirado LA, Caballe-Perez E, Martínez-Hernández JN, Martinez-Alvarez I, Soca-Chafre G, Macedo-Pérez EO, Astudillo-de la Vega H. Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial. Target Oncol 2016;11:619-29. [PMID: 27033062 DOI: 10.1007/s11523-016-0425-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
441 Macedo JE. New era of epidermal growth factor receptor-tyrosine kinase inhibitors for lung cancer. World J Respirol 2016; 6(2): 57-62 [DOI: 10.5320/wjr.v6.i2.57] [Reference Citation Analysis]
442 Castellanos EH, Horn L. Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress. Curr Treat Options Oncol 2015;16:51. [PMID: 26364032 DOI: 10.1007/s11864-015-0365-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
443 Tanaka H, Sakamoto H, Akita T, Ohyanagi F, Kawashima Y, Tambo Y, Tanimoto A, Horiike A, Miyauchi E, Tsuchiya-Kawano Y, Yanagitani N, Nishio M. Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02). Thorac Cancer 2022. [PMID: 35415873 DOI: 10.1111/1759-7714.14415] [Reference Citation Analysis]
444 Bennett CW, Berchem G, Kim YJ, El-Khoury V. Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer. Oncotarget 2016;7:71013-35. [PMID: 27589834 DOI: 10.18632/oncotarget.11717] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 10.3] [Reference Citation Analysis]
445 Wu CE, Chang CF, Huang CY, Yang CT, Kuo CS, Hsu PC, Chang JW. Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study. BMC Cancer 2021;21:859. [PMID: 34315431 DOI: 10.1186/s12885-021-08587-w] [Reference Citation Analysis]
446 An N, Wang H, Zhu H, Yan W, Jing W, Kong L, Zhang Y, Yu J. Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report. Onco Targets Ther 2019;12:7399-404. [PMID: 31686847 DOI: 10.2147/OTT.S221638] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
447 Toschi L, Rossi S, Finocchiaro G, Santoro A. Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. Ecancermedicalscience 2017;11:787. [PMID: 29225694 DOI: 10.3332/ecancer.2017.787] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
448 Shih JY, Inoue A, Cheng R, Varea R, Kim SW. Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review. Cancers (Basel) 2020;12:E2658. [PMID: 32957736 DOI: 10.3390/cancers12092658] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
449 Moehler M, Maderer A, Ehrlich A, Foerster F, Schad A, Nickolay T, Ruckes C, Weinmann A, Sivanathan V, Marquardt JU, Galle PR, Woerns M, Thomaidis T. Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program. BMC Cancer 2019;19:55. [PMID: 30634942 DOI: 10.1186/s12885-018-5223-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
450 Liu L, Qu J, Heng J, Zhou C, Xiong Y, Yang H, Jiang W, Zeng L, Zhu S, Zhang Y, Tan J, Hu C, Deng P, Yang N. A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance. Front Oncol 2021;11:722039. [PMID: 34660287 DOI: 10.3389/fonc.2021.722039] [Reference Citation Analysis]
451 Deng H, Lei Q, Shang W, Li Y, Bi L, Yang N, Yu Z, Li W. Potential applications of clickable probes in EGFR activity visualization and prediction of EGFR-TKI therapy response for NSCLC patients. Eur J Med Chem 2022;230:114100. [PMID: 35007861 DOI: 10.1016/j.ejmech.2022.114100] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
452 Park H, Sholl LM, Hatabu H, Awad MM, Nishino M. Imaging of Precision Therapy for Lung Cancer: Current State of the Art. Radiology 2019;293:15-29. [PMID: 31385753 DOI: 10.1148/radiol.2019190173] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
453 Fu Y, Wang A, Zhou J, Feng W, Shi M, Xu X, Zhao H, Cai L, Feng J, Lv X, Zhang X, Xu W, Zhang Z, Ma G, Wang J, Zhou T, Zhao D, Fang H, Liu Z, Huang JA. Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy. Front Oncol 2021;11:621992. [PMID: 33718183 DOI: 10.3389/fonc.2021.621992] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
454 Tanaka K, Nosaki K, Otsubo K, Azuma K, Sakata S, Ouchi H, Morinaga R, Wataya H, Fujii A, Nakagaki N, Tsuruta N, Takeshita M, Iwama E, Harada T, Nakanishi Y, Okamoto I. Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations. Oncotarget 2017;8:68123-30. [PMID: 28978102 DOI: 10.18632/oncotarget.19243] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
455 Ambrose GO, Afees OJ, Nwamaka NC, Simon N, Oluwaseun AA, Soyinka T, Oluwaseun AS, Bankole S. Selection of Luteolin as a potential antagonist from molecular docking analysis of EGFR mutant. Bioinformation 2018;14:241-7. [PMID: 30108422 DOI: 10.6026/97320630014241] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
456 Kazaz SN, Öztop İ. Treatment After First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small-Cell Lung Cancer. Turk Thorac J 2017;18:66-71. [PMID: 29404164 DOI: 10.5152/TurkThoracJ.2017.16042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
457 Cretella D, Saccani F, Quaini F, Frati C, Lagrasta C, Bonelli M, Caffarra C, Cavazzoni A, Fumarola C, Galetti M, La Monica S, Ampollini L, Tiseo M, Ardizzoni A, Petronini PG, Alfieri RR. Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. Mol Cancer 2014;13:143. [PMID: 24898067 DOI: 10.1186/1476-4598-13-143] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 5.4] [Reference Citation Analysis]
458 Lovly CM. Combating acquired resistance to tyrosine kinase inhibitors in lung cancer. Am Soc Clin Oncol Educ Book 2015;:e165-73. [PMID: 25993168 DOI: 10.14694/EdBook_AM.2015.35.e165] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
459 Malapelle U, Rossi A, Bria E. Relationship between performance status or younger age and osimertinib therapy in T790M-positive NSCLC: are the available data convincing? J Thorac Dis 2019;11:S1837-40. [PMID: 31632763 DOI: 10.21037/jtd.2019.08.99] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
460 Díaz-Serrano A, Gella P, Jiménez E, Zugazagoitia J, Paz-Ares Rodríguez L. Targeting EGFR in Lung Cancer: Current Standards and Developments. Drugs 2018;78:893-911. [PMID: 29915896 DOI: 10.1007/s40265-018-0916-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
461 Yu YY, Zhu YJ, Zou Y, Xiao ZZ, Shi S, Liu YH, Chang XS, Chen YD, Zhang HB. Qing-Kai-Ling Injection Acts Better Than Shen-Fu Injection in Enhancing the Antitumor Effect of Gefitinib in Resistant Non-Small Cell Lung Cancer Models. Evid Based Complement Alternat Med 2021;2021:9911935. [PMID: 34646330 DOI: 10.1155/2021/9911935] [Reference Citation Analysis]
462 Shintani T, Higashisaka K, Maeda M, Hamada M, Tsuji R, Kurihara K, Kashiwagi Y, Sato A, Obana M, Yamamoto A, Kawasaki K, Lin Y, Kijima T, Kinehara Y, Miwa Y, Maeda S, Morii E, Kumanogoh A, Tsutsumi Y, Nagatomo I, Fujio Y. Eukaryotic translation initiation factor 3 subunit C is associated with acquired resistance to erlotinib in non-small cell lung cancer. Oncotarget 2018;9:37520-33. [PMID: 30680067 DOI: 10.18632/oncotarget.26494] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
463 Scheffler M, Schultheis A, Teixido C, Michels S, Morales-Espinosa D, Viteri S, Hartmann W, Merkelbach-Bruse S, Fischer R, Schildhaus HU, Fassunke J, Sebastian M, Serke M, Kaminsky B, Randerath W, Gerigk U, Ko YD, Krüger S, Schnell R, Rothe A, Kropf-Sanchen C, Heukamp L, Rosell R, Büttner R, Wolf J. ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. Oncotarget 2015;6:10577-85. [PMID: 25868855 DOI: 10.18632/oncotarget.3387] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 9.2] [Reference Citation Analysis]
464 Frega S, Lorenzi M, Fassan M, Indraccolo S, Calabrese F, Favaretto A, Bonanno L, Polo V, Zago G, Lunardi F, Attili I, Pavan A, Rugge M, Guarneri V, Conte P, Pasello G. Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. Oncotarget 2017;8:32626-38. [PMID: 28427238 DOI: 10.18632/oncotarget.15945] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
465 Hotta K, Kato Y, Leighl N, Takigawa N, Gaafar RM, Kayatani H, Hirata T, Ohashi K, Kubo T, Tabata M, Tanimoto M, Kiura K. Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review. PLoS One 2015;10:e0121211. [PMID: 25775395 DOI: 10.1371/journal.pone.0121211] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
466 Moiseyenko FV, Kuligina ES, Zhabina AS, Belukhin SA, Laidus TA, Martianov AS, Zagorodnev KA, Sokolova TN, Chuinyshena SA, Kholmatov MM, Artemieva EV, Stepanova EO, Shuginova TN, Volkov NM, Yanus GA, Imyanitov EN. Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer. Int J Clin Oncol 2022. [PMID: 35171360 DOI: 10.1007/s10147-022-02128-6] [Reference Citation Analysis]
467 Min YJ. Anti-Cancer Therapy of Advanced Lung Cancer in Elderly Patients. Korean J Med 2014;87:537. [DOI: 10.3904/kjm.2014.87.5.537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
468 Jones E, Mikropoulos C, Ahmed M. The future of immunotherapy in the treatment of lung cancer. Lung Cancer Management 2015;4:57-73. [DOI: 10.2217/lmt.15.2] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
469 Schoenmaekers JJAO, Paats MS, Dingemans AC, Hendriks LEL. Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when? Transl Lung Cancer Res 2020;9:2599-617. [PMID: 33489821 DOI: 10.21037/tlcr-20-459] [Reference Citation Analysis]
470 Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer 2019;19:495-509. [PMID: 31406302 DOI: 10.1038/s41568-019-0179-8] [Cited by in Crossref: 154] [Cited by in F6Publishing: 144] [Article Influence: 51.3] [Reference Citation Analysis]
471 Greillier L, Tomasini P, Barlesi F. Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience. Ther Adv Respir Dis 2016;10:485-91. [PMID: 27340254 DOI: 10.1177/1753465816652083] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
472 Hsiao SC, Chen YH, Lo CC, Lin CI. A noteworthy treatment of metastatic small-cell lung cancer with afatinib, followed by subsequent development of rare metastatic lesions in the ascending and sigmoid colon. Cancer Rep (Hoboken) 2020;3:e1243. [PMID: 32671978 DOI: 10.1002/cnr2.1243] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
473 Huang WC, Yadav VK, Cheng WH, Wang CH, Hsieh MS, Huang TY, Lin SF, Yeh CT, Kuo KT. The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells. Cancers (Basel) 2021;13:6005. [PMID: 34885115 DOI: 10.3390/cancers13236005] [Reference Citation Analysis]
474 Shen P, Zhong W. Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine. J Thorac Dis 2018;10:1364-9. [PMID: 29708118 DOI: 10.21037/jtd.2018.03.97] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
475 König D, Savic Prince S, Rothschild SI. Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. Cancers (Basel) 2021;13:804. [PMID: 33671873 DOI: 10.3390/cancers13040804] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
476 Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, Yang ZY, Mao C, Tang JL. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 2016;7:78985-93. [PMID: 27738317 DOI: 10.18632/oncotarget.12587] [Cited by in Crossref: 178] [Cited by in F6Publishing: 190] [Article Influence: 44.5] [Reference Citation Analysis]
477 Berz D, Raymond VM, Garst JH, Erlander MG. Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer. Exp Hematol Oncol 2015;5:24. [PMID: 27508108 DOI: 10.1186/s40164-016-0052-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
478 Puri S, Chatwal M, Gray JE. Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents. Expert Review of Respiratory Medicine 2017;11:791-805. [DOI: 10.1080/17476348.2017.1361323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
479 Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, Salgia R. Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014;5:1392-433. [PMID: 24722523 DOI: 10.18632/oncotarget.1891] [Cited by in Crossref: 111] [Cited by in F6Publishing: 110] [Article Influence: 15.9] [Reference Citation Analysis]
480 Saarenheimo J, Eigeliene N, Andersen H, Tiirola M, Jekunen A. The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer. Front Oncol 2019;9:129. [PMID: 30891428 DOI: 10.3389/fonc.2019.00129] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
481 Silva AP, Coelho PV, Anazetti M, Simioni PU. Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors. Hum Vaccin Immunother 2017;13:843-53. [PMID: 27831000 DOI: 10.1080/21645515.2016.1249551] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
482 Aguiar Júnior P, Barreto CMN, Roitberg F, Lopes Júnior G, Giglio AD. Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: Budget impact and strategies to improve access. A pharmacoeconomic study. Sao Paulo Med J 2019;137:505-11. [PMID: 32159636 DOI: 10.1590/1516-3180.2018.0256170919] [Reference Citation Analysis]
483 Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, Rupasinghe HPV. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer 2018;17:48. [PMID: 29455673 DOI: 10.1186/s12943-018-0804-2] [Cited by in Crossref: 331] [Cited by in F6Publishing: 283] [Article Influence: 82.8] [Reference Citation Analysis]
484 Zhang SR, Xu YS, Jin E, Zhu LC, Xia B, Chen XF, Li FZ, Ma SL. Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance. Acta Pharmacol Sin 2017;38:100-9. [PMID: 27840409 DOI: 10.1038/aps.2016.116] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
485 Yamamoto G, Asahina H, Honjo O, Sumi T, Nakamura A, Ito K, Kikuchi H, Hommura F, Honda R, Yokoo K, Fujita Y, Oizumi S, Morita R, Ikezawa Y, Tanaka H, Kimura N, Sasaki T, Sukoh N, Takashina T, Harada T, Dosaka-Akita H, Isobe H; Hokkaido Lung Cancer Clinical Study Group Trial. First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002). Sci Rep 2021;11:23140. [PMID: 34848786 DOI: 10.1038/s41598-021-02561-z] [Reference Citation Analysis]
486 Jin Y, Lin C, Shi X, He Q, Yan J, Yu X, Chen M. Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09683-1] [Reference Citation Analysis]
487 Barrón F, Cardona AF, Corrales L, Ramirez-Tirado LA, Caballe-Perez E, Sanchez G, Flores-Estrada D, Zatarain-Barrón ZL, Arrieta O; Latin American Consortium for the Study of Lung Cancer (CLICaP). Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation. J Thorac Dis 2018;10:2166-78. [PMID: 29850120 DOI: 10.21037/jtd.2018.03.106] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
488 Gower A, Wang Y, Giaccone G. Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. J Mol Med (Berl) 2014;92:697-707. [PMID: 24852181 DOI: 10.1007/s00109-014-1165-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
489 Li M, Yang J, Zhang L, Tu S, Zhou X, Tan Z, Zhou W, He Y, Li Y. A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation. J Exp Clin Cancer Res 2019;38:211. [PMID: 31118055 DOI: 10.1186/s13046-019-1207-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
490 Chang JW, Huang CY, Fang YF, Chang CF, Yang CT, Kuo CS, Hsu PC, Wu CE. Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients. Thorac Cancer 2022. [PMID: 35633141 DOI: 10.1111/1759-7714.14272] [Reference Citation Analysis]
491 Li F, Liu G, Roudi R, Huang Q, Swierzy M, Ismail M, Zhao S, Rueckert JC. Do statins improve outcomes for patients with non-small cell lung cancer? A systematic review and meta-analysis protocol. BMJ Open 2018;8:e022161. [PMID: 30206083 DOI: 10.1136/bmjopen-2018-022161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
492 Hirano T, Yasuda H, Tani T, Hamamoto J, Oashi A, Ishioka K, Arai D, Nukaga S, Miyawaki M, Kawada I, Naoki K, Costa DB, Kobayashi SS, Betsuyaku T, Soejima K. In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Oncotarget 2015;6:38789-803. [PMID: 26515464 DOI: 10.18632/oncotarget.5887] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 12.0] [Reference Citation Analysis]
493 Pender A, Garcia-Murillas I, Rana S, Cutts RJ, Kelly G, Fenwick K, Kozarewa I, Gonzalez de Castro D, Bhosle J, O'Brien M, Turner NC, Popat S, Downward J. Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. PLoS One 2015;10:e0139074. [PMID: 26413866 DOI: 10.1371/journal.pone.0139074] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
494 Kiesewetter B, Raderer M, Steger GG, Bartsch R, Pirker R, Zöchbauer-Müller S, Prager G, Krainer M, Preusser M, Schmidinger M, Zielinski CC. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. ESMO Open 2016;1:e000066. [PMID: 27843624 DOI: 10.1136/esmoopen-2016-000066] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
495 Jensen KV, Hao X, Aman A, Luchman HA, Weiss S. EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo. Neurooncol Adv 2020;2:vdaa020. [PMID: 32226941 DOI: 10.1093/noajnl/vdaa020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
496 Kharbanda A, Rajabi H, Jin C, Tchaicha J, Kikuchi E, Wong KK, Kufe D. Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells. Clin Cancer Res 2014;20:5423-34. [PMID: 25189483 DOI: 10.1158/1078-0432.CCR-13-3168] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
497 Suzawa K, Toyooka S, Sakaguchi M, Morita M, Yamamoto H, Tomida S, Ohtsuka T, Watanabe M, Hashida S, Maki Y, Soh J, Asano H, Tsukuda K, Miyoshi S. Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations. Cancer Sci 2016;107:45-52. [PMID: 26545934 DOI: 10.1111/cas.12845] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 7.1] [Reference Citation Analysis]
498 Nan X, Xie C, Yu X, Liu J. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget 2017;8:75712-26. [PMID: 29088904 DOI: 10.18632/oncotarget.20095] [Cited by in Crossref: 50] [Cited by in F6Publishing: 58] [Article Influence: 10.0] [Reference Citation Analysis]
499 Birkeland AC, Yanik M, Tillman BN, Scott MV, Foltin SK, Mann JE, Michmerhuizen NL, Ludwig ML, Sandelski MM, Komarck CM, Carey TE, Prince ME, Bradford CR, McHugh JB, Spector ME, Brenner JC. Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngol Head Neck Surg 2016;142:559-67. [PMID: 27077364 DOI: 10.1001/jamaoto.2016.0335] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
500 Krishnan S, Miller RM, Tian B, Mullins RD, Jacobson MP, Taunton J. Design of reversible, cysteine-targeted Michael acceptors guided by kinetic and computational analysis. J Am Chem Soc 2014;136:12624-30. [PMID: 25153195 DOI: 10.1021/ja505194w] [Cited by in Crossref: 141] [Cited by in F6Publishing: 117] [Article Influence: 17.6] [Reference Citation Analysis]
501 Lu Y, Gu W, Deng J, Yang H, Yang W. A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma. BMC Cancer 2016;16:775. [PMID: 27717315 DOI: 10.1186/s12885-016-2800-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
502 Shin SH, Bode AM, Dong Z. Addressing the challenges of applying precision oncology. NPJ Precis Oncol 2017;1:28. [PMID: 29872710 DOI: 10.1038/s41698-017-0032-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
503 Zhang Q, Wu C, Ding W, Zhang Z, Qiu X, Mu D, Zhang H, Xi Y, Zhou J, Ma L, Fu S, Gao M, Wang B, Deng J, Lin D, Zhang J. Prevalence of ROS1 fusion in Chinese patients with non-small cell lung cancer. Thorac Cancer 2019;10:47-53. [PMID: 30468296 DOI: 10.1111/1759-7714.12899] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
504 Giusti R, Mazzotta M, Iacono D, Lauro S, Marchetti P. Complete Tumor Response with Afatinib 20 mg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report. Clin Drug Investig 2017;37:581-5. [PMID: 28299582 DOI: 10.1007/s40261-017-0515-2] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
505 Gray J, Haura E. Update on third-generation EGFR tyrosine kinase inhibitors. Transl Lung Cancer Res 2014;3:360-2. [PMID: 25806319 DOI: 10.3978/j.issn.2218-6751.2014.09.08] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
506 Wang S, Li J. Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer. Onco Targets Ther 2019;12:6535-48. [PMID: 31496745 DOI: 10.2147/OTT.S198945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
507 Fang W, Huang Y, Hong S, Zhang Z, Wang M, Gan J, Wang W, Guo H, Wang K, Zhang L. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. BMC Cancer 2019;19:595. [PMID: 31208370 DOI: 10.1186/s12885-019-5820-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 10.7] [Reference Citation Analysis]
508 Stares M, Swan A, Cumming K, Ding TE, Leach J, Stratton C, Thomson F, Barrie C, MacLennan K, Campbell S, Evans T, Tufail A, Harrow S, MacKean M, Phillips I. Hypoalbuminaemia as a Prognostic Biomarker of First-Line Treatment Resistance in Metastatic Non-small Cell Lung Cancer. Front Nutr 2021;8:734735. [PMID: 34660664 DOI: 10.3389/fnut.2021.734735] [Reference Citation Analysis]
509 Zhang J, Zhang Y, Tang S, Liang H, Chen D, Jiang L, He Q, Huang Y, Wang X, Deng K, Jiang S, Zhou J, Xu J, Chen X, Liang W, He J. Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years. Ann Transl Med 2017;5:481. [PMID: 29299443 DOI: 10.21037/atm.2017.11.24] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
510 Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, Sequist LV, Engelman JA. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. Clin Cancer Res 2015;21:3924-33. [PMID: 25964297 DOI: 10.1158/1078-0432.CCR-15-0560] [Cited by in Crossref: 275] [Cited by in F6Publishing: 169] [Article Influence: 39.3] [Reference Citation Analysis]
511 Deng H, Lei Q, Yang N, Dai S, Peng H, Yang K, Xiao Z, Wang D, Yu Z, Li N, Li W. Expanded Application of a Photoaffinity Probe to Study Epidermal Growth Factor Receptor Tyrosine Kinase with Functional Activity. Anal Chem 2022. [PMID: 35729862 DOI: 10.1021/acs.analchem.2c01340] [Reference Citation Analysis]
512 Xie B, Sun L, Cheng Y, Zhou J, Zheng J, Zhang W. Epidermal growth factor receptor gene mutations in non-small-cell lung cancer cells are associated with increased radiosensitivity in vitro. Cancer Manag Res 2018;10:3551-60. [PMID: 30271203 DOI: 10.2147/CMAR.S165831] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
513 Hong IK, Lee JM, Hwang IK, Paik SS, Kim C, Lee SH. Diagnostic and Predictive Values of 18F-FDG PET/CT Metabolic Parameters in EGFR-Mutated Advanced Lung Adenocarcinoma. Cancer Manag Res 2020;12:6453-65. [PMID: 32801885 DOI: 10.2147/CMAR.S259055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
514 Vachani A, Sequist LV, Spira A. AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future. Am J Respir Crit Care Med 2017;195:1150-60. [PMID: 28459327 DOI: 10.1164/rccm.201702-0433CI] [Cited by in Crossref: 44] [Cited by in F6Publishing: 23] [Article Influence: 8.8] [Reference Citation Analysis]
515 Sato M, Watanabe S, Tanaka H, Nozaki K, Arita M, Takahashi M, Shoji S, Ichikawa K, Kondo R, Aoki N, Hayashi M, Ohshima Y, Koya T, Ohashi R, Ajioka Y, Kikuchi T. Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations. PLoS One 2019;14:e0215292. [PMID: 30978241 DOI: 10.1371/journal.pone.0215292] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
516 Kodama H, Wakuda K, Yabe M, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Ono A, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi T. Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma. Invest New Drugs 2021;39:571-7. [PMID: 32955628 DOI: 10.1007/s10637-020-01005-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
517 Hiret S, Isambert N, Gomez-Roca C, Bennouna J, Sassi M, de Mont-Serrat H, Fan J, Schnell D, Delord JP. Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors. Invest New Drugs 2018;36:1044-59. [PMID: 29808308 DOI: 10.1007/s10637-018-0601-1] [Reference Citation Analysis]
518 Steuer CE, Ramalingam SS. Targeting EGFR in lung cancer: Lessons learned and future perspectives. Mol Aspects Med 2015;45:67-73. [PMID: 26022942 DOI: 10.1016/j.mam.2015.05.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
519 Inno A, Di Noia V, Martini M, D'Argento E, Di Salvatore M, Arena V, Schinzari G, Orlandi A, Larocca LM, Cassano A, Barone C. Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis. Pathol Oncol Res 2019;25:513-20. [PMID: 29557085 DOI: 10.1007/s12253-018-0404-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
520 Levantini E, Maroni G, Del Re M, Tenen DG. EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol 2022:S1044-579X(22)00096-7. [PMID: 35427766 DOI: 10.1016/j.semcancer.2022.04.002] [Reference Citation Analysis]
521 Senosain MF, Massion PP. Intratumor Heterogeneity in Early Lung Adenocarcinoma. Front Oncol 2020;10:349. [PMID: 32257951 DOI: 10.3389/fonc.2020.00349] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
522 Passaro A, Malapelle U, Del Re M, Attili I, Russo A, Guerini-Rocco E, Fumagalli C, Pisapia P, Pepe F, De Luca C, Cucchiara F, Troncone G, Danesi R, Spaggiari L, De Marinis F, Rolfo C. Understanding EGFR heterogeneity in lung cancer. ESMO Open 2020;5:e000919. [PMID: 33067323 DOI: 10.1136/esmoopen-2020-000919] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
523 Cummings CT, Zhang W, Davies KD, Kirkpatrick GD, Zhang D, DeRyckere D, Wang X, Frye SV, Earp HS, Graham DK. Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status. Mol Cancer Ther 2015;14:2014-22. [PMID: 26162689 DOI: 10.1158/1535-7163.MCT-15-0116] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
524 Tamura K, Nukiwa T, Gemma A, Yamamoto N, Mizushima M, Ochai K, Ikeda R, Azuma H, Nakanishi Y. Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib. Int J Clin Oncol 2019;24:917-26. [PMID: 30953238 DOI: 10.1007/s10147-019-01439-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
525 Shi Y, Sun Y, Ding C, Wang Z, Wang C, Bai C, Bai C, Feng J, Liu X, Li F, Yang Y, Shu Y, Wu M, He J, Zhang Y, Zhang S, Chen G, Luo H, Luo R, Zhou C, Pang Q, Hu X, Zhao H, Zhao Q, Gu A, Ling Y, Huang C, Han B, Jiao S, Jian H. [China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment
(2016 version)]. Zhongguo Fei Ai Za Zhi 2016;19:489-94. [PMID: 27339727 DOI: 10.3779/j.issn.1009-3419.2016.07.12] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
526 Mak KS, Gainor JF, Niemierko A, Oh KS, Willers H, Choi NC, Loeffler JS, Sequist LV, Shaw AT, Shih HA. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Neuro Oncol 2015;17:296-302. [PMID: 25053852 DOI: 10.1093/neuonc/nou146] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 6.0] [Reference Citation Analysis]
527 Ogura W, Ohtsuka K, Fujiwara M, Tanaka R, Sekiguchi K, Ohnishi H, Watanabe T. Use of a plasma test for verifying epidermal growth factor receptor gene (EGFR) mutations in fluid samples from non-small cell lung cancer patients. Respir Med Case Rep 2020;29:101007. [PMID: 32025485 DOI: 10.1016/j.rmcr.2020.101007] [Reference Citation Analysis]
528 Tessema M, Rossi MR, Picchi MA, Yingling CM, Lin Y, Ramalingam SS, Belinsky SA. Common cancer-driver mutations and their association with abnormally methylated genes in lung adenocarcinoma from never-smokers. Lung Cancer 2018;123:99-106. [PMID: 30089603 DOI: 10.1016/j.lungcan.2018.07.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
529 Yang PY, Tai CJ. Chinese Medicine Treatment for Afatinib-Induced Paronychia. Case Rep Oncol Med 2017;2017:7327359. [PMID: 28948057 DOI: 10.1155/2017/7327359] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
530 Fintelmann FJ, Troschel FM, Kuklinski MW, McDermott S, Petranovic M, Digumarthy SR, Sharma A, Troschel AS, Price MC, Hariri LP, Gilman MD, Shepard JO, Sequist LV, Piotrowska Z. Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor-Mutant Lung Cancer. Oncologist 2019;24:1570-6. [PMID: 31152082 DOI: 10.1634/theoncologist.2019-0158] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
531 García-Campelo R, Bernabé R, Cobo M, Corral J, Coves J, Dómine M, Nadal E, Rodriguez-Abreu D, Viñolas N, Massuti B. SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015. Clin Transl Oncol 2015;17:1020-9. [PMID: 26691657 DOI: 10.1007/s12094-015-1455-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
532 Zhu YJ, Zhang HB, Liu LR, Liu YH, Zhang FL, Bai JP, Li Y, Qu YC, Qu X, Chen X, Li Y, Luo SY, Ou AH. Yin-Cold or Yang-Heat Syndrome Type of Traditional Chinese Medicine Was Associated with the Epidermal Growth Factor Receptor Gene Status in Non-Small Cell Lung Cancer Patients: Confirmation of a TCM Concept. Evid Based Complement Alternat Med 2017;2017:7063859. [PMID: 28203260 DOI: 10.1155/2017/7063859] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
533 Ishii H, Azuma K, Sakai K, Kawahara A, Yamada K, Tokito T, Okamoto I, Nishio K, Hoshino T. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples. Oncotarget. 2015; 6:30850-30858. [PMID: 26334838 DOI: 10.18632/oncotarget.5068] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 9.3] [Reference Citation Analysis]
534 Heist R, Azzoli CG. Adjuvant therapy for a 3.9-cm adenocarcinoma of the lung. Oncologist 2013;18:1258-61. [PMID: 24277772 DOI: 10.1634/theoncologist.2013-0297] [Reference Citation Analysis]
535 Imamura F, Inoue T, Kunimasa K, Kubota A, Kuhara H, Tamiya M, Nishino K, Kimura M, Kuno K, Kawachi H, Kumagai T. Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC. Lung Cancer Manag 2020;9:LMT29. [PMID: 32346403 DOI: 10.2217/lmt-2020-0005] [Reference Citation Analysis]
536 Passaro A, de Marinis F. Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints. Transl Lung Cancer Res 2019;8:S334-8. [PMID: 32038909 DOI: 10.21037/tlcr.2019.06.04] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
537 Gristina V, La Mantia M, Galvano A, Cutaia S, Barraco N, Castiglia M, Perez A, Bono M, Iacono F, Greco M, Calcara K, Calò V, Rizzo S, Incorvaia L, Lisanti MC, Santanelli G, Sardo D, Inguglia S, Insalaco L, Castellana L, Cusenza S, Pantuso G, Russo A, Bazan V. Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma. JMP 2021;2:173-96. [DOI: 10.3390/jmp2020016] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
538 Sárosi V, Balikó Z, Smuk G, László T, Szabó M, Ruzsics I, Mezősi E. The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients. Pathol Oncol Res 2016;22:755-61. [PMID: 27105879 DOI: 10.1007/s12253-016-0063-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
539 Ma C, Zhang J, Tang D, Ye X, Li J, Mu N, Li Z, Liu R, Xiang L, Huang C, Jiang R. Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations. Front Oncol 2020;10:224. [PMID: 32195178 DOI: 10.3389/fonc.2020.00224] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
540 Dungo RT, Keating GM. Afatinib: first global approval. Drugs. 2013;73:1503-1515. [PMID: 23982599 DOI: 10.1007/s40265-013-0111-6] [Cited by in Crossref: 134] [Cited by in F6Publishing: 126] [Article Influence: 16.8] [Reference Citation Analysis]
541 Igawa S, Ono T, Kasajima M, Ishihara M, Hiyoshi Y, Kusuhara S, Nishinarita N, Fukui T, Kubota M, Sasaki J, Hisashi M, Yokoba M, Katagiri M, Naoki K. Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study. Cancer Manag Res 2019;11:4883-92. [PMID: 31213907 DOI: 10.2147/CMAR.S207170] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
542 Ko B, Paucar D, Halmos B. EGFR T790M: revealing the secrets of a gatekeeper. Lung Cancer (Auckl) 2017;8:147-59. [PMID: 29070957 DOI: 10.2147/LCTT.S117944] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
543 Komiya T, Perez RP, Erickson KD, Huang CH. Systematic analysis of design and stratification for phase III trials in first-line advanced non-small cell lung cancer. Thorac Cancer 2016;7:66-71. [PMID: 26813229 DOI: 10.1111/1759-7714.12276] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
544 Kobayashi K, Naoki K, Manabe T, Masuzawa K, Hasegawa H, Yasuda H, Kawada I, Soejima K, Betsuyaku T. Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer. Onco Targets Ther 2018;11:3335-43. [PMID: 29922072 DOI: 10.2147/OTT.S161745] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
545 Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, Janu A, Purandare N, Kumar R, More S, Goud S, Kadam N, Daware N, Bhattacharjee A, Shah S, Yadav A, Trivedi V, Behel V, Dutt A, Banavali SD, Prabhash K. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. J Clin Oncol 2020;38:124-36. [PMID: 31411950 DOI: 10.1200/JCO.19.01154] [Cited by in Crossref: 136] [Cited by in F6Publishing: 67] [Article Influence: 68.0] [Reference Citation Analysis]
546 Ricciuti B, Mecca C, Cenci M, Leonardi GC, Perrone L, Mencaroni C, Crinò L, Grignani F, Baglivo S, Chiari R, Sidoni A, Paglialunga L, Currà MF, Murano E, Minotti V, Metro G. miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance. Ecancermedicalscience 2015;9:569. [PMID: 26435742 DOI: 10.3332/ecancer.2015.569] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
547 Wang Y, Guo Z, Li Y, Zhou Q. Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma. Open Med (Wars) 2016;11:68-77. [PMID: 28352770 DOI: 10.1515/med-2016-0014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
548 Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015;10:S1-63. [PMID: 25535693 DOI: 10.1097/JTO.0000000000000405] [Cited by in Crossref: 95] [Cited by in F6Publishing: 44] [Article Influence: 13.6] [Reference Citation Analysis]
549 Yan D, Earp HS, DeRyckere D, Graham DK. Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer. Cancers (Basel) 2021;13:5639. [PMID: 34830794 DOI: 10.3390/cancers13225639] [Reference Citation Analysis]
550 Chiba M, Togashi Y, Bannno E, Kobayashi Y, Nakamura Y, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K. Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A. BMC Cancer 2017;17:281. [PMID: 28424065 DOI: 10.1186/s12885-017-3263-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
551 Yue-Yun C, Ye H, Yang F, Qing L, Pan-Pan L, Zhen-Yu D. Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours. Asian Pac J Cancer Prev 2019;20:2415-20. [PMID: 31450915 DOI: 10.31557/APJCP.2019.20.8.2415] [Reference Citation Analysis]
552 Tian X, Gu T, Lee MH, Dong Z. Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer. Biochim Biophys Acta Rev Cancer 2021;1877:188645. [PMID: 34793897 DOI: 10.1016/j.bbcan.2021.188645] [Reference Citation Analysis]
553 Deeks ED, Keating GM. Afatinib in advanced NSCLC: a profile of its use. Drugs Ther Perspect 2018;34:89-98. [PMID: 29540977 DOI: 10.1007/s40267-018-0482-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
554 Sun Q, Li W, Liu T, Guo H. Individualized Treatment for Advanced Non-Small Cell Lung Cancer: A Case Report and Literature Review. Front Oncol 2022;12:916681. [DOI: 10.3389/fonc.2022.916681] [Reference Citation Analysis]
555 Huang YH, Hung JY, Ko HW, Su PL, Lai CL, Chang HC, Hsia TC, Lin SH, Wu KL, Yang CT, Su WC, Chu YC, Wang CC, Liao WY, Lin YT, Lin CH, Lin MC, Hsu KH, Tseng JS, Yang TY, Chen KC, Lee MH, Yu SL, Ho CC, Chang GC. The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study. Ther Adv Med Oncol 2021;13:17588359211018022. [PMID: 34093743 DOI: 10.1177/17588359211018022] [Reference Citation Analysis]
556 Santos ES, Hart L. Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib. Onco Targets Ther 2020;13:9305-21. [PMID: 33061419 DOI: 10.2147/OTT.S250446] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
557 Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman JW, Juergens RA, Laurie SA, Nathan FE, Shen Y, Harbison CT, Hellmann MD. Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer. JCO 2016;34:2980-7. [DOI: 10.1200/jco.2016.66.9929] [Reference Citation Analysis]
558 Sotelo MJ, Luis García J, Torres-Mattos C, Milián H, Carracedo C, González-Ruiz MÁ, Mielgo-Rubio X, Trujillo-Reyes JC, Couñago F. Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer. World J Clin Oncol 2021; 12(10): 912-925 [PMID: 34733613 DOI: 10.5306/wjco.v12.i10.912] [Reference Citation Analysis]
559 Slobbe P, Windhorst AD, Stigter-van Walsum M, Smit EF, Niessen HG, Solca F, Stehle G, van Dongen GA, Poot AJ. A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice. EJNMMI Res 2015;5:14. [PMID: 25853020 DOI: 10.1186/s13550-015-0088-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
560 Wang R, Zhang Y, Pan Y, Li Y, Hu H, Cai D, Li H, Ye T, Luo X, Zhang Y, Li B, Shen L, Sun Y, Chen H. Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients. Oncotarget 2015;6:34300-8. [PMID: 26486077 DOI: 10.18632/oncotarget.5549] [Cited by in Crossref: 42] [Cited by in F6Publishing: 51] [Article Influence: 7.0] [Reference Citation Analysis]
561 Harvey RD, Adams VR, Beardslee T, Medina P. Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings. J Oncol Pharm Pract 2020;26:1461-74. [PMID: 32567494 DOI: 10.1177/1078155220931926] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
562 Oronsky B, Ma P, Reid TR, Cabrales P, Lybeck M, Oronsky A, Oronsky N, Carter CA. Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review. Neoplasia 2018;20:92-8. [PMID: 29227909 DOI: 10.1016/j.neo.2017.11.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
563 Santos ES, Kaplan B, Kirshner E, Croft EF, Sequist LV, Chau M, Munley J, Oxnard GR. Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program. Oncol Ther 2018;6:45-58. [PMID: 32700141 DOI: 10.1007/s40487-018-0061-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
564 Liu HL, Han G, Peng M, Weng YM, Yuan JP, Yang GF, Yu JM, Song QB. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis. J Huazhong Univ Sci Technolog Med Sci 2017;37:864-72. [PMID: 29270745 DOI: 10.1007/s11596-017-1819-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
565 Ferrara MG, Di Noia V, D'Argento E, Vita E, Damiano P, Cannella A, Ribelli M, Pilotto S, Milella M, Tortora G, Bria E. Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. Cancers (Basel) 2020;12:E1196. [PMID: 32397295 DOI: 10.3390/cancers12051196] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
566 Chalela R, Curull V, Enríquez C, Pijuan L, Bellosillo B, Gea J. Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy. J Thorac Dis 2017;9:2142-58. [PMID: 28840016 DOI: 10.21037/jtd.2017.06.20] [Cited by in Crossref: 47] [Cited by in F6Publishing: 53] [Article Influence: 9.4] [Reference Citation Analysis]
567 Bui KT, Cooper WA, Kao S, Boyer M. Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists. J Clin Med 2018;7:E192. [PMID: 30065223 DOI: 10.3390/jcm7080192] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
568 Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17:38. [PMID: 29455650 DOI: 10.1186/s12943-018-0777-1] [Cited by in Crossref: 154] [Cited by in F6Publishing: 178] [Article Influence: 38.5] [Reference Citation Analysis]
569 Tan PT, Aziz MIA, Pearce F, Lim WT, Wu DB, Ng K. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective. BMC Cancer 2018;18:352. [PMID: 29587666 DOI: 10.1186/s12885-018-4223-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
570 Tomasini P, Walia P, Labbe C, Jao K, Leighl NB. Targeting the KRAS Pathway in Non-Small Cell Lung Cancer. Oncologist 2016;21:1450-60. [PMID: 27807303 DOI: 10.1634/theoncologist.2015-0084] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 9.3] [Reference Citation Analysis]
571 De Mello RA, Escriu C, Castelo-Branco P, Cabral PL, Mountzios G, Lopes GL, Madureira P. Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis. Oncotarget 2018;9:11805-15. [PMID: 29545937 DOI: 10.18632/oncotarget.23668] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
572 Aguiar P Jr, Roitberg F, Lopes G Jr, Giglio AD. Distinct models to assess the cost-effectiveness of EGFR-tyrosine kinase inhibitors for the treatment of metastatic non-small cell lung cancer in the context of the Brazilian Unified Health Care System. J Bras Pneumol 2020;46:e20180255. [PMID: 32490907 DOI: 10.36416/1806-3756/e20180255] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
573 Ono T, Igawa S, Ozawa T, Kasajima M, Ishihara M, Hiyoshi Y, Kusuhara S, Nishinarita N, Fukui T, Kubota M, Sasaki J, Hisashi M, Katagiri M, Naoki K. Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study. Thorac Cancer 2019;10:880-9. [PMID: 30821083 DOI: 10.1111/1759-7714.13018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
574 Zhou Y, Ma Y, Shi H, Du Y, Huang Y. Epidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China. Sci Rep 2018;8:15426. [PMID: 30337598 DOI: 10.1038/s41598-018-33816-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
575 Puliafito I, Esposito F, Raciti G, Giuffrida P, Caltavuturo C, Colarossi C, Munao S, Sciacca D, Giuffrida D. Metabolic complete tumor response in a patient with epidermal growth factor receptor mutant non-small cell lung cancer treated with a reduced dose of afatinib. J Int Med Res 2022;50:3000605211058864. [PMID: 35291829 DOI: 10.1177/03000605211058864] [Reference Citation Analysis]
576 Wu J, Zhang J, Jiang M, Zhang T, Wang Y, Wang Z, Miao Y, Wang Z, Li W. Comparison between NOD/SCID mice and BALB/c mice for patient-derived tumor xenografts model of non-small-cell lung cancer. Cancer Manag Res 2018;10:6695-703. [PMID: 30584364 DOI: 10.2147/CMAR.S181272] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
577 Du R, Yang H, Zhou H, Ma L, Getu MA, Chen C, Wang T. The relationship between medication literacy and skin adverse reactions in non-small-cell lung cancer patients undergoing targeted EGFR-TKI therapy. BMC Cancer 2022;22:491. [PMID: 35505288 DOI: 10.1186/s12885-022-09599-w] [Reference Citation Analysis]
578 Jin Y, Chen M, Yu X. Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer. Sci Rep 2016;6:31636. [PMID: 27527915 DOI: 10.1038/srep31636] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
579 Passaro A, de Marinis F. Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option. Transl Lung Cancer Res 2018;7:S100-2. [PMID: 29780702 DOI: 10.21037/tlcr.2018.02.09] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
580 Solomon BJ, Loong HH, Summers Y, Thomas ZM, French P, Lin BK, Sashegyi A, Wolf J, Yang JC, Drilon A. Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations. ESMO Open 2022;7:100398. [PMID: 35183043 DOI: 10.1016/j.esmoop.2022.100398] [Reference Citation Analysis]
581 Kiura K, Yoh K, Katakami N, Nogami N, Kasahara K, Takahashi T, Okamoto I, Cantarini M, Hodge R, Uchida H. Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples. Cancer Sci 2018;109:1177-84. [PMID: 29363250 DOI: 10.1111/cas.13511] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
582 Zhang W, Zhang Y, Zhao Q, Liu X, Chen L, Pan H, Li Y, Lu Y, Huang J, Zhang Z, Du K, Zhang S, Li T, Lu L, Yu G, Wang Y, Yuan X, Yang M, Ma Y, Tan F. Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study. J Thorac Dis 2020;12:639-50. [PMID: 32274129 DOI: 10.21037/jtd.2019.12.115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
583 Ewer MS, Patel K, O'Brien D, Lorence RM. Cardiac safety of afatinib: a review of data from clinical trials. Cardiooncology 2015;1:3. [PMID: 33530147 DOI: 10.1186/s40959-015-0006-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
584 Hofheinz RD, Deplanque G, Komatsu Y, Kobayashi Y, Ocvirk J, Racca P, Guenther S, Zhang J, Lacouture ME, Jatoi A. Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors. Oncologist. 2016;21:1483-1491. [PMID: 27449521 DOI: 10.1634/theoncologist.2016-0051] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
585 Kim YS, Ji JH, Oh SY, Lee S, Huh SJ, Lee JH, Song KH, Son CH, Roh MS, Lee GW, Lee J, Kim ST, Kim CK, Jang JS, Hwang IG, Ahn HK, Park LC, Oh SY, Kim SG, Lee SC, Lim DH, Lee SI, Kang JH. A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities. Oncologist 2020;25:e186-93. [PMID: 31492766 DOI: 10.1634/theoncologist.2019-0221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
586 Lin C, Hu F, Chu H, Ren P, Ma S, Wang J, Bai J, Han X, Ma S. The role of EGFR-TKIs as adjuvant therapy in EGFR mutation-positive early-stage NSCLC: A meta-analysis. Thorac Cancer 2021;12:1084-95. [PMID: 33660941 DOI: 10.1111/1759-7714.13874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
587 Yip PY. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer. Transl Lung Cancer Res. 2015;4:165-176. [PMID: 25870799 DOI: 10.3978/j.issn.2218-6751.2015.01.04] [Cited by in F6Publishing: 59] [Reference Citation Analysis]
588 Huang YE, Tsai YH, Huang YJ, Lung JH, Ho KW, Yen TC, Chan SC, Chen ST, Tsai MF, Hung MS. 18F-Fluorodeoxyglucose PET/CT for Early Prediction of Outcomes in Patients with Advanced Lung Adenocarcinomas and EGFR Mutations Treated with First-Line EGFR-TKIs. Cancers (Basel) 2022;14:1507. [PMID: 35326662 DOI: 10.3390/cancers14061507] [Reference Citation Analysis]
589 You JHS, Cho WCS, Ming WK, Li YC, Kwan CK, Au KH, Au JS. EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis. PLoS One 2021;16:e0247860. [PMID: 33647045 DOI: 10.1371/journal.pone.0247860] [Reference Citation Analysis]
590 Ou SH, Soo RA. Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era? Drug Des Devel Ther. 2015;9:5641-5653. [PMID: 26508839 DOI: 10.2147/dddt.s52787] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
591 Keating GM. Afatinib: A Review in Advanced Non-Small Cell Lung Cancer. Target Oncol 2016;11:825-35. [PMID: 27873136 DOI: 10.1007/s11523-016-0465-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
592 Tamiya M, Tamiya A, Okamoto N, Taniguchi Y, Nishino K, Atagi S, Hirashima T, Imamura F, Kumagai T, Suzuki H. The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC. Sci Rep 2021;11:9629. [PMID: 33953280 DOI: 10.1038/s41598-021-89006-9] [Reference Citation Analysis]
593 Ishikawa R, Yamazaki S, Mio T, Kawashima A, Masumoto A, Shiono A, Daito H, Yamaguchi O, Maeno Y, Okano T, Sakaguchi H, Murayama Y, Ishida H, Kato S, Hagiwara K, Kobayashi K. Carcinomatous meningitis and <i>EGFR</i> mutation. ACRT 2015;23:14-8. [DOI: 10.4993/acrt.23.14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
594 Xiong L, Li R, Sun J, Lou Y, Zhang W, Bai H, Wang H, Shen J, Jing B, Shi C, Zhong H, Gu A, Jiang L, Shi J, Fang W, Zhao H, Zhang J, Wang J, Ye J, Han B. Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study. Oncologist 2019;24:157-e64. [PMID: 30158288 DOI: 10.1634/theoncologist.2018-0120] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
595 Wang L, Meng Y, Zhang QY. LAPTM4B is a novel diagnostic and prognostic marker for lung adenocarcinoma and associated with mutant EGFR. BMC Cancer 2019;19:293. [PMID: 30940109 DOI: 10.1186/s12885-019-5506-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
596 Mirtavoos-Mahyari H, Ghadami M, Khosravi A, Esfahani-Monfared Z, Seifi S, Motevaseli E, Pourabdollah M, Modarressi M. Cell Free Tumoral DNA Versus Paraffin Block Epidermal Growth Factor Receptor Mutation Detection in Patients with Non-Small Cell Lung Cancer. Asian Pac J Cancer Prev 2019;20:3591-6. [PMID: 31870098 DOI: 10.31557/APJCP.2019.20.12.3591] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
597 Luo Y, Yang Y, Peng P, Zhan J, Wang Z, Zhu Z, Zhang Z, Liu L, Fang W, Zhang L. Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer. Transl Lung Cancer Res 2021;10:128-42. [PMID: 33569299 DOI: 10.21037/tlcr-20-812] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
598 Yoshioka T, Shien K, Takeda T, Takahashi Y, Kurihara E, Ogoshi Y, Namba K, Torigoe H, Sato H, Tomida S, Yamamoto H, Soh J, Fujiwara T, Toyooka S. Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells. Cancer Sci 2019;110:2549-57. [PMID: 31162771 DOI: 10.1111/cas.14089] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
599 Yoshimura A, Yamada T, Okuma Y, Fukuda A, Watanabe S, Nishioka N, Takeda T, Chihara Y, Takemoto S, Harada T, Hiranuma O, Shirai Y, Nishiyama A, Yano S, Goto Y, Shiotsu S, Kunimasa K, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Kenmotsu H, Takahashi T, Takayama K. Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study. Transl Lung Cancer Res 2021;10:3582-93. [PMID: 34584858 DOI: 10.21037/tlcr-21-461] [Reference Citation Analysis]
600 Soares M, Antunes L, Redondo P, Borges M, Hermans R, Patel D, Grimson F, Munro R, Chaib C, Lacoin L, Daumont M, Penrod JR, O'Donnell JC, Bento MJ, Rocha Gonçalves F. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative. BMC Pulm Med 2020;20:240. [PMID: 32912174 DOI: 10.1186/s12890-020-01270-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
601 Zaman A, Bivona TG. Emerging application of genomics-guided therapeutics in personalized lung cancer treatment. Ann Transl Med 2018;6:160. [PMID: 29911108 DOI: 10.21037/atm.2018.05.02] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
602 Liu M, Xu S, Wang Y, Li Y, Li Y, Zhang H, Liu H, Chen J. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Oncotarget 2016;7:84951-64. [PMID: 27825114 DOI: 10.18632/oncotarget.13069] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
603 He J, Hu X, Chen L, Liu Q, Jiang Y. Characteristics of Genomic Alterations in Pericardial Effusion of Advanced Non-small Cell Lung Cancer. Front Genet 2022;13:850290. [DOI: 10.3389/fgene.2022.850290] [Reference Citation Analysis]
604 Nilsson MB, Le X, Heymach JV. β-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers. J Neuroimmune Pharmacol 2020;15:27-36. [PMID: 31828732 DOI: 10.1007/s11481-019-09891-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
605 Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, Hicks JK, Lovinger KL, Roarty E, Rinsurongkawong W, Tang M, Sun H, Elamin Y, Lacerda LC, Lewis J, Roth JA, Swisher SG, Lee JJ, William WN Jr, Glisson BS, Zhang J, Papadimitrakopoulou VA, Gray JE, Heymach JV. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Clin Cancer Res 2018;24:6195-203. [PMID: 30228210 DOI: 10.1158/1078-0432.CCR-18-1542] [Cited by in Crossref: 126] [Cited by in F6Publishing: 92] [Article Influence: 31.5] [Reference Citation Analysis]
606 Mao L, Tian N, Wei C, Wang H, Yan H. Synthesis and Biological Activity of 3,9-Diazatetraasteranes as Novel EGFR Tyrosine Kinase Inhibitors. Russ J Gen Chem 2022;92:446-56. [DOI: 10.1134/s1070363222030124] [Reference Citation Analysis]
607 Campo M, Al-Halabi H, Khandekar M, Shaw AT, Sequist LV, Willers H. Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer. Oncologist 2016;21:964-73. [PMID: 27354669 DOI: 10.1634/theoncologist.2015-0508] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
608 Torigoe H, Shien K, Takeda T, Yoshioka T, Namba K, Sato H, Suzawa K, Yamamoto H, Soh J, Sakaguchi M, Tomida S, Tsukuda K, Miyoshi S, Toyooka S. Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations. Cancer Sci 2018;109:1493-502. [PMID: 29532558 DOI: 10.1111/cas.13571] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
609 Ocana A, Ethier JL, Díez-González L, Corrales-Sánchez V, Srikanthan A, Gascón-Escribano MJ, Templeton AJ, Vera-Badillo F, Seruga B, Niraula S, Pandiella A, Amir E. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget 2015;6:39538-49. [PMID: 26446908 DOI: 10.18632/oncotarget.5946] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
610 Jotte RM, Spigel DR. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance. Cancer Med 2015;4:1621-32. [PMID: 26310719 DOI: 10.1002/cam4.506] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
611 Zhang J, Zhang Y, Tang S, Jiang L, He Q, Hamblin LT, He J, Xu Z, Wu J, Chen Y, Liang H, Chen D, Huang Y, Wang X, Deng K, Jiang S, Zhou J, Xu J, Chen X, Liang W, He J. Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour. BMJ Open 2018;8:e017240. [PMID: 30206071 DOI: 10.1136/bmjopen-2017-017240] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
612 Eberlein CA, Stetson D, Markovets AA, Al-Kadhimi KJ, Lai Z, Fisher PR, Meador CB, Spitzler P, Ichihara E, Ross SJ, Ahdesmaki MJ, Ahmed A, Ratcliffe LE, O'Brien EL, Barnes CH, Brown H, Smith PD, Dry JR, Beran G, Thress KS, Dougherty B, Pao W, Cross DA. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. Cancer Res 2015;75:2489-500. [PMID: 25870145 DOI: 10.1158/0008-5472.CAN-14-3167] [Cited by in Crossref: 172] [Cited by in F6Publishing: 109] [Article Influence: 24.6] [Reference Citation Analysis]
613 Zhang Y, Zhang Y, Niu W, Ge X, Huang F, Pang J, Li X, Wang Y, Gao W, Fan F, Li S, Liu H. Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models. Front Pharmacol 2021;12:750031. [PMID: 34630120 DOI: 10.3389/fphar.2021.750031] [Reference Citation Analysis]
614 Mitsudomi T, Kobayashi Y. Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven? Transl Lung Cancer Res 2016;5:446-9. [PMID: 27650363 DOI: 10.21037/tlcr.2016.07.06] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
615 Lui M, Gallo-Hershberg D, DeAngelis C. Development and validation of a patient-reported questionnaire assessing systemic therapy induced diarrhea in oncology patients. Health Qual Life Outcomes 2017;15:249. [PMID: 29273046 DOI: 10.1186/s12955-017-0794-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
616 Yu CH, Chou CC, Tu HF, Huang WC, Ho YY, Khoo KH, Lee MS, Chang GD. Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase. Oncotarget 2018;9:21512-29. [PMID: 29765556 DOI: 10.18632/oncotarget.25177] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
617 Kato T, Seto T, Nishio M, Goto K, Yamamoto N, Okamoto I, Tao L, Yu W, Khaznadar T, Tajima K, Shibata M, Seki A, Yamamoto N. Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results. Drug Saf 2018;41:229-37. [PMID: 29043496 DOI: 10.1007/s40264-017-0596-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
618 Minuti G, D'Incecco A, Cappuzzo F. Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly. Drugs Aging 2015;32:907-16. [PMID: 26446154 DOI: 10.1007/s40266-015-0305-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
619 Abdel Karim N, Kelly K. Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review. Oncologist 2019;24:1270-84. [PMID: 30914465 DOI: 10.1634/theoncologist.2018-0112] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
620 Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Kim JH, Ahn MJ, Aerts JG, Vikström A, Groen HJ. Reply to B.M. Strebel. J Clin Oncol 2014;32:479-80. [PMID: 24378413 DOI: 10.1200/JCO.2013.53.7175] [Reference Citation Analysis]
621 Okamoto I, Sakai K, Morita S, Yoshioka H, Kaneda H, Takeda K, Hirashima T, Kogure Y, Kimura T, Takahashi T, Atagi S, Seto T, Sawa T, Yamamoto M, Satouchi M, Okuno M, Nagase S, Takayama K, Tomii K, Maeda T, Oizumi S, Fujii S, Akashi Y, Nishino K, Ebi N, Nakagawa K, Nakanishi Y, Nishio K. Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study. Oncotarget 2014;5:2293-304. [PMID: 24810493 DOI: 10.18632/oncotarget.1906] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
622 Ng TL, Camidge DR. AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC? Ann Transl Med 2017;5:S14. [PMID: 28567396 DOI: 10.21037/atm.2017.03.73] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
623 Chiang C, Shen C, Huang H, Chang H, Huang Y, Chiu C. Cytology–Based Specimen Triage for Epidermal Growth Factor Receptor Mutation Testing of Malignant Pleural Effusions in Non–Small Cell Lung Cancer. Front Oncol 2022;12:810124. [DOI: 10.3389/fonc.2022.810124] [Reference Citation Analysis]
624 Zhang WQ, Li T, Li H. Efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with/without EGFR-mutation: evidence based on recent phase III randomized trials. Med Sci Monit 2014;20:2666-76. [PMID: 25503781 DOI: 10.12659/MSM.892476] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
625 Suh YG, Cho J. Local ablative radiotherapy for oligometastatic non-small cell lung cancer. Radiat Oncol J 2019;37:149-55. [PMID: 31591862 DOI: 10.3857/roj.2019.00514] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
626 Arbour KC, Kris MG, Riely GJ, Ni A, Beal K, Daras M, Hayes SA, Young RJ, Rodriguez CR, Ahn L, Pao W, Yu HA. Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases. Cancer 2018;124:105-9. [PMID: 28940498 DOI: 10.1002/cncr.30990] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
627 Albaba H, Lim C, Leighl NB. Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. Pharmacoeconomics 2017;35:1195-209. [PMID: 28861770 DOI: 10.1007/s40273-017-0563-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
628 Zhao W, Yang J, Ni B, Bi D, Sun Y, Xu M, Zhu X, Li C, Jin L, Gao P, Wang P, Hua Y, Li M. Toward automatic prediction of EGFR mutation status in pulmonary adenocarcinoma with 3D deep learning. Cancer Med 2019;8:3532-43. [PMID: 31074592 DOI: 10.1002/cam4.2233] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
629 Absenger G, Terzic J, Bezan A. ASCO update: lung cancer. Memo 2017;10:224-7. [PMID: 29250201 DOI: 10.1007/s12254-017-0373-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
630 Tamura S, Wang Y, Veeneman B, Hovelson D, Bankhead A 3rd, Broses LJ, Lorenzatti Hiles G, Liebert M, Rubin JR, Day KC, Hussain M, Neamati N, Tomlins S, Palmbos PL, Grivas P, Day ML. Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer. Bladder Cancer 2018;4:77-90. [PMID: 29430509 DOI: 10.3233/BLC-170144] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
631 Shi Y, Sun Y, Ding C, Wang Z, Wang C, Wang Z, Bai C, Bai C, Feng J, Liu X, Li F, Yang Y, Shu Y, Wu M, He J, Zhang Y, Zhang S, Chen G, Luo H, Luo R, Zhou C, Zhou Y, Pang Q, Zhao H, Zhao Q, Gu A, Ling Y, Huang C, Han B, Jiao S, Jiao H. China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version). Ann Transl Med 2015;3:260. [PMID: 26605306 DOI: 10.3978/j.issn.2305-5839.2015.10.30] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
632 Mizugaki H, Oizumi S, Fujita Y, Harada T, Nakahara Y, Takashina T, Ko R, Watanabe K, Hotta T, Minemura H, Saeki S, Asahina H, Nakamura K, Nakamura H, Hosoda F, Yagishita S, Hamada A. Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non-small cell lung cancer. Eur J Cancer 2022;160:227-34. [PMID: 34862083 DOI: 10.1016/j.ejca.2021.10.024] [Reference Citation Analysis]
633 Schremser K, Rogowski WH, Adler-Reichel S, Tufman AL, Huber RM, Stollenwerk B. Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany. Pharmacoeconomics 2015;33:1215-28. [PMID: 26081300 DOI: 10.1007/s40273-015-0305-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
634 Okajima M, Miura S, Watanabe S, Tanaka H, Ito K, Ishida T, Makino M, Iwashima A, Matsumoto N, Sato K, Ichikawa K, Abe T, Yoshizawa H, Kikuchi T. A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401). Transl Lung Cancer Res 2021;10:252-60. [PMID: 33569309 DOI: 10.21037/tlcr-20-649] [Reference Citation Analysis]
635 Bhandari S, Dunlap N, Kloecker G. Radiotherapy in brain metastases from EGFR-mutated non-small cell lung cancer. J Thorac Dis 2021;13:3230-4. [PMID: 34164215 DOI: 10.21037/jtd-2019-rbmlc-04] [Reference Citation Analysis]
636 Guo XF, Zhu XF, Cao HY, Zhong GS, Li L, Deng BG, Chen P, Wang PZ, Miao QF, Zhen YS. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer. Oncotarget 2017;8:27286-99. [PMID: 28460483 DOI: 10.18632/oncotarget.15933] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
637 Iwama E, Sakai K, Azuma K, Harada D, Nosaki K, Hotta K, Nishio M, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I. Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing. Cancer Sci 2018;109:3921-33. [PMID: 30289575 DOI: 10.1111/cas.13820] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
638 Tsakonas G, Ekman S. Oncogene-addicted non-small cell lung cancer and immunotherapy. J Thorac Dis 2018;10:S1547-55. [PMID: 29951305 DOI: 10.21037/jtd.2018.01.82] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
639 Lu S. Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib. Onco Targets Ther 2019;12:1521-38. [PMID: 30863118 DOI: 10.2147/OTT.S188296] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
640 Zhu YC, Xu CW, Ye XQ, Yin MX, Zhang JX, Du KQ, Zhang ZH, Hu J. Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature. Onco Targets Ther. 2016;9:4301-4305. [PMID: 27486332 DOI: 10.2147/ott.s109415] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
641 Woo HS, Ahn HK, Lee HY, Park I, Kim YS, Hong J, Sym SJ, Park J, Lee JH, Shin DB, Cho EK. Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors. Invest New Drugs 2014;32:1311-5. [PMID: 25146938 DOI: 10.1007/s10637-014-0146-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
642 Mountzios G. Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs). Ann Transl Med 2018;6:140. [PMID: 29862229 DOI: 10.21037/atm.2017.10.04] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
643 Yamanaka Y, Sekine A, Kato T, Yamakawa H, Ikeda S, Baba T, Iwasawa T, Okudela K, Ogura T. Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity. Intern Med 2017;56:2895-8. [PMID: 28943548 DOI: 10.2169/internalmedicine.8638-16] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
644 Passaro A, de Marinis F, Tu HY, Laktionov KK, Feng J, Poltoratskiy A, Zhao J, Tan EH, Gottfried M, Lee V, Kowalski D, Yang CT, Srinivasa BJ, Clementi L, Jalikop T, Huang DCL, Cseh A, Park K, Wu YL. Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. Front Oncol 2021;11:709877. [PMID: 34307179 DOI: 10.3389/fonc.2021.709877] [Reference Citation Analysis]
645 Li Y, Appius A, Pattipaka T, Feyereislova A, Cassidy A, Ganti AK. Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA. PLoS One 2019;14:e0209709. [PMID: 30608948 DOI: 10.1371/journal.pone.0209709] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
646 Agema BC, Veerman GDM, Steendam CMJ, Lanser DAC, Preijers T, van der Leest C, Koch BCP, Dingemans AC, Mathijssen RHJ, Koolen SLW. Improving the tolerability of osimertinib by identifying its toxic limit. Ther Adv Med Oncol 2022;14:175883592211032. [DOI: 10.1177/17588359221103212] [Reference Citation Analysis]
647 Chang Q, Qiang H, Qian J, Lei Y, Lu J, Feng H, Zhao Y, Han B, Zhang Y, Chu T. Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study. Front Oncol 2021;11:652560. [PMID: 33869057 DOI: 10.3389/fonc.2021.652560] [Reference Citation Analysis]
648 Bahleda R, Hollebecque A, Varga A, Gazzah A, Massard C, Deutsch E, Amellal N, Farace F, Ould-Kaci M, Roux F, Marzin K, Soria JC. Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours. Br J Cancer 2015;113:1413-20. [PMID: 26512876 DOI: 10.1038/bjc.2015.374] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
649 Bazhenova L, Minchom A, Viteri S, Bauml JM, Ou SI, Gadgeel SM, Trigo JM, Backenroth D, Li T, Londhe A, Mahadevia P, Girard N. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung Cancer 2021;162:154-61. [PMID: 34818606 DOI: 10.1016/j.lungcan.2021.10.020] [Reference Citation Analysis]
650 Tang N, Guo J, Zhang Q, Wang Y, Wang Z. Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis. Oncotarget 2016;7:3635-44. [PMID: 26498354 DOI: 10.18632/oncotarget.6184] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
651 Chang WJ, Sung JS, Lee SY, Kang EJ, Kwon NJ, Kim HM, Shin SW, Choi JY, Choi YJ, Kim JW, Park KH, Kim YH. The Clinical Significance of RAS, PIK3CA, and PTEN Mutations in Non-Small Cell Lung Cancer Using Cell-Free DNA. J Clin Med 2020;9:E2642. [PMID: 32823871 DOI: 10.3390/jcm9082642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
652 Ke EE, Wu YL. Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence. Ther Adv Respir Dis. 2016;10:256-264. [PMID: 26929305 DOI: 10.1177/1753465816634545] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
653 Roh MS. Molecular pathology of lung cancer: current status and future directions. Tuberc Respir Dis (Seoul) 2014;77:49-54. [PMID: 25237374 DOI: 10.4046/trd.2014.77.2.49] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
654 Mann H, Andersohn F, Bodnar C, Mitsudomi T, Mok TSK, Yang JC, Hoyle C. Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI. Clin Drug Investig 2018;38:319-31. [PMID: 29247383 DOI: 10.1007/s40261-017-0611-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
655 Haim O, Abramov S, Shofty B, Fanizzi C, DiMeco F, Avisdris N, Ram Z, Artzi M, Grossman R. Predicting EGFR mutation status by a deep learning approach in patients with non-small cell lung cancer brain metastases. J Neurooncol 2022. [PMID: 35119589 DOI: 10.1007/s11060-022-03946-4] [Reference Citation Analysis]
656 Weng SS, Cao Y, Tang XJ, Zhu LZ, Tan YN, Dong CX, Chen JQ, Shen H, Yuan Y. Epidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database. Oncotarget. 2017;8:25323-25333. [PMID: 28445978 DOI: 10.18632/oncotarget.15831] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
657 Wiebe S, Schnell D, Külzer R, Gansser D, Weber A, Wallenstein G, Halabi A, Conrad A, Wind S. Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study. Eur J Drug Metab Pharmacokinet 2017;42:461-9. [PMID: 27436099 DOI: 10.1007/s13318-016-0359-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
658 Goss GD, Jonker DJ, Laurie SA, Weberpals JI, Oza AM, Spaans JN, la Porte C, Dimitroulakos J. A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies. J Transl Med 2016;14:83. [PMID: 27036206 DOI: 10.1186/s12967-016-0836-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
659 Tan WL, Ng QS. The continuing role of epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung. Transl Lung Cancer Res 2016;5:106-9. [PMID: 26958503 DOI: 10.3978/j.issn.2218-6751.2015.10.12] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
660 Kehl KL, Hassett MJ, Schrag D. Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era. Cancer Med 2020;9:2019-29. [PMID: 31989786 DOI: 10.1002/cam4.2854] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
661 Ko R, Shukuya T, Imamura CK, Tokito T, Shimada N, Koyama R, Yamada K, Ishii H, Azuma K, Takahashi K. Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations. Transl Lung Cancer Res 2021;10:183-92. [PMID: 33569303 DOI: 10.21037/tlcr-20-824] [Reference Citation Analysis]
662 Wang Y, Guo S, Li D, Tang Y, Li L, Su L, Liu X. YIPF2 promotes chemotherapeutic agent-mediated apoptosis via enhancing TNFRSF10B recycling to plasma membrane in non-small cell lung cancer cells. Cell Death Dis 2020;11:242. [PMID: 32303681 DOI: 10.1038/s41419-020-2436-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
663 Bahleda R, Varga A, Bergé Y, Soria JC, Schnell D, Tschoepe I, Uttenreuther-Fischer M, Delord JP. Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. Br J Cancer 2018;118:344-52. [PMID: 29337963 DOI: 10.1038/bjc.2017.436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
664 Hwang IG, Kang JH, Oh SY, Lee S, Kim SH, Song KH, Son C, Park MJ, Kang MH, Kim HG, Lee J, Park YS, Sun JM, Kim HJ, Kim CK, Yi SY, Jang JS, Park K, Kim HJ. Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. Support Care Cancer 2016;24:301-9. [PMID: 26041481 DOI: 10.1007/s00520-015-2783-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
665 Niebecker R, Maas H, Staab A, Freiwald M, Karlsson MO. Modeling Exposure-Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib. CPT Pharmacometrics Syst Pharmacol 2019;8:230-9. [PMID: 30681293 DOI: 10.1002/psp4.12384] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
666 Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, Jänne PA, Johnson BE. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol 2016;11:556-65. [PMID: 26724471 DOI: 10.1016/j.jtho.2015.12.103] [Cited by in Crossref: 125] [Cited by in F6Publishing: 144] [Article Influence: 17.9] [Reference Citation Analysis]
667 Nakao K, Kobuchi S, Marutani S, Iwazaki A, Tamiya A, Isa S, Okishio K, Kanazu M, Tamiya M, Hirashima T, Imai K, Sakaeda T, Atagi S. Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer. Sci Rep 2019;9:18202. [PMID: 31796841 DOI: 10.1038/s41598-019-54804-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
668 Tufman A, Kahnert K, Duell T, Kauffmann-Guerrero D, Milger K, Schneider C, Stump J, Syunyaeva Z, Huber RM, Reu S. Frequency and clinical relevance of EGFR mutations and EML4-ALK translocations in octogenarians with non-small cell lung cancer. Onco Targets Ther 2017;10:5179-86. [PMID: 29123416 DOI: 10.2147/OTT.S140472] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
669 Tseng JS, Yang TY, Chen KC, Hsu KH, Yu CJ, Liao WY, Tsai CR, Tsai MH, Yu SL, Su KY, Chen JJ, Chen HY, Chang GC. Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma. Onco Targets Ther 2014;7:799-805. [PMID: 24920920 DOI: 10.2147/OTT.S62639] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
670 Shi C, Zheng Y, Li Y, Sun H, Liu S. Association between clinical characteristics and the diagnostic accuracy of circulating single-molecule amplification and resequencing technology on detection epidermal growth factor receptor mutation status in plasma of lung adenocarcinoma. J Clin Lab Anal 2018;32. [PMID: 28670719 DOI: 10.1002/jcla.22271] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
671 Wu CE, Chang CF, Huang CY, Yang CT, Kuo CS, Hsu PC, Chang JW. Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma. Cancers (Basel) 2022;14:674. [PMID: 35158940 DOI: 10.3390/cancers14030674] [Reference Citation Analysis]
672 Greig MJ, Niessen S, Weinrich SL, Feng JL, Shi M, Johnson TO. Effects of Activating Mutations on EGFR Cellular Protein Turnover and Amino Acid Recycling Determined Using SILAC Mass Spectrometry. Int J Cell Biol 2015;2015:798936. [PMID: 26689952 DOI: 10.1155/2015/798936] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
673 Martinez-Marti A, Felip E, Matito J, Mereu E, Navarro A, Cedrés S, Pardo N, Martinez de Castro A, Remon J, Miquel JM, Guillaumet-Adkins A, Nadal E, Rodriguez-Esteban G, Arqués O, Fasani R, Nuciforo P, Heyn H, Villanueva A, Palmer HG, Vivancos A. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2017;28:2451-7. [PMID: 28961841 DOI: 10.1093/annonc/mdx396] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
674 Takakuwa O, Oguri T, Uemura T, Sone K, Fukuda S, Okayama M, Kanemitsu Y, Ohkubo H, Takemura M, Ito Y, Maeno K, Niimi A. Osimertinib-induced interstitial lung disease in a patient with non-small cell lung cancer pretreated with nivolumab: A case report. Mol Clin Oncol 2017;7:383-5. [PMID: 28808573 DOI: 10.3892/mco.2017.1349] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
675 Chamberlain MC, Baik CS, Gadi VK, Bhatia S, Chow LQ. Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro Oncol 2017;19:i1-i24. [PMID: 28031389 DOI: 10.1093/neuonc/now197] [Cited by in Crossref: 91] [Cited by in F6Publishing: 76] [Article Influence: 18.2] [Reference Citation Analysis]
676 Li X, Tang J, Mao Y. Incidence and risk factors of drug-induced liver injury. Liver Int 2022. [PMID: 35353431 DOI: 10.1111/liv.15262] [Reference Citation Analysis]
677 Lindner AU, Resler AJ, Carberry S, Oficjalska K, Bacon O, Lee CS, Choudhry A, Burke JP, Sheahan K, Cremona M, Hennessy BT, McNamara D, Doherty G, Ryan EJ, Prehn JHM. Systems biology analysis identifies molecular determinants of chemotherapy-induced diarrhoea. J Mol Med (Berl) 2020;98:149-59. [PMID: 31848663 DOI: 10.1007/s00109-019-01864-z] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
678 Zhang H. Osimertinib making a breakthrough in lung cancer targeted therapy. Onco Targets Ther 2016;9:5489-93. [PMID: 27660466 DOI: 10.2147/OTT.S114722] [Cited by in Crossref: 31] [Cited by in F6Publishing: 12] [Article Influence: 5.2] [Reference Citation Analysis]
679 Takeda M, Nakagawa K. Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor gene mutation-positive lung cancer. Mol Clin Oncol 2017;6:3-6. [PMID: 28123721 DOI: 10.3892/mco.2016.1099] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
680 Chen CW, Wu MH, Chen YF, Yen TY, Lin YW, Chao SH, Tala S, Tsai TH, Su TL, Lee TC. A Potent Derivative of Indolizino[6,7-b]Indole for Treatment of Human Non-Small Cell Lung Cancer Cells. Neoplasia 2016;18:199-212. [PMID: 27108383 DOI: 10.1016/j.neo.2016.02.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
681 Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer 2017;25:1713-39. [PMID: 28224235 DOI: 10.1007/s00520-017-3629-4] [Cited by in Crossref: 65] [Cited by in F6Publishing: 51] [Article Influence: 13.0] [Reference Citation Analysis]
682 Wu WS, Chen YM. Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance. J Pers Med 2014;4:297-310. [PMID: 25563355 DOI: 10.3390/jpm4030297] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
683 Seebacher NA, Stacy AE, Porter GM, Merlot AM. Clinical development of targeted and immune based anti-cancer therapies. J Exp Clin Cancer Res 2019;38:156. [PMID: 30975211 DOI: 10.1186/s13046-019-1094-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 19.3] [Reference Citation Analysis]
684 Shingyoji M, Iuchi T. Considerations on the management of EGF receptor-TKIs for brain metastases in EGFR -mutant lung carcinoma patients. Lung Cancer Management 2015;4:43-9. [DOI: 10.2217/lmt.14.44] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
685 Chmielecki J, Ross JS, Wang K, Frampton GM, Palmer GA, Ali SM, Palma N, Morosini D, Miller VA, Yelensky R. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. Oncologist. 2015;20:7-12. [PMID: 25480824 DOI: 10.1634/theoncologist.2014-0234] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
686 Noonan SA, Camidge DR. PROFILE 1014: lessons for the new era of lung cancer clinical research. Transl Lung Cancer Res 2015;4:642-8. [PMID: 26629438 DOI: 10.3978/j.issn.2218-6751.2015.05.02] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
687 Liu Z, Xu L. UBE2S promotes the proliferation and survival of human lung adenocarcinoma cells. BMB Rep 2018;51:642-7. [PMID: 30545437 [PMID: 30545437 DOI: 10.5483/bmbrep.2018.51.12.138] [Cited by in Crossref: 10] [Article Influence: 3.3] [Reference Citation Analysis]
688 Pinto JA, Vallejos CS, Raez LE, Mas LA, Ruiz R, Torres-Roman JS, Morante Z, Araujo JM, Gómez HL, Aguilar A, Bretel D, Flores CJ, Rolfo C. Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy? ESMO Open 2018;3:e000344. [PMID: 29682332 DOI: 10.1136/esmoopen-2018-000344] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 9.3] [Reference Citation Analysis]
689 Huang AC, Huang CH, Ju JS, Chiu TH, Tung PH, Wang CC, Liu CY, Chung FT, Fang YF, Guo YK, Kuo CS, Yang CT. First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer. Ther Adv Med Oncol 2021;13:17588359211035710. [PMID: 34377157 DOI: 10.1177/17588359211035710] [Reference Citation Analysis]
690 Feldinger K, Kong A. Profile of neratinib and its potential in the treatment of breast cancer. Breast Cancer (Dove Med Press) 2015;7:147-62. [PMID: 26089701 DOI: 10.2147/BCTT.S54414] [Cited by in Crossref: 14] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]